---
document_datetime: 2023-09-21 22:23:17
document_pages: 105
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/comirnaty-h-c-005735-x-0176-epar-assessment-report-extension_en.pdf
document_name: comirnaty-h-c-005735-x-0176-epar-assessment-report-extension_en.pdf
version: success
processing_time: 132.9413574
conversion_datetime: 2025-12-29 22:59:15.553145
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 June 2023 EMA/355550/2023 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report on extension of marketing authorisation

## COMIRNATY

Common name: COVID-19 mRNA vaccine (nucleoside-modified)

Procedure No. EMEA/H/C/005735/X/0176

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 5                                                                                                     |
|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier ...................................................................................        | 5                                                                                                     |
| 1.2. Legal basis, dossier content.................................................................................        | 5                                                                                                     |
| 1.3. Information on Paediatric requirements.................................................................              | 5                                                                                                     |
| 1.4. Information relating to orphan market exclusivity...................................................                 | 5                                                                                                     |
| 1.4.1. Similarity ....................................................................................................... | 5                                                                                                     |
| 1.5. Scientific advice.................................................................................................   | 5                                                                                                     |
| 1.6. Steps taken for the assessment of the product.......................................................                 | 6                                                                                                     |
| 2. Scientific discussion................................................................................                  | 6                                                                                                     |
| 2.1. Problem statement.............................................................................................       | 6                                                                                                     |
| 2.1.1. Disease or condition                                                                                               | ........................................................................................ 6            |
| 2.1.2. Clinical presentation ........................................................................................     | 6                                                                                                     |
| 2.1.3. Management                                                                                                         | .................................................................................................. 7  |
| 2.2. About the product..............................................................................................      | 7                                                                                                     |
| 2.3. Type of Application and aspects on development                                                                       | .................................................... 7                                                |
| 2.4. Quality aspects..................................................................................................    | 8                                                                                                     |
| 2.4.1. Introduction                                                                                                       | ................................................................................................... 8 |
| 2.4.2. Active Substance.............................................................................................      | 9                                                                                                     |
| 2.4.3. Finished Medicinal Product................................................................................         | 9                                                                                                     |
| 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects.......13                             |                                                                                                       |
| 2.4.5. Conclusions on chemical, pharmaceutical and biological aspects............................13                       |                                                                                                       |
| 2.5. Non-clinical aspects...........................................................................................13    |                                                                                                       |
| 2.5.1. Introduction                                                                                                       | ..................................................................................................13  |
| 2.5.2. Pharmacology................................................................................................13     |                                                                                                       |
| 2.5.3. Pharmacokinetics                                                                                                   | ...........................................................................................14         |
| 2.5.4. Toxicology.....................................................................................................15  |                                                                                                       |
| 2.5.5. Ecotoxicity/environmental risk assessment                                                                          | ........................................................15                                            |
| 2.5.6. Discussion on non-clinical aspects                                                                                 | ....................................................................15                                |
| 2.5.7. Conclusion on the non-clinical aspects...............................................................15            |                                                                                                       |
| 2.6. Clinical aspects.................................................................................................15  |                                                                                                       |
| 2.6.1. Introduction                                                                                                       | ..................................................................................................15  |
| 2.6.2. Clinical efficacy                                                                                                  | ..............................................................................................16      |
| 2.6.3. Discussion on clinical efficacy...........................................................................77       |                                                                                                       |
| 2.6.4. Conclusions on clinical efficacy                                                                                   | .........................................................................80                           |
| 2.6.5. Clinical safety                                                                                                    | ................................................................................................81    |
| 2.6.6. Discussion on clinical safety.............................................................................90       |                                                                                                       |
| 2.6.7. Conclusions on clinical safety                                                                                     | ...........................................................................91                         |
| 2.7. Risk Management Plan.......................................................................................91        |                                                                                                       |
| 2.7.1. Safety Specifications                                                                                              | .......................................................................................92             |
| 2.7.2. Pharmacovigilance plan                                                                                             | ...................................................................................93                 |

<div style=\"page-break-after: always\"></div>

| 2.7.3. Plans for post-authorisation efficacy studies .......................................................97           |                                                                                                       |
|--------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| 2.7.4. Risk minimisation measures .............................................................................97        |                                                                                                       |
| 2.7.5. Conclusion on the RMP                                                                                             | ....................................................................................97                |
| 2.8. Pharmacovigilance                                                                                                   | ............................................................................................98        |
| 2.8.1. Pharmacovigilance system...............................................................................98         |                                                                                                       |
| 2.8.2. Periodic Safety Update Reports submission requirements.....................................98                     |                                                                                                       |
| 2.9. Product information...........................................................................................98    |                                                                                                       |
| 2.9.1. User consultation                                                                                                 | ...........................................................................................98         |
| 2.9.2. Labelling exemptions ......................................................................................98     |                                                                                                       |
| 2.9.3. Quick Response (QR) code ..............................................................................99         |                                                                                                       |
| 2.9.4. Additional monitoring......................................................................................99     |                                                                                                       |
| 3. Benefit-Risk Balance .............................................................................                    | 99                                                                                                    |
| 3.1. Introduction.....................................................................................................99 |                                                                                                       |
| 3.2. Therapeutic Context..........................................................................................99     |                                                                                                       |
| 3.2.1. Disease or condition .......................................................................................99    |                                                                                                       |
| 3.2.2. Available therapies and unmet medical need....................................................100                 |                                                                                                       |
| 3.2.3. Main clinical studies......................................................................................100    |                                                                                                       |
| 3.3. Favourable effects...........................................................................................100    |                                                                                                       |
| 3.4. Uncertainties and limitations about favourable effects                                                              | ..........................................101                                                         |
| 3.5. Unfavourable effects                                                                                                | .......................................................................................101            |
| 3.6. Uncertainties and limitations about unfavourable effects.......................................101                  |                                                                                                       |
| 3.7. Effects Table                                                                                                       | ..................................................................................................102 |
| 3.8. Benefit-risk assessment and discussion..............................................................104             |                                                                                                       |
| 3.8.1. Importance of favourable and unfavourable effects                                                                 | ...........................................104                                                        |
| 3.8.2. Balance of benefits and risks..........................................................................104        |                                                                                                       |
| 3.9. Conclusions....................................................................................................104  |                                                                                                       |
| 4. Recommendations...............................................................................                        | 104                                                                                                   |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation   | Definition                                                  |
|----------------|-------------------------------------------------------------|
| AE             | adverse event                                               |
| CDC            | Centers for Disease Control and Prevention                  |
| CMC            | Chemistry Manufacturing and Controls                        |
| CO             | Clinical Overview                                           |
| COVID-19       | coronavinus disease 2019                                    |
| DART           | Development and Reproductive Toxicology                     |
| EC             | European Commission                                         |
| ECDC           | European Centre for Disease Prevention and Control          |
| EU             | European Union                                              |
| EUA            | Emergency Use Authorization                                 |
| FDA            | Food and Drug Administration                                |
| GMT            | geometric mean titer                                        |
| IM             | intramuscular                                               |
| LNP            | lipid nanoparticles                                         |
| modRNA         | nucleoside-modified messenger RNA                           |
| mRNA           | messenger RNA                                               |
| n              | number of participants                                      |
| N-binding      | SARS-CoV-2 nucleoprotein-binding                            |
| PBS            | phosphate buffered saline                                   |
| PCR            | polymerase chain reaction                                   |
| Id             | prescribing information                                     |
| RNA            | ribonucleic acid                                            |
| RSV            | respiratory syncytial vinus                                 |
| SARS           | severe acute respiratory syndrome                           |
| SAE            | serious adverse event                                       |
| SARS-CoV-2     | SARS coronavirus-2                                          |
| UK             | United Kingdom                                              |
| US             | United States                                               |
| VE             | vaccine efficacy                                            |
| VOC            | variant of conicen                                          |
| VRBPAC         | Vaccines and Related Biological Products Advisory Committee |
| WT             | wild-type                                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

BioNTech Manufacturing GmbH submitted on 03 March 2023 an extension of the marketing authorisation.

Extension application to add a new strength of 1.5/1.5 micrograms/dose for the Comirnaty Original/Omicron BA.4-5 concentrate for dispersion for injection for infants and children between 6 months to 4 years of age.

The MAH applied for an addition of a new strength 1.5/1.5 micrograms/dose.

The MAH applied for the following indication for Comirnaty 1.5/1.5 micrograms/dose:

Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.

The use of this vaccine should be in accordance with official recommendations.

## 1.2. Legal basis, dossier content

The legal basis for this application refers to:

Article 19 of Commission Regulation (EC) No 1234/2008 and Annex I of Regulation (EC) No 1234/2008, (2) point (c) - Extensions of marketing authorisations

## 1.3. Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0466/2022 on the agreement of a paediatric investigation plan (PIP). At the time of submission of the application, the PIP P/0466/2022 was not yet completed as some measures were deferred.

## 1.4. Information relating to orphan market exclusivity

## 1.4.1. Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## 1.5. Scientific advice

The MAH did not seek Scientific advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.6. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur: Filip Josephson

The Rapporteur appointed by the PRAC was:

PRAC Rapporteur: Menno van der Elst

| The application was received by the EMA on                                                                                                                                                | 03 March 2023   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|
| The procedure started on                                                                                                                                                                  | 25 March 2023   |
| The CHMP Rapporteur's first Assessment Report was circulated to all CHMP and PRAC members on                                                                                              | 22 May 2023     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC and CHMP members on                                                                                              | 26 May 2023     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                                  | 08 June 2023    |
| ETF discussions took place on                                                                                                                                                             | 13 June 2023    |
| The CHMP Rapporteurs circulated the CHMP and PRAC Rapporteurs Joint Assessment Report on the responses to the List of Questions to all CHMP and PRAC members on                           | 15 June 2023    |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to COMIRNATY on | 22 June 2023    |

## 2. Scientific discussion

## 2.1. Problem statement

## 2.1.1. Disease or condition

COVID-19 is caused by SARS-CoV-2, a zoonotic virus that first emerged as a human pathogen in China and has rapidly spread around the world by human-to-human transmission.

## 2.1.2. Clinical presentation

COVID-19 presentation is generally with cough and fever, with chest radiography showing ground-glass opacities or patchy shadowing. However, many patients present without fever or radiographic changes, and infections may be asymptomatic which is relevant to controlling transmission. For symptomatic patients, disease progression may lead to acute respiratory distress syndrome requiring ventilation, subsequent multiorgan failure, and death.

<div style=\"page-break-after: always\"></div>

Common symptoms in hospitalized patients (in order of highest to lowest frequency) include fever, dry cough, shortness of breath, fatigue, myalgias, nausea/vomiting or diarrhoea, headache, weakness, and rhinorrhoea. Anosmia (loss of smell) or ageusia (loss of taste) may be the sole presenting symptom in approximately 3% of individuals who have COVID-19.

## 2.1.3. Management

Currently available therapies have different benefit-risk considerations depending on the stage of illness and disease manifestations. While care for individuals who have COVID-19 has improved with clinical experience, vaccination is the most effective medical countermeasure to decrease risk and mitigate spread of the SARSCoV-2 virus.

## 2.2. About the product

Given the genetic and resulting antigenic differences in currently circulating Omicron sublineages of SARSCoV-2 (eg, BQ.1, BQ.1.1, BA.5, XBB.1, XBB.1.5) compared to the original strain, the MAH has added the bivalent variant-adapted vaccine to ensure adequate protection in children &lt;5 years of age, as is currently authorized for booster doses in individuals ≥ 5 years of age. The protection provided by the original typebased mRNA vaccines against Omicron-related infection appears to be lower and shorter-lived compared to that seen for prior variants. Vaccine effectiveness against severe disease associated with novel Omicron sublineages has waned even for severe disease among the general population with a booster dose.

The bivalent COMIRNATY Original/Omicron BA.1 vaccine and the bivalent COMIRNATY Original/Omicron BA.4/BA.5 vaccine were approved in the EU for use in individuals ≥12 years of age who have received at least primary vaccination against COVID-19 on 01 September 2022 and 12 September 2022, respectively. On 10 November 2022, the 10 μ g dose of the bivalent COMIRNATY Original/Omicron BA.4/BA.5 vaccine was approved for use in individuals 5 through 11 years of age who have received at least primary vaccination against COVID-19. The immunogenicity assessment of Original/Omi BA.4/BA.5 was based on extrapolation of immunogenicity data from studies with Comirnaty Original and Original/Omi BA.1 and explorative non-clinical immunogenicity data for the Original/Omi BA.4/BA.5.

## 2.3. Type of Application and aspects on development

The authorization of a 3-dose primary series of BNT162b2 3 µg in individuals 6 months to &lt;5 years of age is based on clinical safety and immunogenicity data from approximately 4500 participants (including approximately 3000 participants who received BNT162b2 and 1500 who received placebo) 6 months to &lt;5 years of age with 1.3-to-1.4-month median duration of blinded follow-up in Study C4591007. Effectiveness of the 3-µg dose in the 6 months to &lt;5 years of age group was inferred based on the successful protocolspecified immunobridging analysis, which compared SARS-CoV-2 neutralizing antibody responses in this age group in Study C4591007 to a group of young adult participants 16 to 25 years of age in the C4591001 efficacy study. Protocol-specified efficacy analyses demonstrated &gt;70% VE in this age group from at least 7 days post-Dose 3 to the data cutoff date.

Pfizer/BioNTech requested authorization of the 3 µg formulation of the Comirnaty Original/Omicron BA.4-5 Vaccine as a 3-dose primary series and booster (fourth dose) for use in infants and children 6 months to &lt;5 years of age based upon:

<div style=\"page-break-after: always\"></div>

- Immunogenicity and safety data for a subset of participants ≥ 6 months to &lt;5 years of age in Group 2 of Substudy B of Study C4591048 following administration of BNT162b2 Bivalent (Original/OMI BA.4/BA.5) at 3 µg as a booster (fourth dose).
- Extrapolation of immunogenicity and safety data for participants ≥ 5 years to &lt;12 years of age in Group 2 of Substudy D of Study C4591048 following administration of BNT162b2 Bivalent (Original/OMI BA.4/BA.5) at 10 µg as a booster (fourth dose).
- Extrapolation of immunogenicity and safety data from participants in Cohort 2 ( ≥ 12 years of age) and Cohort 3 ( ≥ 18 years of age) of Study C4591044 following administration of BNT162b2 Bivalent (Original/OMI BA.4/BA.5) at 30 or 60 µg as a booster (fourth dose).
- BNT162b2 Bivalent (original/OMI BA.4/BA.5) 3 µg specific CMC package.

Thus, no data are available for primary vaccination with the bivalent BNT162b2 (Original/Omicron BA.4-5).

## 2.4. Quality aspects

## 2.4.1. Introduction

Pfizer and BioNTech have developed the COMIRNATY vaccine to prevent Coronavirus Disease 2019 (COVID19) caused by the virus SARS-CoV-2. The vaccine is based on SARS CoV-2 spike (S) glycoprotein antigens encoded in RNA and formulated in lipid nanoparticles (LNPs).

There are several approved formulations of Comirnaty vaccine:

- -PBS/Sucrose finished product, Comirnaty, 30 micrograms/dose, concentrate for dispersion for injection which received a conditional approval 21 December 2020 (EMEA/H/C/005735)
- -Tris/Sucrose finished product, Comirnaty, 30 micrograms/dose, dispersion for injection , approved 3 November 2021 (EMEA/H/C/005735/X/0044)
- -Tris/Sucrose finished product, Comirnaty, 10 micrograms/dose, concentrate for dispersion for injection, approved 26 November 2021 (EMEA/H/C/005735/X/0077)
- -Tris/Sucrose finished product, Comirnaty Original/Omicron BA.1, (15/15 micrograms)/dose, dispersion for injection , approved 1 September 2022 (EMEA/H/C/005735/II/0140)
- -Tris/Sucrose finished product, Comirnaty Original/Omicron BA.4-5, (15/15 micrograms)/dose, dispersion for injection , approved 12 September 2022 (EMEA/H/C/005735/II/0143)
- -Tris/Sucrose finished product, Comirnaty, 3 micrograms/dose, concentrate for dispersion for injection, approved 20 October 2022 (EMEA/H/C/005735/X/0138)
- -Tris/Sucrose finished product, Comirnaty Original/Omicron BA.4-5, (5/5 micrograms)/dose, concentrate for dispersion for injection , approved 10 November 2022 (EMEA/H/C/005735/X/0147)
- -Tris/Sucrose finished product, Comirnaty Original/Omicron BA.4-5, (5/5 micrograms)/dose, dispersion for injection , under review, outcome June 2023  (EMEA/H/C/005735/X/180)

<div style=\"page-break-after: always\"></div>

To assist in the public health crisis, a new Pediatric 3 μ g BNT162b2 Bivalent [Original and Omicron (BA.4/BA.5) variant] finished product (herein referred to as Bivalent or 3 μ g dose), consisting of the Original and Omicron (BA.4/BA.5) active substance strains (also referred to as active substance constructs), is being introduced.

The purpose of this submission is to provide details on the Bivalent finished product 3 µg RNA dose presentation, which is filled at 0.4 mL per vial. The 3 µg RNA presentation requires dilution with 2.2 mL 0.9% sodium chloride prior to administration and once diluted provides 10 doses, each containing a 3 µg RNA dose in 0.2 mL injection volume.

The Bivalent vaccine is manufactured using the two active substance RNA constructs in an approximately 1:1 ratio The Bivalent finished product is formulated at 0.1 mg/mL RNA in Tris buffer and sucrose. The platform manufacturing processes from the Original Tris-Sucrose and Bivalent finished product are used for the manufacture of 3 µg dose. Substantial supportive process and characterisation information is available for both the Original Tris-Sucrose and Bivalent finished products. From an active substance perspective, there are no changes to the manufacture, characterisation, control, container closure, or stability required on the basis of this change. Similarly, from a finished product perspective, there are no changes to finished product control of excipients or container closure on the basis of this change. The 3 μ g dose finished product is identical to the 10 and 30 μ g dose finished products, differing only in fill volume and dose specific requirements for dilution prior to administration.

## 2.4.2. Active Substance

The active substances tozinameran and famtozinameran are already approved for the original Comirnaty vaccine formulations (EU/1/20/1528/001-014). No changes to the information are proposed except for a minor and acceptable update in section 3.2.S.4.5.

## 2.4.3. Finished Medicinal Product

## 2 . 4 . 3 . 1 . Description of the product and Pharmaceutical Development

The BNT162b2 Bivalent (Original and Omicron (BA.4/BA.5) Variant) finished product, is supplied as a preservative-free, sterile dispersion of RNA-containing lipid nanoparticles (LNPs) in aqueous cryoprotectant buffer for intramuscular administration.

The Bivalent finished product is formulated at 0.1 mg/mL RNA in Tris bufferand sucrose,and contains an approximately 1:1 ratio of the BNT162b2 Original and Omicron BA.4/BA.5 RNA constructs. There are three dosages of the Bivalent finished product - 30, 10, and 3 µg RNA per dose. The doses differ only in the fill volume and requirement for dilution prior to administration:

- -The Bivalent finished product 30 µg RNA dose is provided in either the multidose (MDV) presentation filled at 2.25 mL fill volume and is administered without dilution, providing 6 doses, each a 30 µg RNA dose in 0.3 mL injection volume or the 30 µg RNA dosage is provided in a single dose (SDV) presentation filled at 0.48 mL fill volume and administered without dilution, providing one 30 μ g RNA dose in 0.3 mL injection volume. Each construct, BNT162b2 Original and Omicron BA.4/BA.5 is present in approximately equal quantities, i.e. 15 µg RNA each, totalling 30 µg RNA per dose.

<div style=\"page-break-after: always\"></div>

- -The Bivalent finished product 10 µg RNA dose is filled at 1.3 mL fill volume and requires dilution with 1.3 mL 0.9% sodium chloride prior to administration, providing 10 doses, each a 10 µg RNA dose in 0.2 mL injection volume. Each construct, BNT162b2 Original and Omicron BA.4/BA.5, is present in approximately equal quantities, i.e. 5 µg RNA each, totalling 10 µg RNA per dose.
- -The Bivalent finished product 3 µg RNA dose is filled at 0.4 mL fill volume and requires dilution with 2.2 mL 0.9% sodium chloride prior to administration, providing 10 doses, each a 3 µg RNA dose in 0.2 mL injection volume. Each construct, BNT162b2 Original and Omicron BA.4/BA.5, is present in approximately equal quantities, i.e. 1.5 µg RNA each, totalling 3 µg RNA per dose.

The section on description and composition of the finished product has been updated to include the 3 µg dose presentation of the bivalent vaccine compared to the already approved procedures EMEA/H/C/005735/X/0077 (10 µg dose presentation), EMEA/H/C/005735/X/0138 (3 µg dose presentation) EMEA/H/C/005735/X/0147 (10 µg, bivalent dose presentation including the original and omicron BA.4/BA.5 strains) and EMEA/H/C/005735/II/0143 (30 µg, bivalent dose presentation including the original and omicron BA.4/BA.5 strains).

The composition of the bivalent finished product 3 µg RNA dose, including quality standard, function, concentration and amount per dose has been provided.

The container closure system is a 2 mL Type I borosilicate or aluminosilicate glass vial and a 13 mm bromobutyl rubber stopper and is the same container closure system as for the already approved Tris/sucrose finished product of Comirnaty.

The processing aids and active substance formulation buffer components are residues that are essentially removed through the manufacturing process and are not considered as ingredients (excipients).

## Pharmaceutical development

The QTPP has been updated for the bivalent vaccine to include the bivalent 3 µg/dose presentation. No changes have been made compared to the QTPP for the original vaccine in Tris/Sucrose formulation except for a reflection of the use of two strains of mRNA, the inclusion of RNA ratio as a quality attribute and for the claimed shelf-life.

No change in physicochemical properties, processability and stability is expected for the bivalent vaccine compared to the original vaccine in the Tris/Sucrose formulation.

The sections on components of the finished product and manufacturing process development and characterization have been updated to include the bivalent 3 µg/dose presentation.

Comparability has previously been convincingly demonstrated for a number of comparisons of Comirnaty finished product, such as between clinical and commercial scale original finished product, between various manufacturing sites, between the PBS/Sucrose finished product and Tris/Sucrose finished product, between the various dosage presentations (30 μ g, 10 μ g and 3 μ g) as well as between the monovalent and bivalent vaccine finished product. Comparability has been demonstrated via comprehensive studies including both release testing and extended characterisation testing. Due to the application of the same formulation, manufacturing process, and the use of the same manufacturing sites as the original and authorised finished product, extensive prior experience is leveraged for the bivalent 3 μ g/dose vaccine finished product and comparability previously convincingly proven and concluded.

For the bivalent 3 µg/dose presentation of finished product, batch analysis data are provided for a large-scale confirmatory batch with a fill volume of 0.4 mL.

<div style=\"page-break-after: always\"></div>

In conclusion, the information provided in the sections on Description and composition of the finished product and Pharmaceutical development is found sufficient and acceptable.

## 2.4.3.2. Manufacture of the product and process controls

The bivalent BA.4-5 vaccine (1.5/1.5 micrograms)/dose is manufactured at manufacturing sites, and using the same platform process, as currently approved Comirnaty vaccines (Tris/Sucrose formulation) (EU/1/20/1528/002-014). The GMP compliance of these sites has been previously confirmed.

The manufacturing process consists of four major manufacturing steps - LNP fabrication, bulk drug product formation, sterile filtration and aseptic filling. The manufacturing process is the same as for the bivalent BA.4-5 vaccine (15/15 micrograms)/dose (EMEA/H/C/005735/II/0143) and the bivalent BA.4 5 vaccine (5/5 micrograms)/dose (EMEA/H/C/005735/X/147) except for a different fill volume. The manufacturing process is sufficiently described, and suitable in-process controls (IPCs) are applied.

No process validation is performed for the bivalent BA.4-5 vaccine (1.5/1.5 micrograms)/dose. This is found acceptable since this line extension is based on the currently approved bivalent vaccines (Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose and (5/5 micrograms)/dose as well as the monovalent Comirnaty 3 micrograms/dos.

## 2.4.3.3. Product specification, analytical procedures, batch analysis

The finished product specifications for the bivalent vaccine finished product include tests for tests for Appearance (Visual), Appearance (Visible Particulates), Subvisible Particles (Ph. Eur.), pH (Ph. Eur.), Osmolality (Osmometry), LNP Size (Dynamic Light Scattering), LNP Polydispersity (Dynamic Light Scattering), RNA Encapsulation (Fluorescence assay), RNA content (Fluorescence assay), RNA ratio (ddPCR), ALC-0315 content (HPLC-CAD, HPLC-ELSD), ALC-0159 content (HPLC-CAD, HPLC-ELSD), DSPC content (HPLC-CAD, HPLC-ELSD), Cholesterol content (HPLC-CAD, HPLC-ELSD), extractable volume (Ph. Eur.), Lipid identities (HPLC-CAD, HPLC-ELSD), Identity of encoded RNA sequence (ddPCR), Potency / in Vitro Expression (Cell-based flow cytometry), RNA Integrity (Capillary Gel Electrophoresis), Bacterial Endotoxin (Ph. Eur.), Sterility (Ph. Eur.) and Container Closure Integrity (Dye incursion).

The specifications for the bivalent 3 μ g/dose vaccine finished product includes a comprehensive set of relevant tests along with corresponding acceptance criteria. The acceptance criteria for release and stability testing for the bivalent 3 μ g/dose vaccine finished product are the same as those for the already approved bivalent 10 μ g/dose and bivalent 30 μ g/dose vaccine finished products for all quality attributes tested, except for vial content (volume) which has different acceptance criteria.

The proposed acceptance criteria for vial content (volume) for the bivalent 3 μ g/dose vaccine finished product is identical to the original 3 μ g/dose monovalent Tris/sucrose vaccine finished product. The vial content (volume) for Tris/Sucrose finished product was determined to ensure that each 0.4 mL filled vial can deliver up to ten 3 µg doses of 0.2 mL each, following the addition of 2.2 mL 0.9% sodium chloride. The provided justification for vial content (volume) of 0.4 fill volume is found acceptable.

Since the acceptance criteria for the bivalent 3 μ g/dose vaccine finished product are based on the currently approved bivalent as well as original Tris/Sucrose vaccine finished products for the majority of test attributes, these acceptance criteria for test attributes are considered as clinically qualified to ensure quality, efficacy and safety.

<div style=\"page-break-after: always\"></div>

Batch data has been provided for a commercial scale confirmatory batch filled at 0.4 mL. The batch was manufactured at the commercial site for the bivalent vaccine finished product (30, 10 and 3 μ g RNA/dose) at Pfizer, Puurs, BE. All results met the acceptance criteria at the time of release. In addition, stability studies have been initiated and are ongoing for the commercial scale batch.

## 2.4.3.4. Stability of the product

Batch release data are provided for one commercial scale batch of the bivalent 3 μ g/dose vaccine finished product and this batch has been placed on stability study at both long-term storage conditions (-90 to -60°C) and accelerated storage conditions (5 ± 3 °C).

The claimed 18 months shelf-life is identical to the already approved shelf-life for the original vaccine finished product (Tris/Sucrose formulation) and is based on the results provided in several recently approved line extensions EMEA/H/C/005735/X/0044 (30 μ g/dose/2.25 mL fill volume), EMEA/H/C/005735/X/0077 (10 μ g/dose/1.3 mL fill volume), EMEA/H/C/005735/X/0138 (3 μ g/dose/0.4 mL fill volume), EMEA/H/C/005735/II/0143 (bivalent 30 μ g/dose/2.25 mL fill volume), EMEA/H/C/005735/X/0147 (bivalent 10 μ g/dose/2.25 mL fill volume) as well as from stability results for the bivalent 3 μ g/dose vaccine finished product provided in this specific line extension EMEA/H/C/005735/X/0176.

This approach to extrapolate the shelf-life from the already authorised vaccine finished products, including both monovalent and bivalent finished products, is found acceptable since comparability has been convincingly demonstrated for a number of various comparisons of Comirnaty finished product such as between clinical and commercial scale finished product, between various manufacturing sites, between the PBS/Sucrose and Tris/Sucrose finished product, between the various dosage presentations (30 μ g, 10 μ g and 3 μ g) as well as between the monovalent and bivalent vaccine finished product. Comparability has been demonstrated via comprehensive studies including both release testing and extended characterisation testing. Due to the application of the same formulation, manufacturing process, and the use of the same manufacturing sites as the original and authorized finished product, extensive prior experience is leveraged for the bivalent 3 μ g/dose vaccine finished product and comparability previously convincingly proven and concluded.

Therefore, it was concluded that the proposed shelf-life for the bivalent 3 μ g/dose vaccine finished product of 18 months when stored at the recommended storage temperature of -90 to -60°C, including a short-term storage at 2-8 °C for up to 10 weeks (within the 18 months shelf-life), as defined in SmPC Section 6.3, is acceptable.

## 2.4.3.5. Post approval change management protocol(s)

Not applicable.

## 2.4.3.6. Adventitious agents

The active substances (tozinameran and famtozinameran) are identical to that used for the currently approved Comirnaty vaccine formulations (EU/1/20/1528/001-014). Consequently, there are no changes to the active substance sections and full reference is made to the active substance data of Comirnaty, concentrate for dispersion for injection (EMEA/H/C/005735). Adequate testing for bioburden, endotoxins and sterility are also included at appropriate stages of the manufacturing process of the finished product.

<div style=\"page-break-after: always\"></div>

## 2.4.3.7. GMO

Not applicable.

## 2.4.4. Discussion and conclusions on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.4.5. Conclusions on chemical, pharmaceutical and biological aspects

This line extension application to register Comirnaty Original/Omicron BA.4-5, (1.5/1.5 micrograms)/dose, concentrate for dispersion for injection is recommended for approval from a quality point of view.

## 2.5. Non-clinical aspects

## 2.5.1. Introduction

New data for this application is limited to studies on the immune response in mice after a primary series with variant vaccines, including the bivalent Omicron BA4/BA5 vaccine.

## 2.5.2. Pharmacology

## 2.5.2.1. Primary pharmacodynamic studies

The monovalent or bivalent Omicron BA.4/BA.5 variant-modified vaccines were tested as a two dose primary series in naïve Balb/c mice and as a 3 rd  dose booster in BNT162b2-experienced Balb/c mice. Omicron BA.4 and BA.5 sublineages contain the same spike sequence, therefore the vaccine is described as 'BA.4/BA.5'.

Five groups of 10 female Balb/c mice were immunized, bled and euthanized after either receiving immunizations either twice, at 0 and 21 days, in the primary series; or one month after the primary series completion, as a third dose booster. Blood was collected at baseline and at 7 days and 28 days after last immunization. At 28 days after last immunization, spleen and lymph nodes were also harvested to analyze the antibody response by a pseudovirus neutralization assay and B-cell and T-cell responses by flow cytometry.

Naïve mice were immunized with a two-dose primary series of monovalent OMI BA.4/BA.5 vaccine, which elicited high neutralizing titers against Omicron sub-lineages BA.2, BA.2.12.1, and BA.4/BA.5 after two

<div style=\"page-break-after: always\"></div>

doses, but reduced neutralization against the Wuhan pseudovirus and the Omicron BA.1 sub-lineage. The bivalent Omicron BA.4/BA.5 vaccine (combination of BNT162b2 and BNT162b2 Omicron BA.4/BA.5) elicited a greater breadth of neutralizing antibody responses against all variants and sub-lineages tested.

Immunization of BNT162b2-experienced Balb/c mice with either the monovalent or bivalent BA.4/BA.5 variant-modified vaccine as a third dose booster, one month after completion of the primary series, increased neutralizing antibody responses against the Wuhan reference, the Delta variant and Omicron BA.1, BA.2, BA.2.12.1 and BA.4/BA.5 sub-lineages. In the monovalent group, Wuhan, Omicron BA.1, BA.2 and BA.4/BA.5 neutralizing titers increased by 2, 2, 17, and 45-fold, respectively, at 7 days post booster compared to 1 month post BNT162b2 Dose 2. At 1 month post-third dose boost, the difference, as compared to 1 month post BNT162b2 Dose 2, was 4, 7, 36, and 94-fold for Wuhan, Omicron BA.1, BA.2 and BA.4/BA.5, respectively.

In the bivalent group, Wuhan, Omicron BA.1, BA.2, and BA.4/BA.5 neutralizing titers increased by 3, 3, 11, and 22-fold, respectively, 7 days post booster compared to 1 month post BNT162b2 Dose 2 and 3, 6, 17, and 66-fold, respectively, 1 month post booster compared to 1 month post BNT162b2 Dose 2. A broad response against Omicron sub-lineages was achieved with both monovalent (BNT162b2 BA.4/BA.5) and bivalent (BNT162b2 + BNT162b2 BA.4/BA.5) formulations. The monovalent BA.4/BA.5 formulation elicited slightly higher Omicron-specific neutralizing titers compared to the bivalent BA.4/BA.5 formulation.

In BNT162b2-experienced mice, both monovalent and bivalent vaccines administered as a third dose booster elicited a high frequency of total spike-specific B cells against any variant or sublineage with the greatest proportion of the response to Omicron BA.4-antigen. Slightly more cross-reactive B cells were observed with the bivalent BNT162b2+Omicron BA.4/BA.5 vaccine compared to the monovalent Omicron BA.4/BA.5 vaccine. Both monovalent Omicron BA.4/BA.5 and bivalent BNT162b2+Omicron BA.4/BA.5 vaccines induced predominantly Omicron BA.4 strain-specific Spike+ B cells compared to a low frequency of WT or Omicron BA.1 Spike+ B cells.

The magnitude of spike-specific T-cell responses induced by both monovalent and bivalent vaccines was similar. Notably, the magnitude of the T-cell response did not change based on the peptide pool (WT vs Omicron BA.4/BA.5), confirming that the variant- and sub-lineage specific mutations have minimal impact on the polyclonal T-cell response.

Overall, two doses of the monovalent BA.4/BA.5 variant-modified vaccine elicited strong neutralizing antibody responses against Omicron BA.2, BA.2.12.1, and BA.4/BA.5 sub-lineages but reduced neutralizing activity against the Wuhan and BA.1. The bivalent formulation induced a broader immune response against all strains tested. In BNT162b2 experienced mice, BA.4/BA.5 variant-modified vaccines induced robust and broad neutralizing antibody responses against the Wuhan reference and Omicron BA.1, BA.2, BA.2.12, and BA.4/BA.5 sub-lineages as well as a strong spike-specific B-cell and T-cell response when administered as a third dose booster.

## 2.5.3. Pharmacokinetics

There are no new pharmacokinetics studies for this application. The pharmacokinetics program supporting the original MAA for BNT162b2 is fully supporting the current extension application.

<div style=\"page-break-after: always\"></div>

## 2.5.4. Toxicology

There are no new toxicology studies for this application. The toxicology program supporting the original MAA for BNT162b2 is fully supporting the current extension application.

## 2.5.5. Ecotoxicity/environmental risk assessment

In accordance with the CHMP Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use (EMEA/CHMP/SWP/4447100 Corr 2), due to their nature, vaccines and lipids are unlikely to result in a significant risk to the environment. Therefore, an environmental risk assessment is not provided in this Application.

## 2.5.6. Discussion on non-clinical aspects

To support the use of the bivalent Original/Omicron BA4/BA5 variant vaccine, the MAH has provided data from studies in mice. Compared to the original vaccine, the bivalent Omicron BA.4/BA.5 vaccine (combination of BNT162b2 and BNT162b2 Omicron BA.4/BA.5) elicited a greater breadth of neutralizing antibody responses against all variants and sub-lineages tested.

The magnitude and specificity of the T-cell response was similar with monovalent and bivalent vaccines.

Since the selection of B-cell repertoire activated by the vaccine is likely to be similar between mice and humans, these data are considered supportive for the use of the bivalent Original/Omicron BA4/BA5 vaccine for a primary vaccination.

## 2.5.7. Conclusion on the non-clinical aspects

The data from studies in mice with the Original/Omicron BA4/BA5 bivalent vaccine are considered supportive for the use of this vaccine for primary vaccination.

## 2.6. Clinical aspects

## 2.6.1. Introduction

## · Tabular overview of clinical studies

| Protocol No. Phase (Country)                                                  |
|-------------------------------------------------------------------------------|
| C4591048 Substudy B Group 2 Safety and Immunogenicity Phase 3 (United States) |
| C4591048 Substudy D Group 2 Safety and Immunogenicity Phase 3 (United States) |

<div style=\"page-break-after: always\"></div>

## 2.6.2. Clinical efficacy

## 2.6.2.1. Dose response studies

No data was submitted for dose-finding for Original/Omicron BA. 4-5 1.5/1.5 micrograms.

## 2.6.2.2. Main study

Overview of the master protocol of C4591048 investigating Comirnaty Original/Omicron BA4-5 in children. The results from substudy B are pivotal and from the substudy D are supportive for the current application.

<div style=\"page-break-after: always\"></div>

High-Level Overview ofSubstudies inMasterProtocol forBivalent BNT162b2

<!-- image -->

Table. Overview of C4591048 substudy B investigating Comirnaty Original/Omicron BA4-5 (1.5/1.5 µg) in children 6m-&lt;5yoa

| Protocol No. Phase (Country)                                            | Study Design and Objective(s) a                                                                                                                                                                                              | Vaccine Groups                                                                | No. of Participants                                                                           |
|-------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
| C4591048 SubstudyB Group 2 Safety Ad Hoc Report Phase 3 (United States) | Primary Objectives: Primary Safety (Safety Population): To describe the safety and tolerability profiles of prophylactic bivalent BNT162b2 given as a third and/or fourth dose in participants ≥6 months to <5 years of age. | Subset of Substudy B Group2(4 th dose) BNT162b2 Bivalent (WT/OMI BA.4-5) 3 µg | BNT162b2 Bivalent (WT/OMI BA.4-5) 3 µg ≥6 Months to <2 Years: N=24 ≥2 Years to <5 Years: N=36 |

<div style=\"page-break-after: always\"></div>

| C4591048 SubstudyB Group 2 Immunogenicity Ad Hoc Report Phase 3 (United States)   | Secondary Objective: Secondary Immunogenicity (Evaluable Immunogenicity Population): To describe the immune response elicited by bivalent BNT162b2 given as the third and/or fourth dose in participants ≥ 6 months <5 years of age.   | Subset of Substudy B(4 th Dose) Group 2 BNT162b2 Bivalent(WT/OMI BA.4- .5) 3 µg Study C4591007 Subset of Participants Original BNT162b2 3 μg (3 rd dose)   | BNT162b2 Bivalent (WT/OMI BA.4-5) 3 µg ≥6 Months to <2 Years: N=23 ≥2 Years to <5 Years: N=35 Original BNT162b2 3 μg ≥6 Months to <2 Years: N=23 ≥2 Years to <5 Years: N=31   |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.6.2.2.1. Study C4591048 Substudy B

## Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate in Healthy Children

This study includes evaluation of the safety, tolerability, and immunogenicity of third and fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) vaccine in individuals ≥6 months to &lt;4 years and 6 months (Group 1) and fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) vaccine in ≥6 months to &lt;5 years of age (Group 2 and Group 3 [safety only]).

This report presents 1-month post dose descriptive immunogenicity data, as of the data cut-off date of 25 November 2022, for a subset of 60 participants in Group 2 of C4591048 Substudy B (the first 24 and 36 part icipants enrolled in ≥6 months to &lt;2 years age group and ≥2 years to &lt;5 years age group, respectively) who received a fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at the 3 μ g dose level after receiving 3 prior doses of BNT162b2 at 3 μ g.

Results include also data, as of the data cut-off date of 07 August 2022, from a comparator subset of 60 participants ≥6 months to &lt;5 years of age (24 and 36 participants ≥6 months to &lt;2 years of age and ≥2 years to &lt;5 years of age, respectively) in Study C4591007 who received 3 doses of BNT162b2 at 3 μ g.

Table. Schema for C4591048 Substudy B, Group 2

Group2:3PriorDosesofBNT162b23μg60to240DaysPriortoEnrollment

|                                                                                    | VisitNumber VisitDescription   | B201 FourthDoseVaccinationVisit   | B202 1-MonthFollow-UpVisitAfter FourthDose   | B203 6-MonthFollow-UpVisitAfter FourthDose   |
|------------------------------------------------------------------------------------|--------------------------------|-----------------------------------|----------------------------------------------|----------------------------------------------|
| Participantshavingreceived 3priordosesofBNT162b2 3μg60to240daysprior to enrollment | Nasalswab                      | BivalentBNT162b23μg X 5mL         |                                              |                                              |
| Participantshavingreceived 3priordosesofBNT162b2 3μg60to240daysprior to enrollment | Blooddrawfor immunogenicity    |                                   | 5mL                                          |                                              |

## Methods

Approximately 300 participants in Group 2, ≥6 months to &lt;5 years of age, who have received 3 prior doses of BNT162b2 3 μ g, with their last dose 60 to 240 days prior to enrolment, will receive 1 dose (fourth) of bivalent BNT162b2 (Original/Omi BA.4/BA.5) 3 μ g.

Enrolment of Group 2 will be stratified by age, such that approximately 30% of participants will be ≥6 months to &lt;2 years of age and approxi mately 70% of participants will be ≥2 years to &lt;5 years of age.

## · Study Participants

Included are male or female participants who are ≥6 months to &lt;5 years of age at the time of enrolment, and who have received 3 prior doses of BNT162b2 3 μ g, with the last dose 60 to 240 days before enrolment.

## Excluded are subjects, who have

<div style=\"page-break-after: always\"></div>

1. Receipt of medications intended to prevent COVID-19.
2. Previous or current diagnosis of MIS-C.
3. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
4. Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
5. Individuals with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic lupus erythematosus. Note: Stable type 1 diabetes and hypothyroidism are permitted.
6. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
7. Other medical or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
8. Prior receipt of any COVID-19 vaccine other than BNT162b2.
9. Receipt of systemic treatment with known immunosuppressant medication (including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease) or radiotherapy, within 60 days before enrollment through the conclusion of the study.
10. Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies (except palivizumab), from 60 days before study intervention administration, or receipt of any passive antibody therapy specific to COVID-19 from 90 days before study intervention administration, or planned receipt throughout the study.
11. Receipt of other study intervention within 28 days prior to study entry through and including 28 days after the dose of study intervention, with the exception of non-Pfizer interventional studies
12. Participants who are direct descendants (child or grandchild) of investigational site staff members or Pfizer/BioNTech and Pfizer/BioNTech delegate employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.

## · Treatments

Bivalent BNT162b2 (Original/Omi BA.4\\_5) at 3 μ g (1.5/1.5 μ g of each) (C4591048 Substudy B) or Original 3 μ g (Study C4591007).

## · Objectives

<!-- image -->

## · Outcomes/endpoints

<div style=\"page-break-after: always\"></div>

Secondary immunogenicity:

- SARS-CoV-2 Omicron BA4-5 and Reference strain neutralizing titers (GMT)

## · Sample size

Approximately 300 participants in Group 2, ≥6 months to &lt;5 years of age, who have received 3 prior doses of BNT162b2 at 3 μ g, with their last dose 60 to 240 days prior to enrolment, will receive 1 dose (fourth) of the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 3 μ g.

For the final immunogenicity assessment, a subset of approximately 240 participants will be selected from 300 participants in Group 2 who received 3 prior doses of BNT162b2 3 μ g and a fourth dose of bivalent BNT162b2, and approximately 240 participants will be selected from participants receiving 3 doses of BNT162b2 3 μ g from the C4591007 study. Assuming a 25% non-evaluable rate, approximately 180 evaluable participants in each arm will contribute to the immunogenicity evaluation. Each hypothesis test will be performed at a 1-sided alpha level of 0.025 as described in Statistical Methods.

In current analysis, the immunogenicity of bivalent vaccine in 60 subjects 6m-5yoa is descriptive and no hypothesis testing will be performed.

## · Randomisation and blinding (masking)

Substudy B is an open-label study to evaluate the safety, tolerability, and immunogenicity of a third or fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 3 μ g.

Enrolment of Group 2 will be stratified by age, su ch that approximately 30% of participants will be ≥6 months to &lt;2 years of age and approximately 70% of participants will be ≥2 years to &lt;5 years of age.

## · Statistical methods

Descriptive immunogenicity analyses were performed to characterize Omicron BA.4/BA.5 and reference strain neutralization responses following a fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) or 3 doses of BNT162b2 each at 3 μ g. The SARS-CoV-2 neutralization assay was used to determine Omicron BA.4/BA.5- and reference strain-specific neutralizing titers.

GMTs and GMFRs with 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and fold rises, respectively, and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Seroresponse was defined as achieving a ≥4 -fold rise from baseline (before the first study vaccination [fourth dose]) for participants. If the baseline measurement was below the LLOQ, the postvaccination measure of ≥4 × LLOQ was considered seroresponse. The exact 2-sided 95% CIs for percentages of participants with seroresponse was calculated using the Clopper-Pearson method.

<div style=\"page-break-after: always\"></div>

## Analysis Sets

| Population                             | Description                                                                                                                                                                                                                                                                                                                                                                                                                       |
|----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Evaluable immunogenicity (third dose)  | All eligible participants in Group 1 who receive the first study intervention as the third dose to which they are assigned, have at least 1 valid and determinate immunogenicity result from the blood sample collected within an appropriate window after the third dose, and have no other important protocol deviations as determined by the clinician.                                                                        |
| Evaluable immunogenicity (fourth dose) | All eligible participants who receive 2 doses of study intervention as the third and fourth dose (Group 1) or receive the study intervention as the fourth dose (Group 2) to which they are assigned, have at least 1 valid and determinate immunogenicity result from the blood sample collected within an appropriate window after fourth dose, and have no other important protocol deviations as determined by the clinician. |
| All-available immunogenicity           | All randomized participants who receive at least 1 dose of the study intervention with at least 1 valid and determinate immunogenicity result after vaccination.                                                                                                                                                                                                                                                                  |

## Results

Available immunogenicity data are summarized below for the subset of 60 participants in Group 2 of Substudy B (as of the cut-off date of 25 November 2022) and a comparator subset of 60 participants from Study C4591007 (as of the cut-off date of 07 August 2022).

<div style=\"page-break-after: always\"></div>

## · Participant flow

Immunogenicity Populations-C4591048 Subset of Substudy B Group 2and Study C4591007 Phase 2/3 Participants -≥6 Months to &lt;5 Years of Age

|                                                                                                                       | Vaccine Group (as Assigned/Randomized)                | Vaccine Group (as Assigned/Randomized)                | Vaccine Group (as Assigned/Randomized)                | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |
|-----------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                                                                       | C4591048 BivalentBNT162b2(Origina/Omi BA.4/BA.5) 3 μg | C4591048 BivalentBNT162b2(Origina/Omi BA.4/BA.5) 3 μg | C4591048 BivalentBNT162b2(Origina/Omi BA.4/BA.5) 3 μg | C4591007 BNT162b23μg                     | C4591007 BNT162b23μg                     | C4591007 BNT162b23μg                     |
|                                                                                                                       | ≥6 Months to <2 Year's (%) eI                         | Year's n (%)                                          | ≥6 Months to <5≥6 Months to Year's na (%)             | <2 Years (%) ell                         | Year's (%) elI                           | ≥6 Months to <5 Year's n (%)             |
| Assigned/Randomizedb                                                                                                  | 24                                                    | 36                                                    | 60                                                    | 24                                       | 36                                       | 60                                       |
| Dose 4 (C4591048)/Dose 3 (C4591007) all-available immunogenicity population                                           | 23 (95.8)                                             | 35 (97.2)                                             | 58 (96.7)                                             | 24 (100.0)                               | 36 (100.0)                               | 60 (100.0)                               |
| Excluded fromDose 4(C4591048)/Dose3(C4591007) all-available immunogenicitypopulation                                  | 1 (4.2)                                               | 1 (2.8)                                               | 2 (3.3)                                               | 0                                        | 0                                        | 0                                        |
| Reasonfor exclusion                                                                                                   |                                                       |                                                       |                                                       |                                          |                                          |                                          |
| Did not have at least 1 valid and determinate immunogenicity result after Dose 4 (C4591048)/Dose3 (C4591007)          | 1 (4.2)                                               | 1 (2.8)                                               | 2 (3.3)                                               | 0                                        | 0                                        | 0                                        |
| Dose 4(C4591048)/Dose3(C4591007)evaluable immunogenicity population                                                   | 23 (95.8)                                             | 35 (97.2)                                             | 58 (96.7)                                             | 23 (95.8)                                | 31 (86.1)                                | 54 (90.0)                                |
| Participants without evidence of infection up to 1 month after Dose 4 (C4591048)/Dose3 (C4591007)c                    | 12 (50.0)                                             | 26 (72.2)                                             | 38 (63.3)                                             | 13 (54.2)                                | 21 (58.3)                                | 34 (56.7)                                |
| Excluded fromDose 4(C4591048)/Dose3(C4591007) evaluable immunogenicity population                                     | 1 (4.2)                                               | 1 (2.8)                                               | 2 (3.3)                                               | 1 (4.2)                                  | 5 (13.9)                                 | 6 (10.0)                                 |
| Reason for exclusiond                                                                                                 |                                                       |                                                       |                                                       |                                          |                                          |                                          |
| Didnothaveatleast1valid anddeterminateimmunogenicityresult within 28-42 days after Dose 4(C4591048)/Dose 3 (C4591007) | 1 (4.2)                                               | 1 (2.8)                                               | 2 (3.3)                                               | 1 (4.2)                                  | 5 (13.9)                                 | 6 (10.0)                                 |
| 1-Month post-Dose 4(C4591048)/post-Dose 3 (C4591007)blood draw outside of window (28-42 days afterDose 4/Dose 3)      | 1 (4.2)                                               | 1 (2.8)                                               | 2 (3.3)                                               | 1 (4.2)                                  | 5 (13.9)                                 | 6 (10.0)                                 |

Note:SubstudyBGroup2includesparticipants≥6monthsto&lt;5yearsof agewhoreceived3dosesof BNT162b23pg60to240dayspriortoenrollment.

a. n=number ofparticipantswith the specified characteristic

b. This value is the denominator for the percentage calculations.

C. blood sample collection. Having no evidence of past SARS-CoV-2 infection up to 1-month post-Dose 4 for C4591048 participants was defined as having a negative N-binding antibody[serum]result at Dose 4visit and1-month post-Dose 4visit; a negativeNAAT[nasal swab]result at Dose 4visit,and anyunscheduledvisit

3 for C4591007 participants was defined as having a negative N-binding antibody [serum] result at the Dose 1, 1-month post-Dose 2 (if available), Dose 3, and up to the1-monthpost-Dose 4 bloodsample collection; and had no medicalhistory of COVID-19.Havingno evidence ofpast SARS-CoV-2infectionup to1-month post-Dose

1-month post-Dose 3visits; a negative NAAT [nasal swab]result at the Dose1, Dose 2,and Dose 3visits and anyunscheduled visitup to the 1-month post-Dose3blood sample collection; andnomedical history of COVID-19.

d.Participants mayhave been excludedformore than1 reason.

PFIZERCONFIDENTIALSourceData:ads1TableGeneration:11JAN2023(00:42)

(Data cutoff date: C4591048 SubstudyB[25NOV2022]/C4591007[07AUG2022])

OutputFile:./nda2\\_ubped2/C4591048\\_B\\_1MPD\\_Group2\\_1007\\_IMM/adva\\_s008\\_p2\\_6m5y

## · Recruitment

The study intends to recruit 300 participants. In current analysis, the first 60 subjects are analysed. The original protocol is signed for 19 August 2022. The cut-off date for data was 25 November 2022.

## · Conduct of the study

The protocol has been amended twice until now.

| Document          | VersionDate   |
|-------------------|---------------|
| Amendment 2       | 18 Nov 2022   |
| Amendment 1       | 21 0ct 2022   |
| Original protocol | 19 Aug 2022   |

<div style=\"page-break-after: always\"></div>

The amendment 2 targeted Substudy C. Protocol amendment 1 is in response to the FDA feedback received on 23 Sep 2022. This feedback requested changes to generate more data on the bivalent vaccine. The substudy B was amended by increased sample size, updated and added objectives, estimands and endpoints to study superiority of the bivalent vaccine compared to the original vaccine in sense of inducing immune response against Omicron BA.4-5 strain and induction of non-inferior level of antibodies against reference strain.

## · Baseline data

Table 1 Demographic Characteristics - Participants with or without evidence of infection - C4591048 subset of Substudy B Group 2 and Study C4591007 Phase 2/3 Participants ≥6 months to &lt;5 years of age -Evaluable immunogenicity population

|                                                                                    | Vaccine Group (as Assigned/Randomized)                 | Vaccine Group (as Assigned/Randomized)                 | Vaccine Group (as Assigned/Randomized)                 | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |
|------------------------------------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                                    | C4591048 Bivalent BNT162b2(Original/Omi BA.4/BA.5)3 μg | C4591048 Bivalent BNT162b2(Original/Omi BA.4/BA.5)3 μg | C4591048 Bivalent BNT162b2(Original/Omi BA.4/BA.5)3 μg | C4591007 BNT162b23μg                     | C4591007 BNT162b23μg                     | C4591007 BNT162b23μg                     |
|                                                                                    | ≥6 Months to <2 Years (N=23)                           | ≥2to<5 Years (N=35) (%) q                              | ≥6 Monthsto<5 Years (N\"=58) (%) q                      | ≥6 Months to <2 Year's (N=23) (%) q      | ≥2to<5 Years (N\"=31) (%) q               | ≥6 Months to <5 Years (N=54)             |
|                                                                                    |                                                        |                                                        |                                                        |                                          |                                          | (%) q                                    |
|                                                                                    | (%) q                                                  |                                                        |                                                        |                                          |                                          |                                          |
| Sex                                                                                |                                                        |                                                        |                                                        |                                          |                                          |                                          |
| Male                                                                               | 9 (39.1)                                               | 20 (57.1)                                              | 29 (50.0)                                              | 14 (60.9)                                | 14 (45.2)                                | 28 (51.9)                                |
| Female                                                                             | 14 (60.9)                                              | 15 (42.9)                                              | 29 (50.0)                                              | 9 (39.1)                                 | 17 (54.8)                                | 26 (48.1)                                |
| Race                                                                               |                                                        |                                                        |                                                        |                                          |                                          |                                          |
| White                                                                              | 13 (56.5)                                              | 21 (60.0)                                              | 34 (58.6)                                              | 19 (82.6)                                | 26 (83.9)                                | 45 (83.3)                                |
| Black or African American                                                          | 1 (4.3)                                                | 2 (5.7)                                                | 3 (5.2)                                                | 1 (4.3)                                  | 0                                        | 1 (1.9)                                  |
| Asian                                                                              | 5 (21.7)                                               | 4 (11.4)                                               | 9 (15.5)                                               | 1 (4.3)                                  | 2 (6.5)                                  | 3 (5.6)                                  |
| Multiracial                                                                        | 4 (17.4)                                               | 8 (22.9)                                               | 12 (20.7)                                              | 2 (8.7)                                  | 3 (9.7)                                  | 5 (9.3)                                  |
| Ethnicity                                                                          |                                                        |                                                        |                                                        |                                          |                                          |                                          |
| Hispanic/Latino                                                                    | 4 (17.4)                                               | 11 (31.4)                                              | 15 (25.9)                                              | 2 (8.7)                                  | 4 (12.9)                                 | 6 (11.1)                                 |
| Non-Hispanic/non-Latino                                                            | 19 (82.6)                                              | 24 (68.6)                                              | 43 (74.1)                                              | 21 (91.3)                                | 27 (87.1)                                | 48 (88.9)                                |
| Age at the Dose 4 (C4591048)/Dose 3 (C4591007) (months/years%)                     |                                                        |                                                        |                                                        |                                          |                                          |                                          |
| Mean (SD)                                                                          | 18.6 (3.65)                                            | 2.6 (0.77)                                             | N/A                                                    | 18.3 (3.27)                              | 2.6 (0.75)                               | N/A                                      |
| Median                                                                             | 19.0                                                   | 2.0                                                    | N/A                                                    | 19.0                                     | 2.0                                      | N/A                                      |
| Min, max                                                                           | (12, 23)                                               | (2,4)                                                  | N/A                                                    | (12,23)                                  | (2.4)                                    | N/A                                      |
| Time (monthsd) from last prior BNT162b2 dose to Dose 4 (C4591048)/Dose3 (C4591007) |                                                        |                                                        |                                                        |                                          |                                          |                                          |
| n                                                                                  | 23                                                     | 35                                                     | 58                                                     | 23                                       | 31                                       | 54                                       |
| Mean (SD)                                                                          | 5.9 (2.02)                                             | 6.8 (1.76)                                             | 6.5 (1.90)                                             | 6.2 (1.82)                               | 6.8 (1.89)                               | 6.6 (1.87)                               |
| Median                                                                             | 6.5                                                    | 7.0                                                    | 6.9                                                    | 6.6                                      | 7.1                                      | 6.9                                      |
| Min, max                                                                           | (2.1, 8.6)                                             | (2.2, 8.5)                                             | (2.1, 8.6)                                             | (2.3, 8.8)                               | (2.2, 9.1)                               | (2.2, 9.1)                               |
| ≥2 to <3 Months                                                                    | 3 (13.0)                                               | 3 (8.6)                                                | 6 (10.3)                                               | 2 (8.7)                                  | 3 (9.7)                                  | 5 (9.3)                                  |
| ≥3 to<4 Months                                                                     | 1 (4.3)                                                | 0                                                      | 1(1.7)                                                 | 0                                        | 2 (6.5)                                  | 2 (3.7)                                  |
| ≥4 to <5 Months                                                                    | 3 (13.0)                                               | 2 (5.7)                                                | 5 (8.6)                                                | 3 (13.0)                                 | 0                                        | 3 (5.6)                                  |
| ≥5 to <6 Months                                                                    | 3 (13.0)                                               | 2 (5.7)                                                | 5 (8.6)                                                | 4 (17.4)                                 | 0                                        | 4 (7.4)                                  |
| ≥6 to <7 Months                                                                    | 6 (26.1)                                               | 10 (28.6)                                              | 16 (27.6)                                              | 7 (30.4)                                 | 6 (19.4)                                 | 13 (24.1)                                |
| ≥7 to <8 Months                                                                    | 1 (4.3)                                                | 7 (20.0)                                               | 8 (13.8)                                               | 2 (8.7)                                  | 10 (32.3)                                | 12 (22.2)                                |
| ≥8 to <9 Months                                                                    | 6 (26.1)                                               | 11 (31.4)                                              | 17 (29.3)                                              | 5 (21.7)                                 | 8 (25.8)                                 | 13 (24.1)                                |
| ≥9 Months                                                                          | 0                                                      | 0                                                      | 0                                                      | 0                                        | 2 (6.5)                                  | 2 (3.7)                                  |
| Time (days) from last prior BNT162b2 dose to Dose 4 (C4591048)/Dose3(C4591007)     |                                                        |                                                        |                                                        |                                          |                                          |                                          |
| n                                                                                  | 23                                                     | 35                                                     | 58                                                     | 23                                       | 31                                       | 54                                       |
| Mean (SD)                                                                          | 166.6 (56.68)                                          | 190.4 (49.34)                                          | 180.9 (53.20)                                          | 174.4 (50.93)                            | 191.6 (52.99)                            | 184.3 (52.35)                            |

<div style=\"page-break-after: always\"></div>

| Median                                                     | 181.0      | 196.0      | 193.5      | 184.0      | 200.0      | 194.0      |
|------------------------------------------------------------|------------|------------|------------|------------|------------|------------|
| Min, max                                                   | (60, 240)  | (62,239)   | (60, 240)  | (63, 246)  | (62,254)   | (62, 254)  |
| 60-240Days                                                 | 23 (100.0) | 35 (100.0) | 58 (100.0) | 22 (95.7)  | 28 (90.3)  | 50 (92.6)  |
| >240 Days                                                  | 0          | 0          | 0          | 1 (4.3)    | 3 (9.7)    | 4 (7.4)    |
| Baseline(Dose 4 C4591048/Dose3 C4591007) SARS-CoV-2 status |            |            |            |            |            |            |
| Positivee                                                  | 9 (39.1)   | 7 (20.0)   | 16 (27.6)  | 9 (39.1)   | 6 (19.4)   | 15 (27.8)  |
| Negativef                                                  | 13 (56.5)  | 28 (80.0)  | 41 (70.7)  | 13 (56.5)  | 23 (74.2)  | 36 (66.7)  |
| Missing                                                    | 1 (4.3)    | 0          | 1 (1.7)    | 1 (4.3)    | 2 (6.5)    | 3 (5.6)    |
| Comorbiditiess                                             |            |            |            |            |            |            |
| Yes                                                        | 1 (4.3)    | 4 (11.4)   | 5 (8.6)    | 0          | 0          | 0          |
| No                                                         | 22 (95.7)  | 31 (88.6)  | 53 (91.4)  | 23 (100.0) | 31 (100.0) | 54 (100.0) |

Abbreviations:BMI =body mass index;N/A =not applicable;NAAT =nucleic acid amplification test; N-binding=SARS-CoV-2 nucleoprotein-binding;SARS-CoV-2 = severe acute respiratory syndromecoronavirus 2.

a. N = number of participants in the specified group. This value is the denominator for the percentage calculations.

Note: Subset of Substudy B Group 2 includes the first 24 and 36 participants enrolled in ≥6 months to &lt;2 years age group and ≥2 years to &lt;5 years age group, respectively. Note:SubstudyBGroup2includesparticipants≥6monthsto&lt;5yearsof agewhoreceived3dosesof BNT162b23μg60to240dayspriortoenrollment.

b. n=Number of participantswith the specified characteristic.

C

'P Monthwas calculated as28 days.

- s

For C4591048SubstudyBGroup2:positive N-binding antibody result at Dose4visit,positiveNAATresult at Dose 4visit,or medical history of COVID-19.For C4591007: positive N-binding antibody result at Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visits, positive NAAT result at Dose 1, Dose 2, Dose 3, or any unscheduled illness visit up to Dose 3 visit, or medical history of COVID-19.

fFor C4591048 Substudy B Group 2: negative N-binding antibody result at Dose 4 visit, negative NAAT result at Dose 4 visit, and no medical history of COVID-19. For C4591007: negative N-binding antibody result at Dose 1, 1-moth post-Dose 2 (if available), and Dose 3 visits, negative NAAT result at Dose 1, Dose 2, Dose 3,and any unscheduled illness visits up toDose3visit, andno medicalhistory of COVID-19.

g.Number of participants who have 1 or more comorbidities that increase the risk of severe COVID-19: defined as participants who had at least 1 of the prespecified comorbidities based onMMWR MorbMortalWklyRep.2020;69(32):1081-8 and/or obesity(BMI≥95th percentile)forparticipants of≥2years to&lt;5years.Comorbidities were assessed at thefirststudyvisitforbothstudies. PFIZER CONFIDENTIAL Source Data: ads1 Table Generation: 11JAN2023 (01:01)

OutputFile:./nda2ubped2/C4591048B1MPDGroup21007IMM/ads1s005demop2ev1wt

(Data cutoff date: C4591048Substudy B[25NOV2022]/C4591007[07AUG2022])

## · Numbers analysed

| Numbers analysed                                       |   6m-<2 yoa |   2 to 5 yoa |   Total 6m-5y |
|--------------------------------------------------------|-------------|--------------|---------------|
| Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 1.5/1.5 μ g |          23 |           35 |            58 |
| C4591007 Original 3 μ g                                |          23 |           31 |            54 |

## · Outcomes and estimation

## Geometric Mean Titers

Omicron BA.4/BA.5 Neutralization

## Participants without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of infection, the GMTs against the Omicron BA.4/BA.5 variant were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group (prevaccination, 86.6; post dose, 1146.6) compared with that in the BNT162b2 group (prevaccination, 37.5; post dose, 401.3) at prevaccination and more substantially at 1month post dose ( Table 3 ). Among participants ≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age, a similar trend as above was observed ( Table 2 ).

## Participants with or without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of infection, the GMTs at prevaccination and 1-month post dose were higher in participants

<div style=\"page-break-after: always\"></div>

who had evidence of prior SARS-CoV-2 infection (baseline positive) compared with those without evidence of prior SARS-CoV-2 infection (baseline negative) in both vaccine groups ( Table 2 ).

Within both baseline positive and baseline negative groups, the GMTs against the Omicron BA.4/BA.5 variant were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with that in the BNT162b2 group at prevaccination and more substantially at 1-month post dose ( Table 3 ). The similar trend was also observed among participants ≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age ( Table 2 ).

## Reference Strain Neutralization

## Participants without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity p opulation without evidence of infection, the GMTs against the reference strain were higher at prevaccination and similar at 1month post dose in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group (prevaccination, 2090.1 and post dose, 9253.1) compared with that in the BNT162b2 group (prevaccination, 412.6 and post dose, 8341.2) ( Table 2 ). The similar trend was also observed among participants ≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age ( Table 2 ).

## Participants with or without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogen icity population with or without evidence of infection, similar to Omicron BA.4/BA.5 neutralizing GMTS, reference strain GMTs at prevaccination and 1-month post dose were higher in participants who were baseline positive compared with those who were baseline negative in both vaccine groups ( Table 2 ).

Within both the baseline positive and negative groups, the observed GMTs against the reference strain were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with that in the BNT162b2 group at prevaccination ( Table 2 ). At 1-month post dose, the observed GMTs were lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with that in the BNT162b2 group within the baseline positive group; within the baseline negative group, the observed GMTs were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and the BNT162b2 groups.

A similar trend was also observed within the baseline positive and baseline negative groups among participants ≥2 to &lt;5 years of age and within the baseline negative group among participants ≥6 months to &lt;2 years of age ( Table 2 ).

Within the baseline positive group among participants ≥6 months to &lt;2 years of age, the GMTs against the reference strain were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups at prevaccination ( Table 2 ). At 1-month post dose, the trend was similar to that observed within baseline positive groups among participants ≥6 months to &lt;5 years of age and ≥2 to &lt;5 years of age discussed above.

<div style=\"page-break-after: always\"></div>

Table 2. Geometric Mean Titers, by Baseline (Dose 4 C4591048/Dose 3 C4591007) SARS-CoV-2 Status C4591048 Subset of Substudy B Group 2 (at Dose 4 and 1 month after dose 4) and C4591007 Phase 2/3 Participants (at Dose 3 and 1 month after dose 3) - Participants with or without evidence of infection ≥6 months to &lt;5 years of age - evaluable immunogenicity population

|                                                                 |                                |                                                             |                      | VaccineGroup(asAssigned/Randomized)                     | VaccineGroup(asAssigned/Randomized)                     | VaccineGroup(asAssigned/Randomized)   | VaccineGroup(asAssigned/Randomized)   |
|-----------------------------------------------------------------|--------------------------------|-------------------------------------------------------------|----------------------|---------------------------------------------------------|---------------------------------------------------------|---------------------------------------|---------------------------------------|
|                                                                 |                                |                                                             |                      | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 3 μg | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 3 μg | C4591007 BNT162b23μg                  | C4591007 BNT162b23μg                  |
| Assay                                                           | Age Group                      | Baseline(Dose4C4591048/ Dose 3 C4591007) SARS-CoV- 2 status | Sampling Time Pointa | nb                                                      | GMTc (I0 %56)                                           | nb                                    | GMTc (10 %56)                         |
| SARS-CoV-2neutralization assay -Omicron BA.4/BA.5 -NT50 (titer) | ≥6 Months to <5  Overall Years |                                                             | Prevax               | 54                                                      | 192.5 (120.4, 307.8)                                    | 54                                    | 70.5 (51.1, 97.2)                     |
|                                                                 |                                |                                                             | 1 Month              | 58                                                      | 1695.2 (1151.8, 2494.9)                                 | 54                                    | 607.9 (431.1, 857.2)                  |
|                                                                 |                                | Positived                                                   | Prevax               | 16                                                      | 1315.4 (789.1, 2192.8)                                  | 15                                    | 351.7 (195.2, 633.8)                  |
|                                                                 |                                |                                                             | 1 Month              | 16                                                      | 4897.7 (3085.5, 7774.1)                                 | 15                                    | 1785.9 (1009.4, 3159.9)               |
|                                                                 |                                | Negativee                                                   | Prevax               | 38                                                      | 85.7 (56.6, 129.8)                                      | 36                                    | 38.2 (34.2, 42.8)                     |
|                                                                 |                                |                                                             | 1 Month              | 41                                                      | 1116.0 (701.3,1776.1)                                   | 36                                    | 416.2 (287.8, 602.0)                  |
|                                                                 | ≥6 Months to <2 Overall Years  |                                                             | Prevax               | 21                                                      | 243.9 (115.3,516.1)                                     | 23                                    | 96.0 (55.3, 166.8)                    |
|                                                                 |                                |                                                             | 1 Month              | 23                                                      | 2011.4 (1141.3, 3544.9)                                 | 23                                    | 625.6 (365.7, 1070.5)                 |
|                                                                 |                                | Positived                                                   | Prevax               | 9                                                       | 1157.5 (653.8, 2049.2)                                  |                                       | 368.1 (189.1, 716.9)                  |
|                                                                 |                                |                                                             | 1 Month              | 9                                                       | 4978.7 (3844.4. 6447.8)                                 | 9                                     | 1378.6 (568.4.3343.3)                 |
|                                                                 |                                | Negativee                                                   | Prevax               | 12                                                      | 75.9 (39.5, 145.7)                                      | 13                                    | 40.9 (30.0, 55.7)                     |
|                                                                 |                                |                                                             | 1 Month              | 13                                                      | 1074.7 (454.2, 2543.0)                                  | 13                                    | 351.3 (186.4, 662.4)                  |
|                                                                 | ≥2 to <5 Years                 | Overall                                                     | Prevax               | 33                                                      | 165.6 (88.3, 310.5)                                     | 31                                    | 56.1 (38.0, 82.7)                     |
|                                                                 |                                |                                                             | 1 Month              | 35                                                      | 1514.9 (882.2,2601.5)                                   | 31                                    | 595.0 (370.5,955.6)                   |
|                                                                 |                                | Positived                                                   | Prevax               | 7                                                       | 1550.5 (498.2,4825.5)                                   | 6                                     | 328.4 (75.7, 1424.1)                  |
|                                                                 |                                |                                                             | 1 Month              | 7                                                       | 4795.4 (1421.9, 16172.9)                                | 6                                     | 2633.3 (1212.8, 5717.8)               |
|                                                                 |                                | Negativee                                                   | Prevax               | 26                                                      | 90.7 (52.1, 157.9)                                      | 23                                    | 36.8 (34.2, 39.6)                     |
|                                                                 |                                |                                                             | 1 Month              | 28                                                      | 1135.7 (630.3,2046.5)                                   | 23                                    | 458.1 (281.6, 745.1)                  |
| SARS-CoV-2neutralization assay-reference strain - NT50 (titer)  | ≥6 Months to<5Overall Years    |                                                             | Prevax               | 57                                                      | 2678.1 (1913.0, 3749.2)                                 | 53                                    | 776.8 (536.4, 1125.0)                 |
|                                                                 |                                |                                                             | 1 Month              | 58                                                      | 9733.0 (7708.2,12289.6)                                 | 53                                    | 9057.3 (7223.4,11356.8)               |
|                                                                 |                                | Positived                                                   | Prevax               | 16                                                      | 5692.3 (3206.9. 10103.6)                                | 15                                    | 3806.2 (2339.5.6192.4)                |

<div style=\"page-break-after: always\"></div>

|                                |           | 1 Month   |   16 | 10659.2 (6612.0, 17183.9)   |   15 | 13024.3 (8318.8, 20391.3)   |
|--------------------------------|-----------|-----------|------|-----------------------------|------|-----------------------------|
|                                | Negativee | Prevax    |   41 | 1995.4 (1355.6, 2937.2)     |   35 | 417.8 (302.7, 576.7)        |
|                                |           | 1 Month   |   41 | 9336.0 (7023.1,12410.5)     |   35 | 8131.1 (6238.2,10598.4)     |
| ≥6 Months to <2  Overall Years |           | Prevax    |   22 | 2491.2 (1432.0, 4333.8)     |   22 | 981.6 (503.5, 1913.7)       |
|                                |           | 1 Month   |   23 | 8737.2 (5959.6, 12809.5)    |   23 | 9221.7 (6734.0, 12628.3)    |
|                                | Positived | Prevax    |    9 | 4005.8 (1612.3, 9953.0)     |    9 | 4026.9 (2343.3, 6920.1)     |
|                                |           | 1 Month   |    9 | 8696.2 (4102.8,18432.5)     |    9 | 11589.2 (5807.3,23127.8)    |
|                                | Negativee | Prevax    |   13 | 1793.0 (853.7,3766.1)       |   12 | 363.8 (181.1, 730.8)        |
|                                |           | 1 Month   |   13 | 8525.7 (4988.2, 14572.1)    |   13 | 7751.6 (5407.5, 11111.9)    |
| ≥2 to <5 Years                 | Overall   | Prevax    |   35 | 2802.7 (1795.7,4374.3)      |   31 | 657.9 (421.5, 1026.9)       |
|                                |           | 1 Month   |   35 | 10448.3 (7685.1. 14205.1)   |   30 | 8933.3 (6388.0.12492.9)     |
|                                | Positived | Prevax    |    7 | 8942.8 (4352.3, 18374.9)    |    6 | 3497.6 (1031.2, 11863.2)    |
|                                |           | 1 Month   |    7 | 13847.7 (6795.9, 28216.6)   |    6 | 15516.7 (7495.6, 32121.4)   |
|                                | Negativee | Prevax    |   28 | 2097.0 (1295.2, 3395.0)     |   23 | 449.1 (309.5, 651.7)        |
|                                |           | 1 Month   |   28 | 9737.9 (6811.7, 13921.2)    |   22 | 8364.0 (5685.0, 12305.6)    |

## Geometric Mean Fold Rises

Omicron BA.4/BA.5 Neutralization

## Participants without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of infection, for the Omicron BA.4/BA.5 variant, the GMFRs were similar in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group (13.6 [95% CI: 8.4, 21.9]) compared with that in the BNT162b2 group (10.7 [95% CI: 7.3, 15.8]) at 1-month post dose ( Table 3 ).

Among participants ≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age, a similar trend as above was observed ( Table 3 ).

Participants with or without evidence of infection

<div style=\"page-break-after: always\"></div>

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of infection, the GMFRs at 1-month post dose were lower in participants who were baseline positive compared with those who were baseline negative in both vaccine groups ( Table 3

Within baseline positive and baseline negative groups, the GMFRs were similar in the bivalent BNT162b2 Original/Omi BA.4/BA.5 and BNT162b2 groups at 1-month post dose ( Table 3 ).

Among participants ≥6 months to &lt;2 years of age, the GMFRs were similar in the bivalent BNT162b2 Original/Omi BA.4/BA.5 and BNT162b2 groups at 1-month post dose within the baseline positive group; within the baseline negative group, the observed GMFRs were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with that in the BNT162b2 group ( Table 3 ). Among participants ≥2 to &lt;5 years of age, the observed GMFRs were lower in the bivalent BNT162b2 Original/Omi BA.4/BA.5 compared with the BNT162b2 group at 1-month post dose within the baseline positive group; within the baseline negative group, the GMFRs were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups.

## Reference Strain Neutralization

## Participants without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of infection, for the reference strain, the GMFRs were lower in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group (4.4 [95% CI: 3.1, 6.3]) compared with that in the BNT162b2 group (19.8 [95% CI: 13.4, 29.2]) at 1-month post dose ( Table 3 ). The lower GMFRs in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group were likely due to the much higher prevaccination titers in this group compared with the BNT162b2 group.

Among participants ≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age, a similar trend as above was observed ( Table 3 ).

## Participants with or without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable i mmunogenicity population with or without evidence of infection, the GMFRs at 1-month post dose were lower in participants who were baseline positive compared with those who were baseline negative in both vaccine groups (Table 3).

At 1-month post dose, within the baseline positive group, the observed GMFRs were slightly lower in the bivalent BNT162b2 Original/Omi BA.4/BA.5 compared with that in the BNT162b2 group ( Table 3 ). A similar trend was also observed in participants ≥2 to 5 years of age. For participants ≥6 months to &lt;2 years of age, the GMFRs were similar in the bivalent BNT162b2 Original/Omi BA.4/BA.5 and BNT162b2 groups.

Within the baseline negative group, among participants ≥6 months to &lt;5 years of age, the GMFRs were lower in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group compared with that in the BNT162b2 group (Table 3 ). A similar trend was also observed among participants ≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age.

<div style=\"page-break-after: always\"></div>

Table 3

GeometricMIeanFoldRises,byBaseline（Dose4 C4591048/Dose3 C4591007)SARS-CoV-2 Status-C4591048 Subset of Substudy B Group 2(From Dose 4 to1 MIonth After Dose 4) and C4591007 Phase 2/3 Participants （FromDose3 to 1 MonthAfterDose3)-ParticipantsWith orWithout EvidenceofInfection-≥6Months to&lt;5 Years of Age-EvaluableImmunogenicityPopulation

|                                                                 |                       |                                                         |                      | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |
|-----------------------------------------------------------------|-----------------------|---------------------------------------------------------|----------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                 |                       |                                                         |                      | C4591048 Bivalent BNT162b2 (Original/0mi BA.4/BA.5) 3 μg | C4591048 Bivalent BNT162b2 (Original/0mi BA.4/BA.5) 3 μg | C4591007 BNT162b2 3 μg                   | C4591007 BNT162b2 3 μg                   |
| Assay                                                           | Age Group             | Baseline(Dose4C4591048/ Dose3C4591007)SARS-CoV-2 status | Sampling Time Pointa | nb                                                       | GMIFRC (95% CI)                                          | nb                                       | GMFRC (95% CI)                           |
| SARS-CoV-2neutralization assay-Omicron BA.4/BA.5 - NT50 (titer) | ≥6 Months to <5 Years | Overall                                                 | 1 Month              | 54                                                       | 9.1 (6.3, 13.3)                                          | 54                                       | 8.6 (6.3, 11.7)                          |
|                                                                 |                       | Positived                                               | 1 Month              | 16                                                       | 3.7 (2.2, 6.2)                                           | 15                                       | 5.1 (2.8, 9.1)                           |
|                                                                 |                       | Negativee                                               | 1 Month              | 38                                                       | 13.3 (8.5, 20.7)                                         | 36                                       | 10.9 (7.5, 15.8)                         |
|                                                                 | ≥6 Months to <2 Years | Overall                                                 | 1 Month              | 21                                                       | 8.2 (4.8, 13.9)                                          | 23                                       | 6.5 (4.2,10.2)                           |
|                                                                 |                       | Positived                                               | 1Month               | 9                                                        | 4.3 (2.5, 7.4)                                           | 9                                        | 3.7 (2.1, 6.7)                           |
|                                                                 |                       | Negative?                                               | 1 Month              | 12                                                       | 13.4 (6.2, 29.0)                                         | 13                                       | 8.6 (4.6, 16.1)                          |
|                                                                 | ≥2 to <5 Years        | Overall                                                 | 1 Month              | 33                                                       | 9.7 (5.7, 16.6)                                          | 31                                       | 10.6 (6.9, 16.3)                         |
|                                                                 |                       | Positived                                               | 1Month               | 7                                                        | 3.1 (1.0, 10.0)                                          | 6                                        | 8.0 (1.9,33.0)                           |
|                                                                 |                       | Negative?                                               | 1 Month              | 26                                                       | 13.2 (7.4, 23.7)                                         | 23                                       | 12.5 (7.6, 20.3)                         |
| SARS-CoV-2neutralization assay-reference strain- NT50 (titer)   | ≥6Months to<5 Years   | Overall                                                 | 1 Month              | 57                                                       | 3.6 (2.7, 4.8)                                           | 52                                       | 11.4 (8.1, 16.1)                         |
|                                                                 |                       | Positived                                               | 1 Month              | 16                                                       | 1.9 (1.2, 2.8)                                           | 15                                       | 3.4 (2.1, 5.5)                           |
|                                                                 |                       | Negativee                                               | 1 Month              | 41                                                       | 4.7 (3.3, 6.6)                                           | 34                                       | 19.1 (13.2,27.5)                         |
|                                                                 | ≥6 Months to <2 Years | Overall                                                 | 1 Month              | 22                                                       | 3.5 (2.1, 5.7)                                           | 22                                       | 9.1 (5.1, 16.2)                          |
|                                                                 |                       | Positived                                               | 1 Month              | 9                                                        | 2.2 (1.2,3.9)                                            | 9                                        | 2.9 (2.0, 4.1)                           |
|                                                                 |                       | Negative?                                               | 1 Month              | 13                                                       | 4.8 (2.3, 10.0)                                          | 12                                       | 19.8 (9.8, 40.0)                         |
|                                                                 | ≥2 to <5 Years        | Overall                                                 | 1 Month              | 35                                                       | 3.7 (2.6, 5.4)                                           | 30                                       | 13.4 (8.6, 21.0)                         |
|                                                                 |                       | Positived Negativee                                     | 1 Month 1 Month      | 7 28                                                     | 1.5 (0.7,3.2) 4.6 (3.1, 7.0)                             | 6 22                                     | 4.4 (1.2, 16.3) 18.6 (11.7, 29.7)        |

<div style=\"page-break-after: always\"></div>

## Seroresponse rates

## Omicron BA.4/BA.5 Neutralization

## Participants without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of infection, 27 (77.1%) participants in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and 21 (61.8%) participants in the BNT162b2 group achieved seroresponse against the Omicron BA.4/BA.5 variant at 1-month post dose (Table 6).

Among participants ≥6 months to &lt;2 years of age, 9 (81.8%) and 6 (46.2%) pa rticipants in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and the BNT162b2 group, respectively, achieved seroresponse against the Omicron BA.4/BA.5 variant. A total of 18 (75.0%) and 15 (71.4%) participants ≥2 to &lt;5 years of age in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and the BNT162b2 group, respectively, achieved seroresponse against the Omicron BA.4/BA.5 variant.

## Participants with or without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunog enicity population with or without evidence of infection, within the baseline positive group, 9 (56.3%) participants in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and 9 (60.0%) participants in the BNT162b2 group achieved seroresponse against the Omicron BA.4/BA.5 variant at 1-month post dose ( Table 4 ). Within the baseline negative group, 29 (76.3%) and 23 (63.9%) participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group and BNT162b2 group, respectively, achieved seroresponse.

A mong participants ≥6 months to &lt;2 years of age and those ≥2 to &lt;5 years of age, the percentages of participants who achieved seroresponse are provided in Table 4 .

## Reference Strain Neutralization

## Participants without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of infection, 20 (52.6%) participants in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and 29 (90.6%) participants in the BNT162b2 group achieved seroresponse against the reference strain at 1month post dose (Table 6). The lower percentage of participants achieving seroresponse in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group was likely a reflection of the higher prevaccination titers in this group compared with the BNT162b2 group.

Among participants ≥6 months to &lt;2 years of age, 6 (50.0%) and 11 (91.7%) participants in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and the BNT162b2 group, respectively, achieved seroresponse against the reference strain. A total of 14 (53.8%) and 18 (90.0%) participants ≥2 to &lt;5 years of age in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and the BNT162b2 group, respectively, achieved seroresponse against the reference strain ( Table 4 ).

## Participants with or without evidence of infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of infection, the percentages of participants who achieved seroresponse were lower in the baseline positive group compared with those in the baseline negative group in both vaccine groups ( Table 4 ).

<div style=\"page-break-after: always\"></div>

Within the baseline positive group, 3 (18.8%) participants in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group and 5 (33.3%) participants in the BNT162b2 group achieved seroresponse against the reference strain at 1-month post dose ( Table 4 ). Within the baseline negative group, 22 (53.7%) and 31 (91.2%) participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group and BNT162b2 group, respectively, achieved seroresponse. The lower percentage of participants achieving seroresponse in the bivalent BNT162b2 Original/Omi BA.4/BA.5 group was likely a reflection of the higher prevaccination titers in this group compared with the BNT162b2 group.

Among participants ≥6 months to &lt;2 years of age and those ≥2 to &lt;5 years of age, the percentages of participants who achieved seroresponse are provided in Table 4 .

Table 4 Number (%o) of Participants With Seroresponse,by Baseline (Dose 4 C4591048/Dose 3 C4591007) SARS-CoV-2 Status-C4591048 Subset of Substudy B Group 2 (1 MIonth After Dose 4) and C4591007 Phase 2/3Participants (1 Month After Dose 3)-Participants With or Without Evidence of Infection-≥6 Months to &lt;5 Years of AgeEvaluableImmunogenicityPopulation

|                                                                   |                                |                                                              |                      | Vaccine Group (as Assigned/Randomized)                  | Vaccine Group (as Assigned/Randomized)                  | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |
|-------------------------------------------------------------------|--------------------------------|--------------------------------------------------------------|----------------------|---------------------------------------------------------|---------------------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                   |                                |                                                              |                      | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5)3 μg | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5)3 μg | C4591007 BNT162b2 3 μg                   | C4591007 BNT162b2 3 μg                   |
| Assay                                                             | Age Group                      | Baseline (Dose 4 C4591048/ Dose3 C4591007)SARS-CoV- 2 status | Sampling Time Pointa | Nb                                                      | (%) ⅡI (95% CId)                                        | Nb                                       | n (%) (95% CI)                           |
| SARS-CoV-2 neutralization assay -Omicron BA.4/BA.5 - NT50 (titer) | ≥6 Months to <5  Overall Years |                                                              | 1 Month              | 54                                                      | 38 (70.4) (56.4, 82.0)                                  | 54                                       | 33 (61.1) (46.9, 74.1)                   |
|                                                                   |                                | Positivee                                                    | 1 Month              | 16                                                      | 9 (56.3) (29.9, 80.2)                                   | 15                                       | 9 (60.0) (32.3, 83.7)                    |
|                                                                   |                                | Negativef                                                    | 1 Month              | 38                                                      | 29 (76.3) (59.8, 88.0)                                  | 36                                       | 23 (63.9) (46.2, 79.2)                   |
|                                                                   | ≥6 Months to <2  Overall Years |                                                              | 1 Month              | 21                                                      | 14 (66.7) (43.0, 85.4)                                  | 23                                       | 11 (47.8) (26.8, 69.4)                   |
|                                                                   |                                | Positive                                                     | 1 Month              | 9                                                       | 5 (55.6) (21.2, 86.3)                                   | 9                                        | 4 (44.4) (13.7, 78.8)                    |
|                                                                   |                                | Negativet                                                    | 1 Month              | 12                                                      | 9 (75.0) (42.8, 94.5)                                   | 13                                       | 6 (46.2) (19.2,74.9)                     |
|                                                                   | ≥2 to <5 Years                 | Overall                                                      | 1Month               | 33                                                      | 24 (72.7) (54.5, 86.7)                                  | 31                                       | 22 (71.0) (52.0, 85.8)                   |
|                                                                   |                                | Positive                                                     | 1 Month              | 7                                                       | 4 (57.1) (18.4, 90.1)                                   | 6                                        | 5 (83.3) (35.9, 99.6)                    |
|                                                                   |                                | Negativef                                                    | 1 Month              | 26                                                      | 20 (76.9) (56.4, 91.0)                                  | 23                                       | 17 (73.9) (51.6, 89.8)                   |
| SARS-CoV-2 neutralization assay -reference strain - NT50 (titer)  | ≥6 Months to <5Overall Years   |                                                              | 1 Month              | 57                                                      | 25 (43.9) (30.7, 57.6)                                  | 52                                       | 39 (75.0) (61.1, 86.0)                   |
|                                                                   |                                | Positivee                                                    | 1 Month              | 16                                                      | 3 (18.8) (4.0, 45.6)                                    | 15                                       | 5 (33.3) (11.8, 61.6)                    |
|                                                                   |                                | Negativef                                                    | 1 Month              | 41                                                      | 22 (53.7) (37.4, 69.3)                                  | 34                                       | 31 (91.2) (76.3, 98.1)                   |
|                                                                   | ≥6Monthsto<2（ Years            | Overall                                                      | 1 Month              | 22                                                      | 9 (40.9) (20.7, 63.6)                                   | 22                                       | 13 (59.1) (36.4, 79.3)                   |
|                                                                   |                                | Positive?                                                    | 1 Month              | 9                                                       | 2 (22.2) (2.8, 60.0)                                    | 9                                        | 1 (11.1) (0.3, 48.2)                     |
|                                                                   |                                | Negativef                                                    | 1 Month              | 13                                                      | 7 (53.8) (25.1, 80.8)                                   | 12                                       | 11 (91.7) (61.5, 99.8)                   |
|                                                                   | ≥2 to <5 Years                 | Overall                                                      | 1 Month              | 35                                                      | 16 (45.7) (28.8, 63.4)                                  | 30                                       | 26 (86.7) (69.3, 96.2)                   |
|                                                                   |                                | Positivee                                                    | 1 Month              | 7                                                       | 1 (14.3) (0.4, 57.9)                                    | 6                                        | 4 (66.7) (22.3,95.7)                     |
|                                                                   |                                | Negativef                                                    | 1 Month              | 28                                                      | 15 (53.6) (33.9, 72.5)                                  | 22                                       | 20 (90.9) (70.8, 98.9)                   |

<div style=\"page-break-after: always\"></div>

Abbreviations:LLOQ=lowerlimitofquantitation;N-binding=SARS-CoV-2nucleoprotein-binding;NAAT=nucleicacidamplificationtest;NT50=50%neutralizingtiter; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note:SubstudyBGroup2includesparticipants≥6monthsto&lt;5yearsofagewhoreceived3dosesofBNT162b23μg60to240dayspriortoenrollment.

Note:ForparticipantsfromC4591048SubstudyBGroup2,seroresponseisdefined as achievinga≥4-foldrisefrombaseline(before thestudyvaccination).Ifthebaseline measurementisbelowtheLLOQ,apostvaccination assayresult≥4xLLoQisconsideredaseroresponse.

- a. Protocol-specifiedtimingforbloodsamplecollection.

timepoint.Thesevaluesarethedenominatorsforthepercentagecalculations.

- c.n=Number of participantswithseroresponsefor thegiven assay at thegivensampling time point.
- d. Exact 2-sided CI,basedontheClopper andPearson method.

e. For C4591048 Substudy B Group 2: positive N-binding antibody result at Dose 4 visit, positive NAAT result at Dose 4 visit, or medical history of COVID-19. For unscheduledillnessvisituptoDose3visit,ormedicalhistoryofCOVID-19.

f.ForC4591048SubstudyBGroup2:negativeN-binding antibodyresult at Dose4visit,negativeNAATresult at Dose4visit,andnomedicalhistory of

COVID-19.ForC4591007:negativeN-bindingantibodyresult at Dose1,1-monthpost-Dose2(ifavailable),andDose3visits,negativeNAATresult at Dose1,Dose2,Dose 3,and anyunscheduledillnessvisitsuptoDose3visit,andnomedicalhistoryofCOVID-19. PFIZERCONFIDENTIALSourceData:advaTableGeneration:11JAN2023(00:33)

(Datacutoffdate:C4591048SubstudyB[25NOV2022]/C4591007[07AUG2022])

Output File:./nda2\\_ubped2/C4591048\\_B\\_1MPD\\_Group2\\_1007\\_IMM/adva\\_s003\\_p2\\_6m5y\\_evl

## · Ancillary analyses

## Neutralization of Omicron sublineages

The MAH submitted additionally 1-month postdose immunogenicity data for Omicron sublineages XBB.1.5, BQ.1.1, and BA.4/BA.5 in a subset of 31 participants ≥6 months to &lt;5 years of age in Group 2 of C4591048 Substudy B who received a fourth dose with 3 μ g of the bivalent BNT162b2 (Original/Omi BA.4/BA.5) vaccine and a comparator subset of 31 participants in Study C4591007 Phase 2/3 who received 3 doses at 3 μ g each of original BNT162b2.

## Selection of participants for additional neutralization testing

Participants in these analyses were among the first 60 assigned participants in C4591048 Substudy B Group 2 and the corresponding comparator group of 60 participants (subset from C4591007 Phase 2/3) who had sufficient sample volume remaining for the additional neutralization testing.

The participants in the comparator group were matched by age, prior SARS-CoV-2 infection status (before Dose 4 for participants in C4591048 Substudy B and before Dose 3 for participants in C4591007 Phase 2/3), and dosing interval (between Dose 3 and Dose 4 for participants in C4591048 Substudy B and between Dose 2 and Dose 3 for participants in C4591007 Phase 2/3) with this subset of participants in C4591048 Substudy B. Participants in C4591048 Substudy B Group 2 received Dose 4 (booster) with bivalent BNT162b2 (Original/Omi BA.4/BA.5) in September-October 2022 and participants in the comparator group from C4591007 Phase 2/3 received Dose 3 of original BNT162b2 in February-July 2022.

## Immunogenicity Endpoints and Analysis Methods

Descriptive immunogenicity analyses were performed to characterize Omicron XBB.1.5, BQ.1.1, and BA.4/BA.5 neutralization responses following a fourth dose with bivalent BNT162b2 (Original/Omi BA.4/BA.5) g each of original BNT162b2. A non-validated recombinant SARS-CoV-2

3 μ g or following 3 doses at 3 μ FFRNT was used to determine Omicron XBB.1.5, BQ.1.1, and BA.4/BA.5 neutralizing titers.

GMTs and GMFRs with 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and fold rises, respectively, and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

Seroresponse was defined as achieving a ≥4 -fold rise from baseline (before the first study vaccination [fourth dose]). If the baseline measurement was below the LLOQ, the postvaccination measure of ≥4 × LLOQ was considered seroresponse.

<div style=\"page-break-after: always\"></div>

## Immunogenicity Results

## Immunogenicity population

In the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group, the evaluable immunogenicity population (with or without evidence of infection up to 1-month post-Dose 4) inclu ded 30 (96.8%) participants ≥6 months to &lt;5 years of age. In the comparator group, the numbers of participants in the evaluable immunogenicity population with or without evidence of infection up to 1-month post-Dose 3 included 27 (87.1%) participants ≥6 mo nths to &lt;5 years of age

## Demographics

In the evaluable immunogenicity population with or without evidence of infection, 10 (33.3%) participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group had evidence of prior SARS-CoV-2 infection ('baseline positive') at the time of study vaccination (Dose 4). Median time since last dose of BNT162b2 before study vaccination (Dose 4) was 7.0 months in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group. In the BNT162b2 group, 33.3% of participants were baseline positive prior to Dose 3. Median time between Dose 2 and Dose 3 of BNT162b2 was 7.0 months in the BNT162b2 group.

## GMTs

## Omicron XBB.1.5

## Participants with or without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluab le immunogenicity population with or without evidence of prior SARS-CoV-2 infection, the observed GMTs against Omicron XBB.1.5 were higher in participants who were baseline positive compared with those who were baseline negative in both vaccine groups at prevaccination and at 1-month postdose ( Table 5 ).

Within baseline positive participants, GMTs against Omicron XBB.1.5 were similar at prevaccination and higher at 1-month postdose in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with the BNT162b2 group ( Table 5 ).

Within baseline negative participants, GMTs against Omicron XBB.1.5 were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups at both prevaccination and at 1-month postdose ( Table 5 ).

GMTs against Omicron XBB.1.5 were lower or similar at prevaccination and lower at 1-month postdose compared with GMTs against BA.4/BA.5 within baseline positive and baseline negative participants in both vaccine groups ( Table 5 ).

## Participants without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection:

-The observed GMTs against Omicron XBB.1.5 were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group at both prevaccination and 1-month postdose ( Table 5 ).

- In both groups, GMTs against Omicron XBB.1.5 were lower compared with GMTs against BA.4/BA.5 at 1month postdose

<div style=\"page-break-after: always\"></div>

## Omicron BQ.1.1

## Participants with or without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of prior SARS-CoV-2 infection, the observed GMTs against Omicron BQ.1.1 were higher in participants who were baseline positive compared with those who were baseline negative in both vaccine groups ( Table 5 ).

Within both baseline positive and negative participants, GMTs against Omicron BQ.1.1 were similar at prevaccination and higher at 1-month postdose in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with the BNT162b2 group ( Table 5 ).

GMTs against Omicron BQ.1.1 were lower or similar at prevaccination and lower at 1-month postdose compared with GMTs against BA.4/BA.5 within baseline positive and baseline negative participants in both vaccine groups ( Table 5 ).

## Participants without evidence of prior infection

Amon g participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection:

-The observed GMTs against Omicron BQ.1.1 were similar at prevaccination and higher at 1-month postdose in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 5 ).

-In both vaccine groups, GMTs against Omicron BQ.1.1 were lower compared with GMTs against BA.4/BA.5 at 1-month postdose ( Table 5 ).

Table 5. GeometricMIeanTiters,byBaselineSARS-CoV-2Status-NewVariantsNeutralization-C459104SSubset of Substudy B Group 2 (at Dose 4 and 1 MIonth After Dose 4) and C4591007 Phase 2/3 Participants (at Dose 3 and 1 MonthAfterDose3)-≥6 Mlonths to&lt;5Years of Age-ParticipantsWith orWithout Evidence of InfectionEvaluableImmunogenicityPopulation

|                                                         |                                                           |                      | VaccineGroup(asAssigned/Randomized)                   | VaccineGroup(asAssigned/Randomized)                   | VaccineGroup(asAssigned/Randomized)   | VaccineGroup(asAssigned/Randomized)   |
|---------------------------------------------------------|-----------------------------------------------------------|----------------------|-------------------------------------------------------|-------------------------------------------------------|---------------------------------------|---------------------------------------|
|                                                         |                                                           |                      | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5)3μg | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5)3μg | C4591007 BNT162b2 3 μg                | C4591007 BNT162b2 3 μg                |
| Assay                                                   | Baseline (Dose 4 C4591048/ Dose3C4591007)SARS-CoV-2Status | Sampling Time Point= | nb                                                    | GMT- (95% CI)                                         | nb                                    | GMT: (95% CI)                         |
| SARS-CoV-2 FFRNT - Omicron XBB.1.5 -NT50 (titer)Overall |                                                           | Prevax               | 30                                                    | 14.6 (11.3, 19.0)                                     | 27                                    | 12.0 (10.4, 13.8)                     |
|                                                         |                                                           | 1Month               | 30                                                    | 37.3 (24.6, 56.6)                                     | 27                                    | 20.3 (15.5, 26.5)                     |
|                                                         | Positive\"                                                 | Prevax               | 10                                                    | 22.2 (13.9, 35.4)                                     | 9                                     | 17.1 (12.0, 24.5)                     |
|                                                         |                                                           | 1 Month              | 10                                                    | 88.8 (40.9, 192.8)                                    | 9                                     | 38.5 (27.4, 54.0)                     |
|                                                         | Negativee                                                 | Prevax               | 20                                                    | 11.9 (8.9, 16.0)                                      | 17                                    | 10.0 (10.0, 10.0)                     |
|                                                         |                                                           | 1 Month              | 20                                                    | 24.2 (16.1, 36.3)                                     | 17                                    | 15.0 (11.3, 20.0)                     |
| SARS-CoV-2 FFRNT - Omicron BQ.1.1 -NT50 (titer)         | Overall                                                   | Prevax               | 30                                                    | 19.3 (13.2, 28.2)                                     | 27                                    | 14.3 (11.5, 17.9)                     |
|                                                         |                                                           | 1 Month              | 30                                                    | 84.8 (54.5, 131.9)                                    | 27                                    | 27.2 (20.5, 36.2)                     |
|                                                         | Positive                                                  | Prevax               | 10                                                    | 38.6 (21.7, 68.9)                                     | 6                                     | 29.4 (22.2, 38.9)                     |
|                                                         |                                                           | 1 Month              | 10                                                    | 234.3 (136.3, 402.5)                                  |                                       | 56.6 (40.8, 78.4)                     |

<div style=\"page-break-after: always\"></div>

|                                               | Negative\"   | Prevax   |   20 | 13.7 (8.8, 21.2)       |   17 | 10.0 (10.0,10.0)     |
|-----------------------------------------------|-------------|----------|------|------------------------|------|----------------------|
|                                               |             | 1 Month  |   20 | 51.0 (31.6, 82.4)      |   17 | 18.8 (14.2,25.0)     |
| SARS-CoV-2FFRNT-OmicronBA.4/BA.5-NT50 (titer) | Overall     | Prevax   |   30 | 54.0 (31.2,93.4)       |   27 | 25.9 (15.4, 43.5)    |
|                                               |             | 1 Month  |   30 | 432.1 (247.3, 755.1)   |   27 | 138.9 (94.6, 204.1)  |
|                                               | Positive*   | Prevax   |   10 | 211.1 (122.3,364.4)    |    9 | 148.1 (92.0, 238.5)  |
|                                               |             | 1 Month  |   10 | 1575.9 (876.4, 2833.5) |    6 | 332.6 (193.8, 570.8) |
|                                               | Negative\"   | Prevax   |   20 | 27.3 (15.3, 48.8)      |   17 | 10.8 (9.6, 12.2)     |
|                                               |             | 1 Month  |   20 | 226.3 (121.4,421.8)    |   17 | 90.4 (59.8, 136.6)   |

nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% meutralizing titer, SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Abbreviations: FFRNT = fluorescent focus reduction neutralization test; GMIT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2

Note: Subset of Substudy B Group 2 for new variants neutralization includes participants who have sufficient blood volume for variant of concems assay testing among the first 24 and 36 participants assigned in &gt;6 months to &lt;2 years age group and ≥2 years to &lt;5 years age group, respectively. Note: Substudy B Group 2 includes participants ≥6 months to &lt;5 years of age who received 3 doses of BNT162b2 3 μg 60 to 240 days prior to enrollment.

b. n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.

a. Protocol-specified timing for blood sample collection.

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below theLLOQwere set to 0.5xLLOQ.

d.For C4591048 Substudy B Group 2: positive N-binding antibody result at Dose 4 visit, positive NAAT result at Dose 4 visit, or medical history of COVID-19.For C4591007: positive N-binding antibody result at Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visits, positive NAAT result at Dose 1, Dose 2, Dose 3, or any unscheduled illness visit up to Dose 3 visit, or medical history of COVID-19.

For C4591048 Substudy B Group 2: negative N-binding antibody result at Dose 4 visit, negative NAAT result at Dose 4 visit, and no medical history of COVID-19. For C4591007: megative N-binding antibody result at Dose l, 1-month post-Dose 2 (if available), and Dose 3 visits, negative NAAT result at Dose 1, Dose 2, Dose 3, and any unscheduled illness visits up to Dose 3 visit, and no medical history of COVID-19.

(Data cutoff date: C4591048 Substudy B[30NOV/2022]/C4591007[07AUG2022])

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 16MAR2023 (03:16)

Output File:./nda2\\_ubped2/C4591048\\_B\\_GP2\\_145\\_1MPD\\_Immunobridging/adva\\_s001\\_p2\\_6m5y\\_evl

## GMFRs

## Omicron XBB.1.5

## Participants with or without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of prior SARS-CoV-2 infection, the observed GMFRs of neutralizing titers from before study vaccination to 1-month postdose for Omicron XBB.1.5 were higher in participants who were baseline positive compared with those who were baseline negative in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group ( Table 6 ). In the BNT162b2 group, the observed GMFRs of Omicron XBB.1.5-neutralizing titers were similar in participants who were baseline positive and those who were baseline negative.

Within baseline positive participants, from before study vaccination to 1-month postdose, GMFRs of neutralizing titers for Omicron XBB.1.5 were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 6 ).

Within baseline negative participants, from before study vaccination to 1-month postdose, GMFRs of neutralizing titers for Omicron XBB.1.5 were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 6 ).

GMFRs against Omicron XBB.1.5 were lower or similar compared with GMFRs against BA.4/BA.5 within baseline positive and baseline negative participants in both vaccine groups ( Table 6 ).

## Participants without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection, from before study vaccination to 1-month postdose,

<div style=\"page-break-after: always\"></div>

-GMFRs of neutralizing titers for Omicron XBB.1.5 were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 ( Table 6 ).

-In both vaccine groups, GMFRs against Omicron XBB.1.5 were lower compared with GMFRs against Omicron BA.4/BA.5.

## Omicron BQ.1.1

## Participants with or without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of prior SARS-CoV-2 infection, the observed GMFRs of neutralizing titers from before study vaccination to 1-month postdose for Omicron BQ.1.1 were higher in participants who were baseline positive compared with those who were baseline negative in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group ( Table 6 ). In the BNT162b2 group, the observed GMFRs of Omicron BQ.1.1-neutralizing titers were similar in participants who were baseline positive and those who were baseline negative.

Within both baseline positive and baseline negative participants, from before study vaccination to 1-month postdose, GMFRs of neutralizing titers for Omicron BQ.1.1 were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 6 ).

GMFRs against Omicron BQ.1.1 were lower or similar compared with GMFRs against BA.4/BA.5 within baseline positive and baseline negative participants in both vaccine groups.

## Participants without evidence of prior infection

Among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection, from before study vaccination to 1-month postdose,

-GMFRs of neutralizing titers for Omicron BQ.1.1 were slightly higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group.

-In both vaccine groups, GMFRs against Omicron BQ.1.1 were lower compared with GMFRs against Omicron BA.4/BA.5

<div style=\"page-break-after: always\"></div>

Table 6.

GeometricMeanFoldRises,byBaselineSARS-CoV-2Status-NewVariantsNeutralization-C4591048Subset ofSubstudyB Group2(FromDose 4 to1 MIonthAfterDose4)and C4591007Phase2/3Participants(FromDose 3 to1 Month AfterDose 3)-≥6Mlonths to&lt;5Years of Age-ParticipantsWith orWithout Evidence of Infection -EvaluableImmunogenicityPopulation

|                                                           |                                 |             | Vaccine Group (asAssigued/Randomized)                    | Vaccine Group (asAssigued/Randomized)                    | Vaccine Group (asAssigued/Randomized)   | Vaccine Group (asAssigued/Randomized)   |
|-----------------------------------------------------------|---------------------------------|-------------|----------------------------------------------------------|----------------------------------------------------------|-----------------------------------------|-----------------------------------------|
|                                                           | Baseline (Dose 4 C4591048/      | Sampling    | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 3 μg | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 3 μg | C4591007 BNT162b2 3μg                   | C4591007 BNT162b2 3μg                   |
| Assay                                                     | Dose3C4591007) SARS-CoV-2Status | Time Pointa | nb                                                       | GMFR- (95% CI)                                           | nb                                      | GMFR- (10 %96)                          |
| SARS-CoV-2 FFRNT - Omicron XBB.1.5 -NT50 (titer)          | Overall                         | 1 Month     | 30                                                       | 2.5 (1.8, 3.6)                                           | 27                                      | 1.7 (1.4, 2.1)                          |
| SARS-CoV-2 FFRNT - Omicron XBB.1.5 -NT50 (titer)          | Positive\"                       | 1 Month     | 10                                                       | 4.0 (1.8, 9.1)                                           | 9                                       | 2.2 (1.6, 3.1)                          |
| SARS-CoV-2 FFRNT - Omicron XBB.1.5 -NT50 (titer)          | Negative*                       | 1 Month     | 20                                                       | 2.0 (1.4, 2.9)                                           | 17                                      | 1.5 (1.1, 2.0)                          |
| SARS-CoV-2 FFRNT - OmicronBQ.1.1 -NT50 (titer)            | Overall                         | 1 Month     | 30                                                       | 4.4 (3.2, 6.0)                                           | 27                                      | 1.9 (1.6, 2.3)                          |
| SARS-CoV-2 FFRNT - OmicronBQ.1.1 -NT50 (titer)            | Positive\"                       | 1 Month     | 10                                                       | 6.1 (3.5, 10.5)                                          | 9                                       | 1.9 (1.4, 2.7)                          |
| SARS-CoV-2 FFRNT - OmicronBQ.1.1 -NT50 (titer)            | Negatives                       | 1 Month     | 20                                                       | 3.7 (2.5, 5.5)                                           | 17                                      | 1.9 (1.4, 2.5)                          |
| SARS-CoV-2 FFRNT - Omicron BA.4/BA.5 -NT50 (titer)Overall |                                 | 1 Month     | 30                                                       | 8.0 (5.2, 12.3)                                          | 27                                      | 5.4 (3.7, 7.7)                          |
| SARS-CoV-2 FFRNT - Omicron BA.4/BA.5 -NT50 (titer)Overall | Positived                       | 1 Month     | 10                                                       | 7.5 (4.2, 13.4)                                          | 9                                       | 2.2 (1.5, 3.3)                          |
|                                                           | Negatives                       | 1 Month     | 20                                                       | 8.3 (4.5, 15.3)                                          | 17                                      | 8.3 (5.6, 12.4)                         |

## Seroresponse rates

## Omicron XBB.1.5

## Participants with or without evidence of prior infection

At 1month postdose, among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of prior SARS-CoV-2 infection, the percentage of participants with seroresponse against Omicron XBB.1.5 were higher in participants who were baseline positive compared with those who were baseline negative in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group ( Table 7 ). In the BNT162b2 group, 1 (11.1%) baseline positive participant and no baseline negative participant achieved seroresponse against Omicron XBB.1.5.

<div style=\"page-break-after: always\"></div>

Within baseline positive participants, at 1-month postdose, the percentage of participants who achieved seroresponse against Omicron XBB.1.5 was higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 7 ).

Within baseline negative participants, at 1-month postdose, 2 (10.0%) participants and no participant achieved seroresponse against Omicron XBB.1.5 in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group and BNT162b2 group, respectively ( Table 7 ).

The percentage of participants who achieved seroresponse against Omicron XBB.1.5 was generally lower compared with participants who achieved seroresponse against Omicron BA.4/BA.5 within baseline positive and negative participants in both vaccine groups ( Table 7 ).

## Participants without evidence of prior infection

At 1month postdose, among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection:

-Two (11.1%) participants and no participant achieved seroresponse against Omicron XBB.1.5 in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group and BNT162b2 group, respectively ( Table 7 ).

- In both vaccine groups, the percentage of participants who achieved seroresponse against Omicron XBB.1.5 was lower compared with participants who achieved seroresponse against Omicron BA.4/BA.5.

## Omicron BQ.1.1

## Participants with or without evidence of prior infection

At 1month postdose, among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population with or without evidence of prior SARS-CoV-2 infection, the percentage of participants with seroresponse against Omicron BQ.1.1 were higher in participants who were baseline positive compared with those who were baseline negative in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group ( Table 7 ). In the BNT162b2 group, 1 (11.1%) baseline positive participant and no baseline negative participant achieved seroresponse against Omicron BQ.1.1.

Within both baseline positive and baseline negative groups, the percentage of participants who achieved seroresponse against Omicron BQ.1.1 was higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 7 ).

The percentage of participants who achieved seroresponse against Omicron BQ.1.1 was lower compared with participants who achieved seroresponse against Omicron BA.4/BA.5 within baseline positive and baseline negative participants in both vaccine groups ( Table 7 ).

## Participants without evidence of prior infection

At 1month postdose, among participants ≥6 months to &lt;5 years of age in the evaluable immunogenicity population without evidence of prior SARS-CoV-2 infection:

-The percentage of participants who achieved seroresponse against Omicron BQ.1.1 was higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group ( Table 7 ).

-In both vaccine groups, the percentage of participants who achieved seroresponse against Omicron BQ.1.1 was lower compared with participants who achieved seroresponse against Omicron BA.4/BA.5.

<div style=\"page-break-after: always\"></div>

Table 7.

Number (%) of Participants With Seroresponse, by Baseline SARS-CoV-2 Status -New Variants Neutralization MonthAfterDose3)-≥6Mlonths to&lt;5Years ofAge-ParticipantsWithorWithoutEvidence ofInfectionEvaluable Immunogenicity Population

|                                                      |                                                        |                      | Vaccine Group(asAssigned/Randomized)                    | Vaccine Group(asAssigned/Randomized)                    | Vaccine Group(asAssigned/Randomized)   | Vaccine Group(asAssigned/Randomized)   |
|------------------------------------------------------|--------------------------------------------------------|----------------------|---------------------------------------------------------|---------------------------------------------------------|----------------------------------------|----------------------------------------|
|                                                      |                                                        |                      | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 3 μg | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 3 μg | C4591007 BNT162b23 μg                  | C4591007 BNT162b23 μg                  |
| Assay                                                | Baseline(Dose4C4591048/ Dose3C4591007)SARS-CoV-2Status | Sampling Time Pointa | Nb                                                      | (%)u (95% C1)                                           | Nb                                     | n (%) (95% C1)                         |
| SARS-CoV-2 FFRNT-OmicronXBB.1.5 -NT50 (titer)Overall |                                                        | 1 Month              | 30                                                      | 8 (26.7) (12.3, 45.9)                                   | 27                                     | 1 (3.7) (0.1, 19.0)                    |
| SARS-CoV-2 FFRNT-OmicronXBB.1.5 -NT50 (titer)Overall | Positivee                                              | 1 Month              | 10                                                      | 6 (60.0) (26.2, 87.8)                                   | 9                                      | 1 (11.1) (0.3, 48.2)                   |
| SARS-CoV-2 FFRNT-OmicronXBB.1.5 -NT50 (titer)Overall | Negativef                                              | 1 Month              | 20                                                      | 2 (10.0) (1.2, 31.7)                                    | 17                                     | 0 (0.0) (0.0, 19.5)                    |
| SARS-CoV-2FFRNT-OmicronBQ.1.1-NT50(titer)            | Overall                                                | 1 Month              | 30                                                      | 15 (50.0) (31.3, 68.7)                                  | 27                                     | 1 (3.7) (0.1, 19.0)                    |
| SARS-CoV-2FFRNT-OmicronBQ.1.1-NT50(titer)            | Positivee                                              | 1 Month              | 10                                                      | 7 (70.0) (34.8, 93.3)                                   | 9                                      | 1 (11.1) (0.3, 48.2)                   |
| SARS-CoV-2FFRNT-OmicronBQ.1.1-NT50(titer)            | Negativef                                              | 1 Month              | 20                                                      | 8 (40.0) (19.1, 63.9)                                   | 17                                     | 0 (0.0) (0.0, 19.5)                    |
| SARS-CoV-2 FFRNT -OmicronBA.4/BA.5-NT50 (titer)      | Overall                                                | 1 Month              | 30                                                      | 20 (66.7) (47.2, 82.7)                                  | 27                                     | 17 (63.0) (42.4, 80.6)                 |
| SARS-CoV-2 FFRNT -OmicronBA.4/BA.5-NT50 (titer)      | Positivee                                              | 1 Month              | 10                                                      | 8 (80.0) (44.4, 97.5)                                   | 9                                      | 3 (33.3) (7.5, 70.1)                   |
| SARS-CoV-2 FFRNT -OmicronBA.4/BA.5-NT50 (titer)      | Negativef                                              | 1 Month              | 20                                                      | 12 (60.0) (36.1, 80.9)                                  | 17                                     | 13 (76.5) (50.1, 93.2)                 |

Note:Subset ofSubstudyB Group2for newvariants neutralization includes participantswhohave sufficient bloodvolumefor variant of concerns assaytesting among thefirst 24 and 36 participants assigned in ≥6 months to &lt;2 years age group and ≥2 years to&lt;5 years age group,respectively.

Abbreviations:FFRNT = fluorescent focus reduction neutralization test; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note:SubstudyBGroup2includes participants≥6months to&lt;5years of agewhoreceived3doses of BNT162b23μg 60to240days priorto enrollment.

Protocol-specified timingfor blood sample collection.

Note: For participants from C4591048 Substudy B Group 2, seroresponse is defined as achieving a ≥4-fold rise from baseline (before the study vaccination).If the baseline measurement is below the LLOQ, a postvaccination assay result ≥4 ×LLOQ is considered a seroresponse.

b.N = number of participants with valid and determinate assay results for the specified assay both before Dose 4 (C4591048)/Dose 3 (C4591007) and at the given sampling time point.These values are the denominators for the percentage calculations.

d. Exact 2-sided CI, based on the Clopper and Pearson method.

C. n =Number of participants with seroresponse for the given assay at the given sampling time point.

e. For C4591048Substudy B Group 2: positive N-binding antibody result at Dose 4 visit, positive NAAT result at Dose 4 visit, or medical history of COVID-19. For C4591007: positive N-binding antibody result at Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visits, positive NAAT result at Dose 1,Dose 2,Dose 3, or any unscheduled illness visit up toDose 3visit, or medical history of COVID-19.

PFIZER CONFIDENTIALSource Data: adva TableGeneration:16MAR2023 (03:16)

For C4591048 Substudy B Group 2: negative N-binding antibody result at Dose 4 visit, negative NAAT result at Dose 4 visit, and no medical history of COVID-19.For C4591007: negative N-binding antibody result at Dose 1, 1-month post-Dose 2 (if available), and Dose 3 visits,negative NAAT result at Dose 1, Dose 2,Dose 3, and any unscheduled illness visits up to Dose 3 visit, and no medical history of COVID-19.

(Data cutoff date:C4591048SubstudyB[30NOV2022]/C4591007[07AUG2022])

Output File:./nda2\\_ubped2/C4591048\\_B\\_GP2\\_145\\_1MPD\\_Immunobridging/adva\\_s003\\_p2\\_6m5y\\_evl

## · Summary of main efficacy results

MAH immunogenicity conclusions for the descriptive preliminary data for Omicron BA.4-5 and Reference Strain

At 1-month post dose, a fourth dose with bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 3 μ g in a subset of participants ≥6 months to &lt;5 years of age in the C4591048 Substudy B Group 2 who received 3 prior doses of BNT162b2 at 3 μ g elicited

- Higher Omicron BA.4/BA.5-specific neutralizing titers compared with the titers in a comparator group of participants in C4591007 Phase 2/3 who received 3 doses of BNT162b2.
- Similar reference strain-specific titers compared with the titers in the comparator group of participants in C4591007 Phase 2/3 who received 3 doses of BNT162b2.

<div style=\"page-break-after: always\"></div>

- The control group participants had matched prior infection status (by baseline serology [Nbinding],PCR, and medical history) to the bivalent BNT162b2 group. Given the higher prevaccination GMTs in the control group, further understanding of the sensitivity of N-binding to detect prior infection in children who overall have more asymptomatic infection and less severe disease compared with adults may need to be further explored.

These descriptive data align with the adult data and reinforce the importance of a bivalent booster dose in this age group.

MAH immunogenicity conclusions for Omicron sublineage XBB.1.5 and BQ.1.1 neutralization

At 1-month postdose, a fourth dose with bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 3 μ g in a subset of particip ants ≥6 months to &lt;5 years of age in the C4591048 Substudy B Group 2 who received 3 prior doses of original BNT162b2 at 3 μ g each elicited lower levels of neutralizing antibodies against BQ.1.1 and XBB.1.5 compared with Omicron BA.4/BA.5 neutralizing titers.

The following table summarises the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

Table 8. Summary of efficacy for trial C4591048 Substudy B

| Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate in Healthy Children   | Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate in Healthy Children   | Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate in Healthy Children   | Title: A Master Phase 1/2/3 Protocol to Investigate the Safety, Tolerability, and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate in Healthy Children   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                        | C4591048 Substudy B                                                                                                                                                     | C4591048 Substudy B                                                                                                                                                     | C4591048 Substudy B                                                                                                                                                     |
| Design                                                                                                                                                                  | Substudy B is open-label                                                                                                                                                | Substudy B is open-label                                                                                                                                                | Substudy B is open-label                                                                                                                                                |
| Design                                                                                                                                                                  | Follow-up for immunogenicity                                                                                                                                            | Follow-up for immunogenicity                                                                                                                                            | 19.08. 2022- 25.11.2022 (immunogenicity)                                                                                                                                |
| Hypothesis                                                                                                                                                              | Descriptive immunogenicity analysis for sentinel cohort                                                                                                                 | Descriptive immunogenicity analysis for sentinel cohort                                                                                                                 | Descriptive immunogenicity analysis for sentinel cohort                                                                                                                 |
| Treatments groups Children 6m- <5 yoa                                                                                                                                   | Active arm C4591048                                                                                                                                                     | Active arm C4591048                                                                                                                                                     | Original/Omicron BA4-5 (1.5/1.5 µg) as 4th dose for subjects previously vaccinated with 3 doses of Original 3 µg                                                        |
| Treatments groups Children 6m- <5 yoa                                                                                                                                   | Historical control arm C4591007                                                                                                                                         | Historical control arm C4591007                                                                                                                                         | Original Comirnaty (3 µg), 3 doses                                                                                                                                      |
| Endpoints and definitions                                                                                                                                               | Immunogenicity endpoint                                                                                                                                                 | GMT                                                                                                                                                                     | geometric mean titers (GMTs) at 1 month after Dose 4 (bivalent) or Dose 3 (Original)                                                                                    |
| Endpoints and definitions                                                                                                                                               | Immunogenicity endpoint                                                                                                                                                 | GMFR                                                                                                                                                                    | geometric mean fold rise (GMFR) of titers (GMTs) at 1 month after last dose compared to the baseline                                                                    |
| Endpoints and definitions                                                                                                                                               | Immunogenicity endpoint                                                                                                                                                 | Sero respon se rate                                                                                                                                                     | percentage of participants with a ≥4 -fold rise in neutralizing titers from before vaccination to 1 month after last dose (seroresponse rate).                          |
| Database lock                                                                                                                                                           | 25.11.2022                                                                                                                                                              | 25.11.2022                                                                                                                                                              | 25.11.2022                                                                                                                                                              |
| Results and Analysis                                                                                                                                                    | Results and Analysis                                                                                                                                                    | Results and Analysis                                                                                                                                                    | Results and Analysis                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                 | Analysis description Immunogenicity Analysis                                                    | Analysis description Immunogenicity Analysis                                                    | Analysis description Immunogenicity Analysis                                                    |
|---------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                                 | Analysis population and time point description 1 month after last dose Evaluable Immunogenicity | Analysis population and time point description 1 month after last dose Evaluable Immunogenicity | Analysis population and time point description 1 month after last dose Evaluable Immunogenicity |
| Effect estimate per comparison  | Treatment group                                                                                 | C4591048 4 th dose with Original/Omicron (1.5/1.5 μg)                                           | C4591007 3 doses with Original 3 μg                                                             |
| Effect estimate per comparison  | Omicron BA4-5 neutralization                                                                    | Omicron BA4-5 neutralization                                                                    | Omicron BA4-5 neutralization                                                                    |
| Effect estimate per comparison  | Number of subject                                                                               | Baseline N= 54 Post 4th dose N= 58                                                              | Baseline N= 54 Post 3rd dose N= 54                                                              |
| Effect estimate per comparison  | Baseline GMT (95% CI)                                                                           | 192.5 (120.4, 307.8)                                                                            | 70.5 (51.1, 97.2)                                                                               |
| Effect estimate per comparison  | 1m post last dose GMT (95% CI)                                                                  | 1695.2 (1151.8, 2494.9)                                                                         | 607.9 (431.1, 857.2)                                                                            |
| Effect estimate per comparison  | GMFR (GMT 1m post last dose/ baseline)                                                          | 9.1 (6.3, 13.3)                                                                                 | 8.6 (6.3, 11.7)                                                                                 |
| Effect estimate per comparison  | Seroresponse rate %(95% CI)                                                                     | 38 out of 54 (70.4 %) (56.4, 82.0 %)                                                            | 33 out of 54 (61.1 %) (46.9, 74.1 %)                                                            |
| Reference Strain Neutralization | Reference Strain Neutralization                                                                 | Reference Strain Neutralization                                                                 | Reference Strain Neutralization                                                                 |
|                                 | Number of subject                                                                               | Baseline N= 57 Post 4th dose N= 58                                                              | Baseline N= 53 Post 3rd dose N= 53                                                              |
|                                 | Baseline GMT (95% CI)                                                                           | 2678.1 (1913.0, 3749.2)                                                                         | 776.8 (536.4, 1125.0)                                                                           |
|                                 | 1m post last dose GMT (95% CI)                                                                  | 9733.0 (7708.2, 12289.6)                                                                        | 9057.3 (7223.4, 11356.8)                                                                        |
|                                 | GMFR (GMT 1m post last dose/ baseline)                                                          | 3.6 (2.7, 4.8)                                                                                  | 11.4 (8.1, 16.1)                                                                                |
|                                 | Seroresponse rate %(95% CI)                                                                     | 25 out of 57 (43.9%) (30.7, 57.6 %)                                                             | 39 out of 52 (75.0 %) (61.1, 86.0 %)                                                            |

<div style=\"page-break-after: always\"></div>

## 2.6.2.3. Supportive studies

| C4591048 SubstudyD Group 2 Safety and Immunogeni city Ad Hoc Report Phase 3 (United States)                          | BioNTech (Pfizer)   | Primary Objectives: Primary Safety (Safety Population) To describe the safety and tolerability profiles of prophylactic bivalent BNT162b2 given as a third or fourth dose in participants ≥5 to <12 years of age. Primary immunogenicity To descriptively compare the anti-Omicron BA.4/BA.5 immune response between participants ≥5 to <12 years of age who received 3 prior doses of BNT162b2 10 µg and received bivalent BNT162b2 as a fourth dose in Group 2 and Study C4591007 Phase 2/3 participants ≥5 to <12 years of age who received 3 doses of BNT162b2 10 µg. Secondary immunogenicity To describe the immune response elicited by bivalent BNT162b2 given as a fourth dose in participants ≥5 to <12 years of age.   | Subset of Substudy D Group 2 (4 th dose) BNT162b2 Bivalent(WT/OMI BA.4/BA.5) 10 µg Substudy D Group2(4 th dose) BNT162b2 Bivalent(WT/OMI BA.4/BA.5) 10 µg Study C4591007 Phase 2/3 participants ≥5 to <12 years of age who received 3 doses of BNT162b2 10 µg.   | BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 10 µg ≥5 years to <12 Years: N=113 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 10 µg (4 th dose) ≥5 years to <12 Years: N=113 BNT162b2 Original 10 µg (3 rd dose) N=113   |
|----------------------------------------------------------------------------------------------------------------------|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| C4591044 Cohort 2 and Combined Cohort 2 (Groups 2 &4) + Cohort 3 (Groups 1 &2) Interim CSR Phase 2/3 (United States) | BioNTech (Pfizer)   | Primary Objectives: Primary Safety (Safety Population): To describe the safety and tolerability profile of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg given as a second booster dose to BNT162b2- experienced participants 12 through 17, 18 through 55, and >55 years of age, and BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 60 μg given as a second booster dose to BNT162b2-experienced participants 18 through 55 and >55 years of age.                                                                                                                                                                                                                                                                                             | Cohort 2 BNT162b2 Bivalent (WT/ OMIBA.4/BA.5) 30 µg BNT162b2 Bivalent (WT/ OMIBA.4/BA.5) 60 µg                                                                                                                                                                   | BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg 12 to 17 Years: N=107 18 to 55 Years: N=104 >55 Years: N=106 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 60 µg 18 to 55 Years: N=110 >55 Years N=102                |
|                                                                                                                      |                     | Primary Objective: Primary Immunogenicity (Evaluable Immunogenicity Population): Cohort 2: To describe the immune response to BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg or 60 µg and BNT162b2 Bivalent (WT/OMI BA.1) 30 µg r 60 µg given as a second booster dose to BNT162b2-experienced participants 12 through 17, 18 through 55, and >55 years of age.                                                                                                                                                                                                                                                                                                                                                                       | Cohort 2 BNT162b2 Bivalent (WT/ OMIBA.4/BA.5) 30 µg BNT162b2 Bivalent (WT/ OMIBA.4/BA.5) 60 µg Study C4591031 Substudy E Expanded Cohort BNT162b2                                                                                                                | BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg 12 to 17 Years: N=105 18 to 55 Years: N=95 >55 Years: N=102 BNT162b2 Bivalent                                                                                |

<div style=\"page-break-after: always\"></div>

|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Bivalent(WT/OMI BA.1) 30 µg BNT162b2 Bivalent(WT/OMI BA.1) 60 µg                                             | (WT/OMI BA.4/BA.5) 60 µg 18 to 55 Years: N=102 >55 Years N=99 BNT162b2 Bivalent (WT/OMI BA.1) 30 µg 18 to 55 Years: N=100 >55 Years: N=100 BNT162b2 Bivalent (WT/OMI BA.1) 60 µg 18 to 55 Years: N=100 >55 Years N=100   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Primary Immunogenicity: Cohort 2/Group 4 + Cohort 3/ Group 2 combined: To demonstrate the superiority with respect to level of neutralizing titer and noninferiority with respect to seroresponse rate of the anti-Omicron BA.4/BA.5 immune response after BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg compared to afterBNT162b2 30 µg given as a second booster dose to BNT162b2- experienced participants >55 years of age. Primary Immunogenicity: Cohort 2/Group 2 +Cohort 3/Group 1 combined and Cohort 2/Group 4 + Cohort 3/Group 2 combined: To demonstrate the noninferiority with respect to level of neutralizing titer and with respect to seroresponse rate of the anti-Omicron BA.4/BA.5immune response after BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg given as a second booster dose to BNT162b2-experienced participants 18 through 55 years of age compared to participants >55 years of age. Secondary Objectives: Secondary Immunogenicity (Evaluable Immunogenicity Population): Cohort 2/Group 4 + Cohort 3/Group 2 combined: To demonstrate the noninferiority of the anti- reference-strain immune response after BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) 30 µg compared to BNT162b2 30 µg given as a second booster dose in BNT162b2- experienced participants >55 years of age. Secondary Immunogenicity (Evaluable Immunogenicity Population): Cohort 2/Group 2 + Cohort 3/Group 1 combined and | BNT162b2 Bivalent (WT/ OMIBA.4/BA.5) 30 µg Study C4591031 Substudy E Expanded Cohort Original BNT162b2 30 µg | BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg 18 to 55 Years: N=297 >55 Years: N=286 BNT162b2 Original >55 Years: N=289                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Cohort 2/Group 4 + Cohort 3/Group 2 combined: To describe the immune response to BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) 30 µg compared to BNT162b2 30 µggiven as a second booster dose to BNT162b2- experienced participants 18 through 55 and >55 years of age.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## 2.6.2.3.1. Study C4591048, substudy D

Substudy D is a Phase 3 open-label study to evaluate the safety, tolerability, and immunogenicity of a third or fourth dose with bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10 µg in approximately 250 participants.

The protocol planned for enrolment of approximately 200 participants ≥ 5 to &lt;12 years of age, who have received 2 or 3 prior doses of Original BNT162b2 10 µg, with their last dose 90 to 240 days prior to enrolment, that were offered a third or fourth dose of bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10-µg. This would include 100 participants who have completed 2 prior doses of original BNT162b2 10-µg and up to 100 participants who have completed 3 prior doses of original BNT162b2 10-µg.

Up to approximately 50 participants ≥ 5 to &lt;12 years of age, who have completed 3 prior doses of original BNT162b2 at least 90 days prior to enrolment, were enrolled from Study C4591007 Phase 1 and offered a fourth dose of bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10-µg.

This report for Substudy D presents the following 1-month postdose data for approximately 100 participants ≥5 to &lt;12 years of age from C4591048 Substudy D (Group 2) as of 25 NOV 2022 and approximately 100 participants of the same age from Study C4591007 (Phase 2/3) as of 27 MAY 2022:

- Immunogenicity data from C4591048 Substudy D (Group 2) participants who received a fourth dose (booster) with bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10-µg after receiving 3 prior doses of original BNT162b2 10-µg compared with C4591007 Phase 2/3 participants who received 3 doses of original BNT162b2 10 µg.

## · Immunogenicity Endpoints and Analysis Methods

| Primary Immunogenicity Objectives                                                                                                                                                                                                                                                                                                  | Primary Immunogenicity Estimands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | Primary Immunogenicity Endpoints                    |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------|
| • To descriptively compare the anti-Omicron BA.4/BA.5 immune response between participants ≥5 to <12 years of age who received 3 prior doses of BNT162b2 10 µg and received bivalent BNT162b2 as a fourth dose in Group 2 and Study C4591007 Phase 2/3 participants ≥5 to <12 years of age who received 3 doses of BNT162b2 10 µg. | In participants complying with the key protocol criteria (evaluable participants): GMR, estimated by the ratio of the geometric mean of SARS- CoV-2 Omicron BA.4/BA.5-neutralizing titers at 1 month after Dose 4 for participants who received 3 prior doses of BNT162b2 10 µg and a fourth dose of bivalent BNT162b2 to those at 1 month after Dose 3 for Study C4591007 Phase 2/3 participants who received 3 doses of BNT162b2 10 µg. The difference in percentage of participants with seroresponse to the Omicron BA.4/BA.5 strain between participants who received 3 prior doses of BNT162b2 10 µg and a fourth dose of bivalent BNT162b2 and Study C4591007 Phase 2/3 participants who received 3 doses of BNT162b2 10 µg at 1 month after Dose 3 | • SARS-CoV-2 Omicron BA.4/BA.5- neutralizing titers |

<div style=\"page-break-after: always\"></div>

| • Secondary Immunogenicity:                                                                                                    | Secondary Immunogenicity:                                                                                                                                                                                                                                                                                              | • Secondary Immunogenicity:                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|
| • To describe the immune response elicited by bivalent BNT162b2 given as a fourth dose in participants ≥5 to <12 years of age. | In participants complying with the key protocol criteria (evaluable participants), for each strain-specific neutralizing titer: • GMTs at each time point • GMFRfrom before the study vaccination to each subsequent time point Percentages of participants with seroresponse at each time point following vaccination | • SARS-CoV-2 Omicron BA.4/BA.5- neutralizing titers • SARS-CoV-2reference- strain-neutralizing titers |

Descriptive immunogenicity analyses were performed to characterize Omicron BA.4/BA.5 and reference strain neutralization responses following a fourth dose with bivalent BNT162b2 (Original/Omi BA.4/BA.5) (C4591048 Substudy D Group 2 participants) or after 3 doses of BNT162b2 (C4591007 Phase 2/3 Participants) each at 10 µg. The validated SARS-CoV-2 neutralization assay was used to determine Omicron BA.4/BA.5- and reference strain-specific neutralizing titers.

GMTs and GMFRs with 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the tiers and fold rises, respectively, and the corresponding CIs (based on Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.

GMR and associated 95% CIs were calculated by exponentiating the difference in LS means and the corresponding CIs based on analysis of logarithmically transformed assay results using a linear regression model that includes the baseline neutralizing titer, postbaseline infection status, and vaccine group as covariates.

Unadjusted GMR was calculated as the mean of the difference of logarithmically transformed assay results and exponentiating the mean. Two-sided CIs were obtained by calculating CIs using the Student t distribution for the mean difference of the logarithmically transformed assay results and exponentiating the confidence limits.

Seroresponse was defined as achieving a ≥4 -fold rise from baseline (before the study vaccination [fourth dose If the baseline measurement was below the LLOQ, the postvaccination measure of ≥4 × LLOQ was considered seroresponse.

The adjusted difference in percentages of participants with seroresponse, and the associated 2-sided 95% CIs, were calculated using the Miettinen and Nurminen method stratified by baseline neutralizing titer category (&lt;median, ≥median). The unadjusted difference in percentages of participants with seroresponse and the associated 2-sided 95% CIs were calculated using the Miettinen and Nurminen method.

## · Immunogenicity Population

A total of 115 participants ≥ 5 to &lt;12 years of age were assigned to receive a fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 10 μ g ( Table 9 ).

<div style=\"page-break-after: always\"></div>

Table 9. ImmunogenicityPopulations-C4591048SubstudyD Group2and Study C4591007Phase2/3Participants

|                                                                                                                              | Vaccine Group (as Assigned/Randomized)                         | Vaccine Group (as Assigned/Randomized)   |
|------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|------------------------------------------|
|                                                                                                                              | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10μg (%) e | C4591007 BNT162b2 10 μg na (%)           |
| Assignedb                                                                                                                    | 115 (100.0)                                                    | 113 (100.0)                              |
| Dose 4(C4591048)/Dose3 (C4591007)all-available immunogenicity population                                                     | 104 (90.4)                                                     | 113 (100.0)                              |
| Excluded from Dose 4 (C4591048)/Dose 3 (C4591007) all-available immunogenicity population                                    | 11 (9.6)                                                       | 0                                        |
| Reason for exclusion Participant did not receive Dose 4 (C4591048)/Dose 3 (C4591007)                                         | 2 (1.7)                                                        | 0                                        |
| Did not have at least 1valid and determinateimmunogenicity result after Dose 4 (C4591048)/Dose 3 (C4591007)                  | 9 (7.8)                                                        | 0                                        |
| Dose 4 (C4591048)/Dose 3 (C4591007) evaluable immunogenicity population                                                      | 103 (89.6)                                                     | 113 (100.0)                              |
| Participants without evidence of infection up to 1 month after Dose 4 (C4591048)/D0se3 (C4591007)c                           | 43 (37.4)                                                      | 45 (39.8)                                |
| Excluded from Dose 4 (C4591048)/Dose 3 (C4591007) evaluable immunogenicity population                                        | 12 (10.4)                                                      | 0                                        |
| Reason for exclusiond Did not receive Dose 4(C4591048)/Dose 3 (C4591007) vaccine as assigned/randomized                      | 2 (1.7)                                                        | 0                                        |
| Didnot have at least 1valid and determinate immunogenicity result within28-42 days after Dose 4 (C4591048)/Dose 3 (C4591007) | 9 (7.8)                                                        | 0                                        |
| Had blood draw within the window but no valid and determinate immunogenicity result obtained in laboratory                   | 1 (0.9)                                                        | 0                                        |
| No blood drawn at 1-Month post-Dose 4(C4591048)/post- Dose 3 (C4591007)                                                      | 8 (7.0)                                                        | 0                                        |
| Had other important protocol deviation                                                                                       | 2 (1.7)                                                        | 0                                        |

Abbreviations: N/A = not applicable; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoproteinbinding;SARS-CoV-2= severe acute respiratory syndrome coronavirus 2.

Note: Substudy D Group 2 includes participants 5-11 years of age who received 3 prior doses of BNT162b2 10 μg 90 to 240 days prior to enrollment.

a. n = Number of participants with the specified characteristic.

C. Participants with no serological or virological evidence of past SARS-CoV-2 infection up to the 1-month post-Dose 4 (C4591048) or the 1-month post-Dose 3 (C4591007) blood sample collection. Having no evidence of past SARS-CoV(serum)result attheDose 4visit and1-monthpost-Dose 4visit;anegative b. This value is the denominator for the percentage calculations.

NAAT (nasal swab) result at the Dose 4 visit, and any unscheduled visit up to the 1-month post-Dose 4 blood sample collection;andhadnomedicalhistoryofCOVID-19.HavingnoevidenceofpastSARS-CoV-2infectionupto1-month post-Dose 3 for C4591007 participants was defined as having a negative N-binding antibody (serum) result at the Dose 1, 1-month post-Dose 2 (if available), Dose 3, and 1-month post-dose 3 visits; a negative NAAT

(nasal swab) result at the Dose 1, Dose 2, and Dose 3 visits and any unscheduled visit up to the 1-month post-Dose 3 bloodsamplecollection; and nomedical history of COVID-19.

d.Participants may have been excluded for more than 1 reason.

PFIZERCONFIDENTIALSourceData:adslTableGeneration:02MAR2023(10:03)

(Data cutoff date: C4591048Substudy D[25NOV2022]/C4591007[27MAY2022])

Output File:./nda2 ubped2/C4591048 D 1MPD 1007 Immuno/adva s008 immu pop p2 12

## · Demographics of Immunogenicity Population

Demographic characteristics of participants with or without evidence of infection in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups are shown in Table 10 . A total of 57.3% of

<div style=\"page-break-after: always\"></div>

participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group were baseline positive at the time of study vaccination (Dose 4). Median time since last dose of BNT162b2 before study vaccination (Dose 4) was 5.5 months in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group. In the BNT162b2 group, 58.4% of participants were baseline positive prior to Dose 3. Median time between Dose 2 and Dose 3 of BNT162b2 was 6.5 months in the BNT162b2 group.

Demographic characteristics for participants without evidence of infection up to 1 month after study vaccination in the evaluable immunogenicity population and the all-available immunogenicity population with or without evidence of infection were generally similar.

Table 10. DemographicCharacteristics-ParticipantsWithorWithoutEvidence of Infection -C4591048 Substudy D Group 2 and Study C4591007 Phase 2/3 Participants-EvaluableImmunogenicityPopulation

|                                                                                     | Vaccine Group (as Assigned/Randomized)                             | Vaccine Group (as Assigned/Randomized)   |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------|------------------------------------------|
|                                                                                     | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10 μg (N²=103) | C4591007 BNT162b2 10 μg (N\"=113)         |
|                                                                                     | n' (%)                                                             | n' (%)                                   |
| Sex                                                                                 |                                                                    |                                          |
| Male                                                                                | 49 (47.6)                                                          | 63 (55.8)                                |
| Female                                                                              | 54 (52.4)                                                          | 50 (44.2)                                |
| Race                                                                                |                                                                    |                                          |
| White                                                                               | 63 (61.2)                                                          | 91 (80.5)                                |
| Black or African American                                                           | 8 (7.8)                                                            | 4 (3.5)                                  |
| Asian                                                                               | 12 (11.7)                                                          | 11 (9.7)                                 |
| Native Hawaiian or other Pacific Islander                                           | 0                                                                  | 2 (1.8)                                  |
| Multiracial                                                                         | 17 (16.5)                                                          | 4 (3.5)                                  |
| Not reported                                                                        | 3 (2.9)                                                            | 1 (0.9)                                  |
| Ethnicity                                                                           |                                                                    |                                          |
| Hispanic/Latino                                                                     | 23 (22.3)                                                          | 16 (14.2)                                |
| Non-Hispanic/non-Latino                                                             | 80 (77.7)                                                          | 97 (85.8)                                |
| Age (years) at Dose 4 (C4591048)/Dose 3 (C4591007)                                  |                                                                    |                                          |
| Mean (SD)                                                                           | 8.6 (1.65)                                                         | 8.6 (1.65)                               |
| Median                                                                              | 9.0                                                                | 9.0                                      |
| Min, max                                                                            | (5, 11)                                                            | (5, 11)                                  |
| Time (months9) from last prior BNT162b2 dose to Dose 4 (C4591048)/Dose 3 (C4591007) |                                                                    |                                          |
| n                                                                                   | 103                                                                | 113                                      |
| Mean (SD)                                                                           | 6.0 (1.45)                                                         | 6.6 (0.31)                               |
| Median                                                                              | 5.5                                                                | 6.5                                      |
| Min, max                                                                            | (3.5, 8.5)                                                         | (6.3, 7.6)                               |
| ≥3 to <4 Months                                                                     | 7 (6.8)                                                            | 0                                        |
| ≥4 to <5 Months                                                                     | 26 (25.2)                                                          | 0                                        |
| ≥5 to <6 Months                                                                     | 22 (21.4)                                                          | 0                                        |
| ≥6 to <7 Months                                                                     | 13 (12.6)                                                          | 99 (87.6)                                |
| ≥7 to <8 Months                                                                     | 23 (22.3)                                                          | 14 (12.4)                                |
| ≥8 to <9 Months                                                                     | 12 (11.7)                                                          | 0                                        |
| Time (days) from last prior BNT162b2 dose to Dose 4 (C4591048)/Dose 3 (C4591007)    |                                                                    |                                          |

<div style=\"page-break-after: always\"></div>

| 11                                                          | 103           | 113          |
|-------------------------------------------------------------|---------------|--------------|
| Mean (SD)                                                   | 168.5 (40.51) | 185.1 (8.60) |
| Median                                                      | 154.0         | 183.0        |
| Min, max                                                    | (98,239)      | (175,212)    |
| 90-240 Days                                                 | 103 (100.0)   | 113 (100.0)  |
| Baseline (Dose 4 C4591048/Dose3 C4591007)SARS-CoV- 2 status |               |              |
| Positived                                                   | 59 (57.3)     | 66 (58.4)    |
| Negativee                                                   | 44 (42.7)     | 47 (41.6)    |
| Comorbiditiesf                                              |               |              |
| Yes                                                         | 28 (27.2)     | 33 (29.2)    |
| No                                                          | 75 (72.8)     | 80 (70.8)    |

Abbreviations: NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; SARS-CoV-2 =severe acuterespiratory syndrome coronavirus 2.

Note:Substudy D Group 2 includes participants 5-11 years of age who received 3 prior doses of BNT162b210 pg 90 to 240 days prior to enrollment.

a. N = number of participants in the specified group. This value is the denominator for the percentage calculations.

- b. n = Number of participants with the specified characteristic.
- C. Month was calculated as 28 days.

d. the Dose 4 visit, or medical history of COVID-19. For C4591007: positive N-binding antibody result at the Dose 1, 1month post-Dose 2 (if available), or Dose 3 visit, positive NAAT result at the Dose 1, Dose 2, Dose 3, or any unscheduled illness visit up to the Dose 3 visit, or medical history of COVID-19.

For C4591048 Substudy D Group 2: negative N-binding antibody result at the Dose 4 visit, negative NAAT result at the Dose 4 visit,and no medical history of COVID-19.For C4591007: negative N-binding antibody result at the Dose 1, 1-month post-Dose 2 (if available), and Dose 3 visits, negative NAAT result at the Dose 1, Dose 2, Dose 3, and any unscheduled illness visits up to the Dose 3 visit, and no medical history of COVID-19.

f.Number of participants who have 1 or more comorbidities that increase the risk of severe COVID-19: defined as participants who had at least 1 of the prespecified comorbidities based on MMWR Morb Mortal Wkly Rep. 2020;69(32):1081-8 and/or obesity (BMI ≥95th percentile). Comorbidities were assessed at the first study visit for both studies.

PFIZER CONFIDENTIAL Source Data: adsl Table Generation:02MAR2023 (09:47) (Data cutoff date: C4591048 Substudy D[25NOV2022]/C4591007[27MAY2022]) Output File:./nda2\\_ubped2/C4591048\\_D\\_1MPD\\_1007\\_Immuno/adsl\\_s005\\_demo\\_p2\\_12\\_evl

## · Immunogenicity results

## GMR

## Participants With or Without Evidence of Infection

In the evaluable immunogenicity population with or without evidence of prior infection up to 1 month after study vaccination, model-based GMR of Omicron BA.4/BA.5-neutralizing titers for the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group to the BNT162b2 group was 1.12 (2-sided 95% CI: 0.92, 1.37) ( Table 11 ). Unadjusted GMR was 1.57 (2-sided 95% CI: 1.18, 2.09).

<div style=\"page-break-after: always\"></div>

Table 11.

Mlodel-Based GeometricMIeanRatio-C4591048SubstudyD Group2(1 MonthAfterDose4)toC4591007Phase2/3Participants(1MonthAfter Dose3)-With orWithoutEvidence ofInfection-Evaluable genicity Population

|                                                                  | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   | BivalentBNT162b2 (Original/OmiBA.4/BA.5)   |
|------------------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------|------------------------------------------|--------------------------------------------|
| Issay                                                            | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591007 BNT162b2 10 μg                  | C4591007 BNT162b2 10 μg                  | 10 μg/BNT162b2 10 μg                       |
|                                                                  | na                                                       | GMT(95%C1)                                               | na                                       | GMT' (95% CI°)                           | GMR (95% C1)                               |
| ;ARS-CoV-2 neutralization ssay -Omicron BA.4/BA.5 - IT50 (titer) | 101                                                      | 1836.1 (1593.8,2115.2)                                   | 112                                      | 1632.5 (1427.5,1867.0)                   | 1.12 (0.92, 1.37)                          |

## Seroresponse

## Omicron BA.4/BA.4 Neutralization

## Participants With or Without Evidence of Infection

In the evaluable immunogenicity participants with or without evidence of prior infection up to 1-month postdose, 53.5% of participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group achieved seroresponse to Omicron BA.4/BA.5. The adjusted difference in percentages of participants with seroresponse between the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group and the BNT162b2 group was 8.76% (95% CI: -2.47, 19.99) ( Table 11 ). Unadjusted difference in seroresponse rates was 0.79% (95% CI: -12.57, 14.10).

<div style=\"page-break-after: always\"></div>

Table 12. AdjustedDifferenceinPercentagesofParticipantsWithSeroresponse BetweenC4591048SubstudyDGroup2(1 MonthAfterDose4)and C4591007Phase2/3Participants (1 MonthAfterDose3)-With or WithoutEvidenceofInfection-EvaluableImmunogenicityPopulation

|                                                                    | Vaccine Group (as Assigned/Randomized)                    | Vaccine Group (as Assigned/Randomized)                    | Vaccine Group (as Assigned/Randomized)                    | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |                |
|--------------------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|----------------|
|                                                                    | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591048 Bivalent BNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591007 BNT162b2 10 μg                  | C4591007 BNT162b2 10 μg                  | Difference                               | Difference     |
| Assay                                                              |                                                           |                                                           | Na n(%) (95% CI) N nb(%) (95% C1) %d                      |                                          |                                          |                                          | (95% CI)       |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 101                                                       | 54 (53.5)                                                 | (43.3, 63.5)                                              | 112                                      | 59 (52.7)                                | (43.0, 62.2) 8.76                        | (-2.47, 19.99) |

Abbreviations: LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Note:Substudy D Group 2includes participants 5-11 years of agewhoreceived3prior doses of BNT162b210μg 90 to 240 days prior to enrollment.

a.N = number of participants with valid and determinate assay results for the specified assay both before Dose 4 (C4591048)/Dose 3 (C4591007) and at the given dose/sampling time point. These values are the denominators for the percentage calculations.

Note: Seroresponse is defined as achieving a ≥4-fold rise from baseline (before Dose 4 for C4591048 Substudy D Group 2 and before Dose 3 for C4591007). If the baseline measurement is below the LLOQ, a postvaccination assay result ≥4 x LLOQ is considered a seroresponse.

b.

C. Exact 2-sided CI based on the Clopper and Pearson method.

d. Adjusted difference in proportions based on the Mietinen and Nurminen method stratified by baseline neutralizing titer category (&lt; median, ≥ median), expressed as a percentage (bivalent BNT162b2 [original/Omi BA.4/BA.5] 10 μg BNT162b2 10 μg). The median of baseline neutralizing titers was calculated based on the pooled data in 2 comparator groups.

- e.  2-Sided CI, based on the Miettinen and Nurminen method for the difference in proportions stratified by baseline

PFIZERCONFIDENTIALSourceData:advaTableGeneration:02MAR2023(09:44)

(Data cutoff date: C4591048 Substudy D[25NOV2022]/C4591007[27MAY2022])

Output File: ./nda2\\_ubped2/C4591048\\_D\\_1MPD\\_1007\\_Immuno/adva\\_s003\\_diff\\_sero\\_p2\\_evl

## GMT

## Omicron BA.4/BA.5 neutralization

## Participants With or Without Evidence of Infection

In the evaluable immunogenicity population with or without evidence of prior infection, for both vaccine groups, GMTs against the Omicron BA.4/BA.5 variant were higher at predose and at 1-month postdose in participants who were baseline positive compared with those who were baseline negative ( Table 13 ).

Within both baseline positive and baseline negative groups, BA.4/BA.5-neutralizing GMTs were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with that in the BNT162b2 group at prevaccination. For baseline positive participants, BA.4/BA.5- neutralizing GMTs at 1month postdose were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group. For baseline negative participants, the observed GMTs at 1-month postdose were generally similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups, despite lower prevaccination values in the BNT162b2 group. The results are not as good as observed in previous studies for the bivalent group relative to the original vaccine group, especially for baseline negative participants. Lack of randomization (which results in substantial prevaccination titer differences between groups and potential imbalance in some participants characteristics) makes it very difficult to interpret the results.

GMTs across both sexes were similar within both vaccine groups.

<div style=\"page-break-after: always\"></div>

Table 13 GeometricMeanTiters,bySubgroup-C4591048SubstudyDGroup2(at Dose 4and1 MonthAfterDose4)andC4591007Phase2/3Participants (atDose3and1MonthAfterDose3)-ParticipantsWithorWithout EvidenceofInfection-EvaluableImmunogenicityPopulation

|                                                                    |                                                              |                      | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |
|--------------------------------------------------------------------|--------------------------------------------------------------|----------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                    |                                                              |                      | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 10 μg | BNT162b2 10 μg                           | BNT162b2 10 μg                           | BNT162b2 10 μg                           |
| Assay                                                              | Subgroup                                                     | Sampling Time Pointa | nb                                                       | GMTc (95% CI)                                            | nb                                       | GMTc (95% CI)                            |                                          |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | Overall                                                      | Prevax               | 102                                                      | 488.3 (361.9, 658.8)                                     | 112                                      | 248.3 (187.2, 329.5)                     |                                          |
|                                                                    |                                                              | 1 Month              | 102                                                      | 2189.9 (1742.8, 2751.7)                                  | 113                                      | 1393.6 (1175.8, 1651.7)                  |                                          |
|                                                                    | Baseline (Dose 4 C4591048/Dose 3 C4591007)SARS-CoV-2 Statusd |                      |                                                          |                                                          |                                          |                                          |                                          |
|                                                                    | Positive                                                     | Prevax               | 58                                                       | 1069.2 (782.4, 1461.1)                                   | 65                                       | 695.0 (538.4, 897.3)                     |                                          |
|                                                                    |                                                              | 1 Month              | 58                                                       | 3465.6 (2682.8, 4476.7)                                  | 66                                       | 1893.9 (1547.6, 2317.7)                  |                                          |
|                                                                    | Negative                                                     | Prevax               | 44                                                       | 173.8 (117.3, 257.4)                                     | 47                                       | 59.8 (49.0, 73.1)                        |                                          |
|                                                                    |                                                              | 1 Month              | 44                                                       | 1195.8 (850.2,1681.9)                                    | 47                                       | 905.8 (703.0, 1167.2)                    |                                          |
|                                                                    | Sex                                                          |                      |                                                          |                                                          |                                          |                                          |                                          |
|                                                                    | Male                                                         | Prevax               | 49                                                       | 608.6 (394.7, 938.4)                                     | 62                                       | 242.0                                    |                                          |
|                                                                    |                                                              | 1 Month              | 48                                                       | 2442.8 (1749.9, 3410.2)                                  | 63                                       | (164.1, 356.8) 1506.8                    |                                          |
|                                                                    | Female                                                       | Prevax               | 53                                                       | 398.3 (261.5, 606.6)                                     | 50                                       | (1203.1,1887.2) 256.5 (167.3,393.2)      |                                          |
|                                                                    |                                                              | 1 Month              | 54                                                       | 1987.2 (1441.3, 2739.8)                                  | 50                                       | 1263.0 (968.7,1646.6)                    |                                          |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | Overall                                                      | Prevax               | 102                                                      | 2904.0 (2372.6, 3554.5)                                  | 113                                      | 1323.1 (1055.7,1658.2)                   |                                          |
|                                                                    |                                                              | 1 Month              | 102                                                      | 8245.9 (7108.9, 9564.9)                                  | 113                                      | 7235.1 (6331.5, 8267.8)                  |                                          |
|                                                                    | Baseline (Dose 4 C4591048/Dose 3 C4591007)SARS-CoV-2 Statusd |                      |                                                          |                                                          |                                          |                                          |                                          |
|                                                                    | Positive                                                     | Prevax               |                                                          | 58                                                       | 4198.4 (3342.9, 5272.8)                  | 66 2672.7 (2122.4, 3365.6)               |                                          |
|                                                                    |                                                              |                      | 1 Month                                                  | 58                                                       | 9228.4 (7707.0, 11050)                   | 66 7632.5 (6471.6, 9001.5)               |                                          |
|                                                                    | Negative                                                     |                      | Prevax                                                   | 44                                                       | 1786.4 (1305.0, 2445.5)                  | 47 492.9 (390.9, 621.6)                  |                                          |
|                                                                    |                                                              |                      | 1 Month                                                  | 44                                                       | 7108.8 (5534.0, 9131.8)                  | 47 6711.9 (5345.4, 8427.7)               |                                          |
|                                                                    | Sex                                                          |                      |                                                          |                                                          |                                          |                                          |                                          |
|                                                                    | Male                                                         |                      | Prevax                                                   | 49                                                       | 3369.3 (2480.9, 4575.8)                  | 63 1337.6 (1001.9, 1785.7)               |                                          |
|                                                                    |                                                              |                      | 1 Month                                                  | 48                                                       | 8728.6 (6921.6, 11007)                   | 63 7912.0 (6652.6, 9409.9)               |                                          |
|                                                                    | Female                                                       |                      | Prevax                                                   | 53                                                       | 2531.3 (1929.9, 3320.0)                  | 50 1305.1 (902.3, 1887.7)                |                                          |
|                                                                    |                                                              | 1 Month              |                                                          | 54                                                       | 7839.4 (6443.6. 9537.5)                  | 50 6464.1 (5237.5.7977.9)                |                                          |

<div style=\"page-break-after: always\"></div>

Abbreviations: GMT =geometric mean titer;LLOQ=lowerlimit of quantitation;NAAT=nucleic acid amplification respiratorysyndromecoronavirus2

test;N-binding=SARS-CoV-2 nucleoprotein-binding;NT50=50%neutralizing titer;SARS-CoV-2=severe acute Note:Substudy D Group 2includes participants 5-11years of age who received 3prior doses ofBNT162b210 μg 90 to 240dayspriorto enrollment. a. Protocol-specified timing for blood sample collection. b.n = Number of participants with valid and determinate assay results for the specified assay at the given sampling timepoint. C. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution).Assay results below the LLOQwere set to O.5×LLOQ. d.Positive =For C4591048Substudy D Group 2:positive N-binding antibody result at theDose 4visit,positive NAATresult attheDose4visit,ormedicalhistoryofCOVID-19.ForC4591007:positiveN-bindingantibodyresult at the Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visit, positive NAAT result at the Dose 1,Dose 2, Dose 3, or anyunscheduledillnessvisit uptotheDose3visit,ormedicalhistoryofCOVID-19. Negative =For C4591048Substudy D Group 2: negative N-binding antibody result at theDose 4visit, negative NAAT result attheDose4visit,andnomedicalhistoryofCOVID-19.ForC4591007:negativeN-binding antibodyresult at the Dose 1, 1-month post-Dose 2 (if available), and Dose 3 visits,negative NAAT result at the Dose 1, Dose 2, Dose 3, and anyunscheduledillnessvisitsupto theDose3visit,andnomedical historyofCOVID-19. PFIZER CONFIDENTIAL Source Data: adva Table Generation:02MAR2023 (09:44) OutputFile:./nda2\\_ubped2/C4591048\\_D\\_1MPD\\_1007\\_Immuno/adva\\_s001\\_gmt\\_p2\\_evl

## Reference Strain Neutralization

Participants With or Without Evidence of Infection

In the evaluable immunogenicity population with or without evidence of prior infection, for both vaccine groups, the observed reference strain GMTs were higher at predose and generally similar or higher at 1 month postdose in participants who were baseline positive compared with those who were baseline negative (Table 16).

Within both baseline positive and baseline negative groups, the observed reference strain- neutralizing GMTs were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with that in the BNT162b2 group at prevaccination. For baseline positive participants, at 1-month postdose, the observed reference strainneutralizing GMTs were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group. For baseline negative participants, reference strain-specific neutralizing GMTs were generally similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups.

GMTs across both sexes were similar within both vaccine groups.

## Participants Without Evidence of Infection

In the evaluable immunogenicity population without evidence of prior infection, the observed reference strain-neutralizing GMTs at pre-vaccination were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group.

At 1-month postdose, the observed GMTs were generally similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with those in the BNT162b2 group

## GMFR

## Omicron BA.4/BA.5 neutralization

## Participants With or Without Evidence of Infection

In the evaluable immunogenicity populations with or without evidence of prior infection, for both vaccine groups, GMFRs of Omicron BA.4/BA.5 at 1-month post dose were higher in participants who were baseline negative compared with those who were baseline positive (bivalent BNT162b2 [Original/Omi BA.4/BA.5]: 6.9 vs 3.3, BNT162b2: 15.1 vs 2.7) ( Table 14 ).

For baseline positive participants, GMFRs at 1-month postdose were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups. For baseline negative participants, GMFRs were lower in the

<div style=\"page-break-after: always\"></div>

bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group, which may relate to the higher prevaccination titers in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group.

GMFRs across both sexes were similar within both vaccine groups.

## Participants Without Evidence of Infection

In the evaluable immunogenicity population without evidence of infection, GMFRs for Omicron BA.4/BA.5 at 1-month postdose were lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group (6.9; 2sided 95% CI: 5.4, 8.8) compared with the BNT162b2 group (15.0; 2-sided 95% CI: 12.2, 18.4).

## Reference Strain Neutralization

Participants With or Without Evidence of Infection

In the evaluable immunogenicity populations with or without evidence of infection, for both vaccine groups, GMFRs of reference strain at 1-month postdose were higher for participants who were baseline negative compared with those who were baseline positive (bivalent BNT162b2 [Original/Omi BA.4/BA.5]: 4.0 vs 2.2, BNT162b2: 13.6 vs 2.9) ( Table 14 ).

For baseline positive participants, GMFRs at 1-month postdose were similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups. For baseline negative participants, GMFRs were lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group, which may relate to the higher prevaccination titers in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group.

GMFRs across both sexes were similar within both vaccine groups.

## Participants Without Evidence of Infection

In the evaluable immunogenicity population without evidence of infection, reference strain GMFRs from prevaccination to 1-month postdose were lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group (4.0; 2-sided 95% CI: 3.3, 4.8) compared with the BNT162b2 group (13.1; 2-sided 95% CI: 10.5, 16.4).

<div style=\"page-break-after: always\"></div>

Table 14

| GeometricMeanFoldRisesbySubgroup-C4591048SubstudyD Group 2 (FromDose 4 to1 MonthAfter Dose 4) and C4591007Phase 2/3       | GeometricMeanFoldRisesbySubgroup-C4591048SubstudyD Group 2 (FromDose 4 to1 MonthAfter Dose 4) and C4591007Phase 2/3       | GeometricMeanFoldRisesbySubgroup-C4591048SubstudyD Group 2 (FromDose 4 to1 MonthAfter Dose 4) and C4591007Phase 2/3       | GeometricMeanFoldRisesbySubgroup-C4591048SubstudyD Group 2 (FromDose 4 to1 MonthAfter Dose 4) and C4591007Phase 2/3       | GeometricMeanFoldRisesbySubgroup-C4591048SubstudyD Group 2 (FromDose 4 to1 MonthAfter Dose 4) and C4591007Phase 2/3       | GeometricMeanFoldRisesbySubgroup-C4591048SubstudyD Group 2 (FromDose 4 to1 MonthAfter Dose 4) and C4591007Phase 2/3       | p (as mized)          |
|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Participants(FromDose3to1MonthAfterDose3)-ParticipantsWith orWithoutEvidenceofInfection-EvaluableImmunogenicityPopulation | Participants(FromDose3to1MonthAfterDose3)-ParticipantsWith orWithoutEvidenceofInfection-EvaluableImmunogenicityPopulation | Participants(FromDose3to1MonthAfterDose3)-ParticipantsWith orWithoutEvidenceofInfection-EvaluableImmunogenicityPopulation | Participants(FromDose3to1MonthAfterDose3)-ParticipantsWith orWithoutEvidenceofInfection-EvaluableImmunogenicityPopulation | Participants(FromDose3to1MonthAfterDose3)-ParticipantsWith orWithoutEvidenceofInfection-EvaluableImmunogenicityPopulation | Participants(FromDose3to1MonthAfterDose3)-ParticipantsWith orWithoutEvidenceofInfection-EvaluableImmunogenicityPopulation | C4591007 T162b2 10 μg |
|                                                                                                                           |                                                                                                                           |                                                                                                                           | BN110Z0Z (Original/Omi BA.4/BA.5) 10 μg                                                                                   | BN110Z0Z (Original/Omi BA.4/BA.5) 10 μg                                                                                   |                                                                                                                           |                       |
| Assay                                                                                                                     | Subgroup                                                                                                                  | Sampling Time Pointa                                                                                                      | nb                                                                                                                        | GMFRc (95% C1)                                                                                                            | nb                                                                                                                        | GMFRc (95% CI)        |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer)                                                        | Overall                                                                                                                   | 1 Month                                                                                                                   | 101                                                                                                                       | 4.5 (3.8, 5.4)                                                                                                            | 112                                                                                                                       | 5.6 (4.5, 6.9)        |
|                                                                                                                           | Baseline (Dose 4 C4591048/Dose 3 C4591007) SARS-CoV-2 Statusd                                                             |                                                                                                                           |                                                                                                                           |                                                                                                                           |                                                                                                                           |                       |
|                                                                                                                           | Positive                                                                                                                  | 1 Month                                                                                                                   | 57                                                                                                                        | 3.3 (2.6, 4.1)                                                                                                            | 65                                                                                                                        | 2.7 (2.2,3.3)         |
|                                                                                                                           | Negative                                                                                                                  | 1 Month                                                                                                                   | 44                                                                                                                        | 6.9 (5.4, 8.7)                                                                                                            | 47                                                                                                                        | 15.1 (12.1, 18.9)     |
|                                                                                                                           | Sex                                                                                                                       |                                                                                                                           |                                                                                                                           |                                                                                                                           |                                                                                                                           |                       |
|                                                                                                                           | Male                                                                                                                      | 1 Month                                                                                                                   | 48                                                                                                                        | 4.0 (3.2, 5.1)                                                                                                            | 62                                                                                                                        | 6.2 (4.6, 8.4)        |
|                                                                                                                           | Female                                                                                                                    | 1 Month                                                                                                                   | 53                                                                                                                        | 5.0 (3.8, 6.5)                                                                                                            | 50                                                                                                                        | 4.9 (3.6, 6.8)        |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)                                                         | Overall                                                                                                                   | 1 Month                                                                                                                   | 101                                                                                                                       | 2.8 (2.5, 3.3)                                                                                                            | 113                                                                                                                       | 5.5 (4.5, 6.7)        |
|                                                                                                                           | Baseline (Dose 4 C4591048/Dose3C4591007) SARS-CoV-2 Statusd                                                               |                                                                                                                           |                                                                                                                           |                                                                                                                           |                                                                                                                           |                       |
|                                                                                                                           | Positive                                                                                                                  | 1 Month                                                                                                                   | 57                                                                                                                        | 2.2 (1.8, 2.6)                                                                                                            | 66                                                                                                                        | 2.9 (2.4, 3.4)        |
|                                                                                                                           | Negative                                                                                                                  | 1 Month                                                                                                                   | 44                                                                                                                        | 4.0 (3.3, 4.7)                                                                                                            | 47                                                                                                                        | 13.6 (10.9, 17.1)     |
|                                                                                                                           | Sex                                                                                                                       |                                                                                                                           |                                                                                                                           |                                                                                                                           |                                                                                                                           |                       |
|                                                                                                                           | Male                                                                                                                      | 1 Month                                                                                                                   | 48                                                                                                                        | 2.6 (2.1, 3.2)                                                                                                            | 63                                                                                                                        | 5.9 (4.5, 7.8)        |
|                                                                                                                           | Female                                                                                                                    | 1 Month                                                                                                                   | 53                                                                                                                        | 3.1 (2.5, 3.7)                                                                                                            | 50                                                                                                                        | 5.0 (3.7, 6.6)        |

amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: Substudy D Group 2 includes participants 5-11 years of age who received 3 prior doses of BNT162b2 10 μug 90 to 240 days prior to enrollment.

a. Protocol-specified timing for blood sample collection.

b. n = number of participants with valid and determinate assay results for the specified assay both before Dose 4 (C4591048)/Dose 3 (C4591007) and at the given dose/sampling time point.

C. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs(based on the Student t distribution).Assay results below the LLOQwere set to O.5× LLOQ in the analysis.

d. Positive = For C4591048 Substudy D Group 2: positive N-binding antibody result at the Dose 4 visit, positive NAAT result at the Dose 4 visit, or medical history of COVID-19. For C4591007: positive N-binding antibody result at the Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visit, positive NAAT result at the Dose 1, Dose 2, Dose 3, or any unscheduled illness visit up to the Dose 3 visit, or medical history of COVID-19.

Negative = For C4591048 Substudy D Group 2: negative N-binding antibody result at the Dose 4 visit, negative NAAT result at the Dose 4 visit, and no medical history of COVID-19. For C4591007: negative N-binding antibody result at the Dose 1, 1-month post-Dose 2 (if available), and Dose 3 visits, negative NAAT result at the Dose 1, Dose 2, Dose 3, and any unscheduled illness visits up to the Dose 3 visit, and no medical history of COVID-19.

PFIZER CONFIDENTIAL SourceData: advaTableGeneration:02MAR2023(09:44)

(Data cutoff date: C4591048 Substudy D[25NOV2022]/C4591007[27MAY2022])

Output File: ./nda2\\_ubped2/C4591048\\_D\\_1MPD\\_1007\\_Immuno/advas\\_s001\\_gmfr\\_p2\\_evl

<div style=\"page-break-after: always\"></div>

## Seroresponse

## Omicron BA.4/BA.5 neutralization

## Participants With or Without Evidence of Infection

In the evaluable immunogenicity population with or without evidence of prior infection, seroresponse rates  at  1-month  postdose  were  generally  higher  for  participants  who  were  baseline  negative compared with those who were baseline positive (bivalent BNT162b2 [Original/Omi BA.4/BA.5]: 75.0% vs. 36.8%, BNT162b2: 89.4% vs 26.2%) ( Table 15 ).

For baseline positive groups, seroresponse rates at 1-month postdose were slightly higher in participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with the BNT162b2 group. For baseline negative groups, seroresponse rates at 1-month postdose were slightly lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with the BNT162b2 group ( Table 15 ).

Seroresponse rates across both sexes were generally similar within both vaccine groups.

## Participants Without Evidence of Infection

In the evaluable immunogenicity population without evidence of prior infection, the proportion of participants who achieved seroresponse at 1-month postdose were generally lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group (74.4%) compared with the BNT162b2 group (91.1%).

## Reference Strain Neutralization

## Participants With or Without Evidence of Infection

In the evaluable immunogenicity population with or without evidence of prior infection, seroresponse rates at 1-month postdose were higher for participants who were baseline negative compared to those who were baseline positive (bivalent BNT162b2 [Original/Omi BA.4/BA.5]: 47.7% vs. 17.5%, BNT162b2: 95.7% vs 25.8%) ( Table 15 ).

For baseline positive participants, seroresponse rates at 1-month postdose were generally similar in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) and BNT162b2 groups. For baseline negative participants, seroresponse rates were lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group compared with the BNT162b2 group, which relate to the higher prevaccination titers in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group ( Table 15 ).

Seroresponse rates across both sexes were generally similar within both vaccine groups.

## Participants Without Evidence of Infection

In the evaluable immunogenicity population without evidence of prior infection, the proportion of participants who achieved seroresponse at 1-month postdose were lower in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group (48.8%) compared with the BNT162b2 group (95.6%).

<div style=\"page-break-after: always\"></div>

Table 15.

Number(%)of ParticipantsWithSeroresponse,by Subgroup-C4591048 SubstudyD Group 2(at1 MonthAfterDose4)and C4591007Phase 2/3 Participants(1MonthAfterDose3)-ParticipantsWithorWithout Evidence of Infection-EvaluableImmunogenicityPopulation

|                                                                  |                                                             |                      | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)                   | Vaccine Group (as Assigned/Randomized)   | Vaccine Group (as Assigned/Randomized)   |
|------------------------------------------------------------------|-------------------------------------------------------------|----------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                  |                                                             |                      | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591048 BivalentBNT162b2 (Original/Omi BA.4/BA.5) 10 μg | C4591007 BNT162b2 10 μg                  | C4591007 BNT162b2 10 μg                  |
| Assay                                                            | Subgroup                                                    | Sampling Time Pointa | Nb                                                       | n (%) (95% C1)                                           | Nb                                       | n (%) (95% C1)                           |
| SARS-CoV-2neutralization assay-Omicron BA.4/BA.5- NT50 (titer)   | Overall                                                     | 1 Month              | 101                                                      | 54 (53.5) (43.3, 63.5)                                   | 112                                      | 59 (52.7) (43.0, 62.2)                   |
|                                                                  | Baseline (Dose 4 C4591048/D0se3C4591007) SARS-CoV-2Statuse  |                      |                                                          |                                                          |                                          |                                          |
|                                                                  | Positive                                                    | 1 Month              | 57                                                       | 21 (36.8) (24.4, 50.7)                                   | 65                                       | 17 (26.2) (16.0, 38.5)                   |
|                                                                  | Negative                                                    | 1 Month              | 44                                                       | 33 (75.0) (59.7, 86.8)                                   | 47                                       | 42 (89.4) (76.9, 96.5)                   |
|                                                                  | Sex                                                         |                      |                                                          |                                                          |                                          |                                          |
|                                                                  | Male                                                        | 1 Month              | 48                                                       | 23 (47.9) (33.3, 62.8)                                   | 62                                       | 35 (56.5) (43.3, 69.0)                   |
|                                                                  | Female                                                      | 1 Month              | 53                                                       | 31 (58.5) (44.1, 71.9)                                   | 50                                       | 24 (48.0) (33.7, 62.6)                   |
| SARS-CoV-2 neutralization assay -reference strain - NT50 (titer) | Overall                                                     | 1 Month              | 101                                                      | 31 (30.7) (21.9, 40.7)                                   | 113                                      | 62 (54.9) (45.2, 64.2)                   |
|                                                                  | Baseline Dose 4 C4591048/Dose 3 C4591007) SARS-CoV-2Statuse |                      |                                                          |                                                          |                                          |                                          |
|                                                                  | Positive                                                    | 1 Month              | 57                                                       | 10 (17.5) (8.7, 29.9)                                    | 66                                       | 17 (25.8) (15.8, 38.0)                   |
|                                                                  | Negative                                                    | 1 Month              | 44                                                       | 21 (47.7) (32.5, 63.3)                                   | 47                                       | 45 (95.7) (85.5, 99.5)                   |
|                                                                  | Sex                                                         |                      |                                                          |                                                          |                                          |                                          |
|                                                                  | Male                                                        | 1 Month              | 48                                                       | 13 (27.1) (15.3, 41.8)                                   | 63                                       | 36 (57.1) (44.0, 69.5)                   |
|                                                                  | Female                                                      | 1 Month              | 53                                                       | 18 (34.0) (21.5, 48.3)                                   | 50                                       | 26 (52.0) (37.4, 66.3)                   |

Note: Seroresponse is defined as achieving a ≥4-fold rise from baseline (before Dose 4 for C4591048 Substudy D Group 2 and before Dose 3 for C4591007). If the baseline measurement is below the LLOQ, a postvaccination assay result ≥4 x LLOQ is considered a seroresponse.

Abbreviations: LLOQ = lower limit of quantitation; NAAT = nucleic acid amplification test; N-binding = SARS-CoV-2 nucleoprotein-binding;NT50=50%neutralizing titer;SARS-CoV-2=severe acute respiratory syndrome coronavirus 2. Note: Substudy D Group 2 includes participants 5-11 years of age who received 3 prior doses of BNT162b2 10 μg 90 to 240days prior to enrollment.

- a. Protocol-specified timingfor blood sample collection.
- b. N = number of participants with valid and determinate assay results for the specified assay both before vaccination and at the given dose/sampling time point. These values are the denominators for the percentage calculations.
- C. n = Number of participants with seroresponse for the given assay at the given dose/sampling time point.
- d. Exact 2-sided CI based on the Clopper and Pearson method.
- e. Positive = For C4591048 Substudy D Group 2: positive N-binding antibody result at the Dose 4 visit, positive NAAT result at the Dose 4 visit, or medical history of COVID-19. For C4591007: positive N-binding antibody result at the Dose 1, 1-month post-Dose 2 (if available), or Dose 3 visit, positive NAAT result at the Dose 1, Dose 2, Dose 3, or any unscheduled illness visit up to the Dose 3 visit, or medical history of COVID-19.

Negative = For C4591048 Substudy D Group 2: negative N-binding antibody result at the Dose 4 visit, negative NAAT result at the Dose 4 visit, and no medical history of COVID-19. For C4591007: negative N-binding antibody result at the Dose 1, 1-month post-Dose 2 (if available), and Dose 3 visits, negative NAAT result at the Dose 1, Dose 2, Dose 3, and any unscheduled illness visits up to the Dose 3visit, and no medical history of COVID-19.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 02MAR2023 (09:44)

(Data cutoff date:C4591048SubstudyD[25NOV2022]/C4591007[27MAY2022])

Output File:./nda2 ubped2/C4591048 D1MPD1007 Immuno/adva s003 fr4 p2 evl

<div style=\"page-break-after: always\"></div>

## MAH discussion of immunogenicity results for C4591048 Substudy D Group 2 (5y&lt;12 yoa)

At 1-month postdose, a fourth dose with bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 10 μ g in participants ≥ 5 years to &lt;12 years of age in the C4591048 Substudy D Group 2 who received 3 prior doses of original BNT162b2 at 10 μ g indicated a robust immune response against Omicron BA.4/BA.5. The immune response elicited by bivalent BNT162b2 (Original/Omi BA.4/BA.5) were generally similar for Omicron BA.4/BA.5- and reference strain-specific neutralizing titers and percentage of participants with seroresponse to Omicron BA.4/BA.5 compared with C4591007 Phase 2/3 participants of the same age who received 3 doses of original BNT162b2.

The magnitude of the Omicron BA.4/BA.5 immune response after Dose 3 of BNT162b2 is unexpected and may be related to natural exposure and dose interval. As this analysis did not compare 2 contemporaneous randomized groups, there may have been an imbalance between the 2 groups in some measurable or nonmeasurable factors, such as those described below. This imbalance may have contributed to the unexpected results. Participants in C4591007 Phase 2/3 received the third dose in March-April 2022, shortly after the Omicron BA.1 wave.

Whilst not reflected in the N-binding antibody responses, this may have resulted in a significant level of natural exposure to Omicron BA.1; thereby, potentially augmenting the response to Dose 3 of BNT162b2. The prevaccination GMTs also may have influenced the magnitude of the response to the booster dose (either Dose 3 or Dose 4), as they were higher in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group than in the comparator group. In addition, this difference may be due to the shorter interval between Dose 3 and Dose 4 in the BNT162b2 (Original/Omi BA.4/BA.5) group (5.5 months, range 3.5-8.5 months) compared with the dose interval between Dose 2 and Dose 3 in the BNT162b2 group (6.5 months, range 6.3-7.6 months). However, it may be more likely due to participants in the bivalent BNT162b2 (Original/Omi BA.4/BA.5) group receiving the fourth dose in September- October 2022. Hence, these participants had a 6-month longer period of potential exposure to SARS-CoV-2 during the waves of multiple Omicron sublineages in 2022. The higher prevaccination GMTs were reflected in the lower GMFRs and seroresponse rates in participants who received a fourth dose with the bivalent BNT162b2 (Original/Omi BA.4/BA.5) compared with participants in C4591007 Phase 2/3 who received 3 doses of original BNT162b2.

## 2.6.2.3.2. Study C4591044

Study C4591044 is a randomized, active-controlled study to evaluate the safety, tolerability, and immunogenicity of new bivalent vaccines. The study participants are divided into cohorts, which may be studied in a staggered or parallel manner. Cohorts 2 and 3 in the study consist of participants ≥ 12 years of age who received 3 doses of BNT162b2, each at 30 µg, prior to receiving a booster (fourth dose) with BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at the 30- or 60-µg dose level. The groups within each cohort and the dose level of the study vaccine are defined in Table 16 . The MAH has provided 1-month post dose (four) immunogenicity data for the participants.

<div style=\"page-break-after: always\"></div>

Table 16. StudyC4591044Cohorts2and3

| Cohort Number   | Group Number   | Age (Years)   |   Booster (Fourth Dose) With BNT162b2Bivalent (WT/OMIBA.4/BA.5) (μg) |
|-----------------|----------------|---------------|----------------------------------------------------------------------|
| 2               | 1              | 12 to 17      |                                                                   30 |
|                 | 2              | 18 to 55      |                                                                   30 |
|                 | 3              | 18 to 55      |                                                                   60 |
|                 | 十              | >55           |                                                                   30 |
|                 | 5              | >55           |                                                                   60 |
|                 | 1              | 18 to 55      |                                                                   30 |
|                 | 2              | >55           |                                                                   30 |

## · Immunogenicity Endpoints and Analysis Methods

## Objectives, Estimands and Endpoints

| Objectives                                                                                                                                                                                                                                                                                                                                                                                            | Estimands                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Endpoints                                             | Reference                       |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------|---------------------------------|
| Primary Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                | Primary Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Primary Immunogenicity                                | Primary Immunogenicity          |
| Cohort 2/Group 4 + Cohort 3/ Group 2 combined: To demonstrate the superiority with respect to level of neutralizing titer and noninferiority with respect to seroresponse rate of the anti-Omicron BA.4/BA.5 immune response after BNT162b2 Bivalent (WT/OMIBA.4/BA.5) 30 µg compared to after BNT162b2 30 µg c given as a second booster dose to BNT162b2-experienced participants >55 years of age. | In participants complying with the key protocol criteria (evaluable participants): • GMRof the Omicron (BA.4/BA.5)-neutralizing titers 1 month after BNT162b2 Bivalent (WT/ OMIBA.4/BA.5) to 1 month after BNT162b2, given as a second booster dose in BNT162b2- experienced participants • The difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain at 1 month after BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) and at 1 month after BNT162b2 given as a second booster dose in BNT162b2- experienced participants | • SARS-CoV-2 Omicron (BA.4/BA.5)- neutralizing titers | • Data are reported in this CSR |

<div style=\"page-break-after: always\"></div>

| Cohort 2/Group 2 + Cohort 3/Group 1 combined and Cohort 2/Group 4 + Cohort 3/Group 2 combined: To demonstrate the noninferiority with respect to level of neutralizing titer and with respect to seroresponse rate of the anti-Omicron BA.4/BA.5 immune response after BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg given as a second booster dose to BNT162b2-experienced participants 18 through 55 years of age compared to participants >55 years of age.   | In participants complying with the key protocol criteria (evaluable participants): • GMRof the Omicron (BA.4/BA.5)-neutralizing titers at 1 month after BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) given as a second booster dose in BNT162b2-experienced participants 18 through 55 years of age compared to participants >55 years of age • The difference in percentages of participants with seroresponse to the Omicron BA.4/BA.5 strain at 1 month after BNT162b2 Bivalent (WT/OMIBA.4/BA.5)given as a second booster dose in BNT162b2-experienced participants 18 through 55 years of age compared to participants >55 years of age   | • SARS-CoV-2 Omicron (BA.4/BA.5)- neutralizing titers                                                                                                         | • Data are reported in this CSR                                                              |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Cohort 2: To describe the immune response to BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg or 60 µg and BNT162b2 Bivalent (WT/OMI BA.1) 30 µg e or 60 µg e given as a second booster dose to BNT162b2-experienced participants 12 through 17, 18 through 55 e , and > 55 e years of age.                                                                                                                                                                         | In participants complying with the key protocol criteria (evaluable participants): • GMTat each time point for each strain-specific neutralizing titer • GMFRfrombefore the study vaccination to each subsequent time point for each strain-specific neutralizing titer • Percentages of participants with seroresponse at each time point following vaccination for each strain- specific neutralizing titer Estimands                                                                                                                                                                                                                 | • SARS-CoV-2 Omicron (BA.4/BA.5)- neutralizing titers • SARS-CoV-2 Omicron (BA.1)- neutralizing titers • SARS-CoV-2 reference- strain c - neutralizing titers | • Immunogenicity data before and at 1 month after study vaccination are reported in this CSR |
| Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Endpoints                                                                                                                                                     | Reference                                                                                    |
| Secondary Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                      | Secondary Immunogenicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | Secondary Immunogenicity                                                                                                                                      | Secondary Immunogenicity                                                                     |

<div style=\"page-break-after: always\"></div>

| Cohort 2/Group 4 + Cohort 3/Group 2 combined: To demonstrate the noninferiority of the anti-reference-strain immune response after BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) 30 µg compared to BNT162b2 30 µg c given as a second booster dose in BNT162b2-experienced participants >55 years of age.                  | In participants complying with the key protocol criteria (evaluable participants): • GMRofthereference-strain- neutralizing titers at 1 month after BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) and at 1 month after BNT162b2 given as a second booster dose in BNT162b2- experienced participants                                                                                                                    | • SARS-CoV-2 reference- strain c - neutralizing titers                                                       | • Data are reported in this CSR                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|
| Cohort 2/Group 2 + Cohort 3/Group 1 combined and Cohort 2/Group 4 + Cohort 3/Group 2 combined: To describe the immune response to BNT162b2 Bivalent (WT/ OMI BA.4/BA.5) 30 µg compared to BNT162b2 30 µg c given as a second booster dose to BNT162b2-experienced participants 18 through 55 and >55 years of age. | In participants complying with the key protocol criteria (evaluable participants): • GMTat each time point for each strain-specific neutralizing titer • GMFRfrombefore the study vaccination to each subsequent time point for each strain-specific neutralizing titer • Percentages of participants with seroresponse b at each time point following vaccination for each strain- specific neutralizing titer | • SARS-CoV-2 Omicron (BA.4/BA.5)- neutralizing titers • SARS-CoV-2 reference- strain c - neutralizing titers | • Immunogenicity data before and 1 month after study vaccination are reported in this CSR |

a. SAEs are presented from vaccination through 1 month after vaccination in this interim CSR.

b. Seroresponse was defined as achieving a ≥4 -fold rise from the baseline (before the study vaccination) at each timepoint after vaccination. If the baseline measurement was below the LLOQ, the postvaccination measure of ≥4 × LLOQ was considered seroresp onse.

c. Reference strain was also referred to as the wild type or ancestral strain (Wuhan-Hu-1; USA-WA1/2020).

d. The participants &gt;55 years of age from C4591031 Substudy E expanded cohort who received BNT162b2 30 µg as a second booster dose will be used as comparator group for this objective.

e. A subset of approximately 100 participants in each age group (18 through 55 years of age, &gt;55 years of age) and dose group (30 µg, 60 µg) from C4591031 Substudy E expanded cohort who received BNT162b2 Bivalent (WT/OMI BA.1) 30 µg or 60 µg as a second booster dose will be selected for this objective. The subset selected from C4591031 Substudy E will include similar percentage of participants with baseline positive SARS-CoV-2 infection status as the groups in Cohort 2 of this study, whenever feasible.

f. If the COVID-19 illness visit was conducted as an in-person visit, a blood sample was taken for this assessment. No blood samples were obtained for remote (telehealth) COVID-19 illness visits.

## · Immunogenicity Population

This part of the immunogenicity analysis included approximately 100 randomized participants per vaccine group ( Table 17 ).

<div style=\"page-break-after: always\"></div>

Table 17. Immunogenicity Populations - Study C4591044 Cohort 2 and Study C4591031 Substudy E Expanded Cohort

|                                                                                                   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            |
|---------------------------------------------------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                                                   | C4591044                        | C4591044                        | C4591044                        | C4591044                        | C4591044                        | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) |
|                                                                                                   | 12-17 Years                     | Bivalent 18-55 Years            | Bivalent 18-55 Years            | (WT/OMI BA.4/BA.5) >55 Years    | (WT/OMI BA.4/BA.5) >55 Years    | 18-55 Years                              | 18-55 Years                              | >55 Years                                | >55 Years                                |
|                                                                                                   | 30 μg n a (%)                   | 30 μg n a (%)                   | 60 μg n a (%)                   | 30 μg n a (%)                   | 60 μg n a (%)                   | 30 μg n a (%)                            | 60 μg n a (%)                            | 30 μg n a (%)                            | 60 μg n a (%)                            |
| Randomized b                                                                                      | 108 (100.0)                     | 104 (100.0)                     | 110 (100.0)                     | 106 (100.0)                     | 102 (100.0)                     | 100 (100.0)                              | 100 (100.0)                              | 100 (100.0)                              | 100 (100.0)                              |
| All-available immunogenicity population                                                           | 107 (99.1)                      | 97 (93.3)                       | 105 (95.5)                      | 105 (99.1)                      | 101 (99.0)                      | 100 (100.0)                              | 100 (100.0)                              | 100 (100.0)                              | 100 (100.0)                              |
| Excluded from all-available immunogenicity population                                             | 1 (0.9)                         | 7 (6.7)                         | 5 (4.5)                         | 1 (0.9)                         | 1 (1.0)                         | 0                                        | 0                                        | 0                                        | 0                                        |
| Reason for exclusion c Participant did not receive study intervention                             | 0                               | 1 (1.0)                         | 0                               | 0                               | 0                               | 0                                        | 0                                        | 0                                        | 0                                        |
| Did not have at least 1 valid and determinate immunogenicity result after study vaccination       | 0                               | 7 (6.7)                         | 5 (4.5)                         | 1 (0.9)                         | 1 (1.0)                         | 0                                        | 0                                        | 0                                        | 0                                        |
| Did not provide informed consent                                                                  | 1 (0.9)                         | 0                               | 0                               | 0                               | 0                               | 0                                        | 0                                        | 0                                        | 0                                        |
| Evaluable immunogenicity population                                                               | 105 (97.2)                      | 95 (91.3)                       | 102 (92.7)                      | 102 (96.2)                      | 99 (97.1)                       | 100 (100.0)                              | 100 (100.0)                              | 100 (100.0)                              | 100 (100.0)                              |
| Participants without evidence of infection up to 1 month after study vaccination d                | 25 (23.1)                       | 32 (30.8)                       | 23 (20.9)                       | 40 (37.7)                       | 31 (30.4)                       | 67 (67.0)                                | 30 (30.0)                                | 64 (64.0)                                | 65 (65.0)                                |
| Excluded from evaluable immunogenicity population                                                 | 3 (2.8)                         | 9 (8.7)                         | 8 (7.3)                         | 4 (3.8)                         | 3 (2.9)                         | 0                                        | 0                                        | 0                                        | 0                                        |
| Reason for exclusion c Did not meet eligibility and randomization criteria                        | 0                               | 5 (4.8)                         | 3 (2.7)                         | 0                               | 0                               | 0                                        | 0                                        | 0                                        | 0                                        |
| Participant did not receive study intervention as randomized                                      | 0                               | 1 (1.0)                         | 0                               | 0                               | 0                               | 0                                        | 0                                        | 0                                        | 0                                        |
| Did not have at least 1 valid and determinate immunogenicity result within 28-42 days after study | 2 (1.9)                         | 9 (8.7)                         | 6 (5.5)                         | 4 (3.8)                         | 3 (2.9)                         | 0                                        | 0                                        | 0                                        | 0                                        |
| Had important protocol deviation                                                                  | 1 (0.9)                         | 5 (4.8)                         | 4 (3.6)                         | 0                               | 0                               | 0                                        | 0                                        | 0                                        | 0                                        |
| Did not provide informed consent                                                                  | 1 (0.9)                         | 0                               | 0                               | 0                               | 0                               | 0                                        | 0                                        | 0                                        | 0                                        |

Abbreviations: N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

<div style=\"page-break-after: always\"></div>

Note: All participants enrolled in Study C4591044 Cohort 2 and subsets of approximately 100 participants selected from each age group (18-55 years, &gt;55 years) and dose group (BNT162b2 Bivalent (WT/OMI BA.1) 30μg and 60μg group) of Study C4591031 Substudy E expanded cohort were included in the analysis.

- a. n = Number of participants with the specified characteristic.
- b. This value is the denominator for the percentage calculations.
- c. Participants may have been excluded for more than 1 reason.

d. Participants who had no serological or virological evidence (up to the 1-month post-study vaccination blood sample collection) of past SARS-CoV-2 infection (ie, negative N-binding antibody [serum] result at the study vaccination, the 7- day (if available) and the 1month post-study vaccination visits, negative NAAT [nasal swab] at the study vaccination visit, and any unscheduled visit up to the 1month post-study vaccination blood sample collection) and had no medical history of COVID-19 were included in the analysis. PFIZER CONFIDENTIAL Source Data: adsl Table Generation: 10JAN2023 (20:14) (Data cutoff date : C4591044 [12OCT2022]/C4591031 18-55 Years[25AUG2022]/&gt;55 Years[16MAY2022]) Output File: ./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adsl\\_s009\\_immpop\\_1m\\_c2f

## · Demographic

Demographic characteristics for participants in Cohort 2 with or without evidence of infection up to 1 month after study vaccination in the evaluable immunogenicity population are presented in Table 18 .

Demographic characteristics for participants in the evaluable immunogenicity population with or without evidence of infection up to 1 month after study vaccination were similar to the safety population.

Demographic characteristics for participants without evidence of infection up to 1 month after study vaccination in the evaluable immunogenicity population and for participants with or without evidence of infection up to 1 month after study vaccination in the all-available immunogenicity population were generally similar to those in Table 18 .

Table 18. Demographic Characteristics - Study C4591044 Cohort 2 and Study C4591031 Substudy E Expanded Cohort - Participants With or Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                  | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            |
|----------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|------------------------------------------|
|                                  | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) |
|                                  | 12-17 Years                                   | 18-55 Years                                   | 18-55 Years                                   | >55 Years                                     | >55 Years                                     | 18-55 Years                              | 18-55 Years                              | >55 Years                                | >55 Years                                |
|                                  | 30 μg (N a =105) n b (%)                      | 30 μg (N a =95) n b (%)                       | 60 μg (N a =102) n b (%)                      | 30 μg (N a =102) n b (%)                      | 60 μg (N a =99) n b (%)                       | 30 μg (N a =100) n b (%)                 | 60 μg (N a =100) n b (%)                 | 30 μg (N a =100) n b (%)                 | 60 μg (N a =100) n b (%)                 |
| Sex                              |                                               |                                               |                                               |                                               |                                               |                                          |                                          |                                          |                                          |
| Male                             | 58 (55.2)                                     | 40 (42.1)                                     | 41 (40.2)                                     | 62 (60.8)                                     | 45 (45.5)                                     | 51 (51.0)                                | 58 (58.0)                                | 57 (57.0)                                | 53 (53.0)                                |
| Female                           | 47 (44.8)                                     | 55 (57.9)                                     | 61 (59.8)                                     | 40 (39.2)                                     | 54 (54.5)                                     | 49 (49.0)                                | 42 (42.0)                                | 43 (43.0)                                | 47 (47.0)                                |
| Race                             |                                               |                                               |                                               |                                               |                                               |                                          |                                          |                                          |                                          |
| White                            | 89 (84.8)                                     | 75 (78.9)                                     | 83 (81.4)                                     | 80 (78.4)                                     | 89 (89.9)                                     | 77 (77.0)                                | 86 (86.0)                                | 89 (89.0)                                | 83 (83.0)                                |
| Black or African American        | 9 (8.6)                                       | 9 (9.5)                                       | 11 (10.8)                                     | 16 (15.7)                                     | 8 (8.1)                                       | 7 (7.0)                                  | 7 (7.0)                                  | 7 (7.0)                                  | 11 (11.0)                                |
| American Indian or Alaska Native | 0                                             | 0                                             | 0                                             | 1 (1.0)                                       | 0                                             | 0                                        | 0                                        | 0                                        | 0                                        |

<div style=\"page-break-after: always\"></div>

| Asian                                                                                                  | 3 (2.9)     | 9 (9.5)     | 8 (7.8)     | 3 (2.9)     | 2 (2.0)     | 14 (14.0)   | 4 (4.0)     | 4 (4.0)     | 5 (5.0)     |
|--------------------------------------------------------------------------------------------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Native Hawaiian or other Pacific Islander                                                              | 0           | 0           | 0           | 1 (1.0)     | 0           | 2 (2.0)     | 1 (1.0)     | 0           | 0           |
| Multiracial                                                                                            | 3 (2.9)     | 2 (2.1)     | 0           | 1 (1.0)     | 0           | 0           | 2 (2.0)     | 0           | 1 (1.0)     |
| Not reported                                                                                           | 1 (1.0)     | 0           | 0           | 0           | 0           | 0           | 0           | 0           | 0           |
| Age at vaccination (years)                                                                             |             |             |             |             |             |             |             |             |             |
| Median                                                                                                 | 15.0        | 40.0        | 41.0        | 65.0        | 63.0        | 42.0        | 39.5        | 66.0        | 67.0        |
| Min, max                                                                                               | (12, 17)    | (19, 55)    | (18, 55)    | (56, 79)    | (56, 85)    | (22, 55)    | (18, 55)    | (56, 85)    | (56, 86)    |
| Baseline SARS- CoV-2 status                                                                            |             |             |             |             |             |             |             |             |             |
| Positive c                                                                                             | 79 (75.2)   | 62 (65.3)   | 75 (73.5)   | 62 (60.8)   | 67 (67.7)   | 33 (33.0)   | 70 (70.0)   | 36 (36.0)   | 35 (35.0)   |
| Negative d                                                                                             | 26 (24.8)   | 33 (34.7)   | 27 (26.5)   | 40 (39.2)   | 32 (32.3)   | 67 (67.0)   | 30 (30.0)   | 64 (64.0)   | 65 (65.0)   |
| Time from the last dose of BNT162b2 (received prior to the study) to the study vaccination (months e ) |             |             |             |             |             |             |             |             |             |
| n                                                                                                      | 105         | 95          | 102         | 102         | 99          | 100         | 100         | 100         | 100         |
| Median                                                                                                 | 8.4         | 10.9        | 10.8        | 10.9        | 10.9        | 8.6         | 8.5         | 6.3         | 6.3         |
| Min, max                                                                                               | (5.6, 12.0) | (5.5, 12.8) | (6.6, 13.0) | (5.5, 12.9) | (6.6, 13.0) | (5.6, 13.0) | (5.4, 12.3) | (4.7, 11.5) | (5.4, 11.1) |
| Time from the last dose of BNT162b2 (received prior to the study) to the study vaccination (days)      |             |             |             |             |             |             |             |             |             |
| n                                                                                                      | 105         | 95          | 102         | 102         | 99          | 100         | 100         | 100         | 100         |
| Median                                                                                                 | 234.0       | 305.0       | 302.0       | 306.0       | 306.0       | 239.5       | 239.0       | 175.5       | 175.0       |
| Min, max                                                                                               | (157, 335)  | (155, 357)  | (184, 364)  | (153, 362)  | (184, 363)  | (158, 365)  | (151, 343)  | (131, 322)  | (150, 312)  |
| Body mass index (BMI)                                                                                  |             |             |             |             |             |             |             |             |             |
| Number of participants ≥16 years of age f                                                              | 44          | 95          | 102         | 102         | 99          | 100         | 100         | 100         | 100         |
| Underweight (<18.5 kg/m 2 )                                                                            | 5 (11.4)    | 1 (1.1)     | 6 (5.9)     | 3 (2.9)     | 1 (1.0)     | 1 (1.0)     | 2 (2.0)     | 0           | 0           |
| Normal weight (≥18.5 -24.9 kg/m 2 )                                                                    | 28 (63.6)   | 38 (40.0)   | 23 (22.5)   | 27 (26.5)   | 22 (22.2)   | 20 (20.0)   | 27 (27.0)   | 22 (22.0)   | 23 (23.0)   |
| Overweight (≥25.0 -29.9 kg/m 2 )                                                                       | 8 (18.2)    | 32 (33.7)   | 31 (30.4)   | 33 (32.4)   | 41 (41.4)   | 31 (31.0)   | 30 (30.0)   | 42 (42.0)   | 41 (41.0)   |
| Obese (≥30.0 kg/m 2 )                                                                                  | 3 (6.8)     | 24 (25.3)   | 42 (41.2)   | 39 (38.2)   | 35 (35.4)   | 48 (48.0)   | 41 (41.0)   | 36 (36.0)   | 36 (36.0)   |

<div style=\"page-break-after: always\"></div>

## · Immunogenicity results

## GMT

Analysis of immunogenicity data at 1 month after study vaccination in the evaluable immunogenicity population with or without evidence of infection for BNT162b2- experienced participants showed that BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at 30 µg and 60 µg dose elicited robust immune response against Omicron BA.4/BA.5 in all age groups and the response was higher than the corresponding BNT162b2 Bivalent (WT/OMI BA.1) dose groups.

Omicron BA.4/BA.5 GMTs at prevaccination and 1 month after study vaccination were higher in participants who were baseline positive compared with those were baseline negative in all age and vaccine groups.

Within baseline positive or baseline negative groups, Omicron BA.4/BA.5 GMTs were:

- Higher in participants 12 through 17 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg compared with other age and vaccine groups at both prevaccination and 1 month after vaccination.
- Larger increase from prevaccination in participants 18 through 55 and &gt;55 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30-µg and 60-µg groups compared with participants in the corresponding BNT162b2 Bivalent (WT/OMI BA.1) dose groups. The differences between BNT162b2 Bivalent (WT/OMI BA.4/BA.5) groups and BNT162b2 Bivalent (WT/OMI BA.1) were more substantial in the baseline negative groups.
- Generally similar in participants 18 through 55 and &gt;55 years of age who received BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at either dose.
- Higher overall in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 60-µg group compared with that in the 30-µg group.
- Generally similar across both sexes within each age and dose group.

<div style=\"page-break-after: always\"></div>

Table 19 14.20. Geometric Mean Titers, by Subgroup - Study C4591044 Cohort 2 and Study Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity

C4591031 Substudy E Expanded Cohort - Participants With or Without Evidence of Population

|                                                                  |                   |                             |                       | VaccineGroup (asRandomized)                  | VaccineGroup (asRandomized)                  | VaccineGroup (asRandomized)              | VaccineGroup (asRandomized)              |
|------------------------------------------------------------------|-------------------|-----------------------------|-----------------------|----------------------------------------------|----------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                  |                   |                             |                       | C4591044 BNT162b2Bivalent (WT/OMI BA.4/BA.5) | C4591044 BNT162b2Bivalent (WT/OMI BA.4/BA.5) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) |
| Assay                                                            | Dosage/Age Group  | Subgroup                    | Sainpling Time Pointa | nb                                           | GMTc (95% CI)                                | nb                                       | GMTc (95% CI)                            |
| SARS-CoV-2 neutralization assay - OmicronBA.4/BA.5- NT50 (titer) | 30 μg/12-17 years | All                         | Prevax                | 104                                          | 1105.8 (835.1, 1464.3)                       | N/A                                      | N/A                                      |
|                                                                  |                   |                             | 1 Month               | 105                                          | 8212.8 (6807.3, 9908.7)                      | N/A                                      | N/A                                      |
|                                                                  |                   | Baseline SARS- CoV-2 status |                       |                                              |                                              |                                          |                                          |
|                                                                  |                   | Positived                   | Prevax                | 78                                           | 1791.1 (1379.6, 2325.3)                      | N/A                                      | N/A                                      |
|                                                                  |                   |                             | 1 Month               | 79                                           | 9892.5 (8114.6, 12059.8)                     | N/A                                      | N/A                                      |
|                                                                  |                   | Negativee                   | Prevax                | 26                                           | 260.2 (157.1, 430.9)                         | N/A                                      | N/A                                      |
|                                                                  |                   |                             | 1 Month               | 26                                           | 4666.1 (3096.1, 7032.2)                      | N/A                                      | N/A                                      |
|                                                                  | 30 μg/18-55 years | All                         | Prevax                | 95                                           | 338.3 (238.1, 480.7)                         | 100                                      | 151.5 (113.4, 202.3)                     |
|                                                                  |                   |                             | 1 Month               | 95                                           | 2839.0 (2150.0, 3748.8)                      | 100                                      | 1072.0 (816.1, 1408.1)                   |
|                                                                  |                   | Baseline SARS- CoV-2 status |                       |                                              |                                              |                                          |                                          |
|                                                                  |                   | Positived                   | Prevax                | 62                                           | 900.3 (661.5, 1225.2)                        | 33                                       | 558.4 (338.6, 920.9)                     |
|                                                                  |                   |                             | 1 Month               | 62                                           | 4678.4 (3438.9, 6364.6)                      | 33                                       | 2271.4 (1346.7, 3831.2)                  |
|                                                                  |                   | Negativee                   | Prevax                | 33                                           | 53.8 (41.1, 70.5)                            | 67                                       | 79.7 (62.7, 101.1)                       |
|                                                                  |                   |                             | 1 Month               | 33                                           | 1110.7 (743.9, 1658.4)                       | 67                                       | 740.6 (557.2, 984.2)                     |

<div style=\"page-break-after: always\"></div>

|                                                                   | 30 μg/>55 years   | All                         | Prevax   | 101   | 301.9 (215.6,422.8)        | 99   | 225.4 (164.1, 309.6)      |
|-------------------------------------------------------------------|-------------------|-----------------------------|----------|-------|----------------------------|------|---------------------------|
|                                                                   |                   |                             | 1 Month  | 102   | 3019.8 (2327.5, 3918.0)    | 100  | 943.4 (733.4, 1213.6)     |
|                                                                   |                   | Baseline SARS- CoV-2 status |          |       |                            |      |                           |
|                                                                   |                   | Positived                   | Prevax   | 61    | 745.8 (516.5, 1076.9)      | 36   | 948.9 (576.4, 1562.1)     |
|                                                                   |                   |                             | 1 Month  | 62    | 4386.5 (3263.2, 5896.4)    | 36   | 2334.3 (1524.5, 3574.3)   |
|                                                                   |                   | Negative                    | Prevax   | 40    | 76.0 (54.7, 105.7)         | 63   | 99.1 (78.1, 125.8)        |
|                                                                   |                   |                             | 1 Month  | 40    | 1693.1 (1094.0, 2620.1)    | 64   | 566.7 (446.2, 719.9)      |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer) | 30 μg/12-17 years | A11                         | Prevax   | 105   | 6863.3 (5587.8, 8430.1)    | N/A  | N/A                       |
|                                                                   |                   |                             | 1 Month  | 105   | 23641.3 (20473.1, 27299.8) | N/A  | N/A                       |
|                                                                   |                   | Baseline SARS- CoV-2 status |          |       |                            |      |                           |
|                                                                   |                   | Positived                   | Prevax   | 79    | 8685.4 (7062.7, 10680.9)   | N/A  | N/A                       |
|                                                                   |                   |                             | 1 Month  | 79    | 25991.8 (22377.5, 30189.8) | N/A  | N/A                       |
|                                                                   |                   | Negativee                   | Prevax   | 26    | 3356.2 (2106.9, 5346.2)    | N/A  | N/A                       |
|                                                                   |                   |                             | 1 Month  | 26    | 17725.2 (12376.4, 25385.7) | N/A  | N/A                       |
|                                                                   | 30 μg/18-55 years | Al1                         | Prevax   | 95    | 2349.0 (1693.4, 3258.4)    | 100  | 1338.4 (1056.9, 1695.1)   |
|                                                                   |                   |                             | 1 Month  | 95    | 11919.3 (9839.1, 14439.3)  | 99   | 6913.9 (5690.4, 8400.5)   |
|                                                                   |                   | Baseline SARS- CoV-2 status |          |       |                            |      |                           |
|                                                                   |                   | Positived                   | Prevax   | 62    | 5615.4 (4406.4, 7156.1)    | 33   | 3183.8 (2185.4, 4638.2)   |
|                                                                   |                   |                             | 1 Month  | 62    | 16214.4 (13340.3, 19707.6) | 32   | 10119.7 (7341.3, 13949.6) |
|                                                                   |                   | Negativee                   | Prevax   | 33    | 456.8 (291.5, 716.0)       | 67   | 873.5 (682.8, 1117.3)     |
|                                                                   |                   |                             | 1 Month  | 33    | 6685.8 (4731.8, 9446.9)    | 67   | 5763.8 (4550.1, 7301.1)   |

<div style=\"page-break-after: always\"></div>

| 30μg/>55 years   | A11                                  | Prevax   |   101 | 2643.1 (1990.8, 3509.1)    |   100 | 1985.7 (1510.1, 2611.0)   |
|------------------|--------------------------------------|----------|-------|----------------------------|-------|---------------------------|
|                  |                                      | 1 Month  |   102 | 12103.8 (9992.0, 14662.0)  |   100 | 7128.6 (5954.4, 8534.3)   |
|                  | BaselineSARS- CoV-2 status Positived | Prevax   |    61 | 5428.8 (4112.6, 7166.3)    |    36 | 6390.0 (4353.9, 9378.3)   |
|                  |                                      | 1 Month  |    62 | 15336.7 (12079.9, 19471.6) |    36 | 12362.0 (9000.5, 16978.9) |
|                  | Negativee                            | Prevax   |    40 | 881.9 (601.6, 1292.7)      |    64 | 1028.9 (795.8, 1330.3)    |
|                  |                                      | 1 Month  |    40 | 8386.3 (6235.4, 11279.2)   |    64 | 5230.2 (4357.9, 6277.2)   |

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; N/A =not applicable; N-binding = SARS-CoV-2 nucleoprotein-binding: NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Note: All participants enrolled in Study C4591044 Cohort 2 and subsets of approximately 100 participants selected from each age group (18-55 years, &gt;55 years) and dose group (BNT162b2 Bivalent (WT/OMI BA.1) 30-μg and 60-pg group) of Study C4591031 Substudy E expanded cohort were included in the analysis.

- a. Protocol-specified timing for blood sample collection.
- b. point.
- C. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean 1ogarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
- d. Positive N-binding antibody result at baseline, positive NAAT result at baseline, or medical history of COVD-19.
- e. Negative N-binding antibody result at baseline, negative NAAT result at baseline, and no medical history of COVID19.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 08JAN2023 (20:49) (Data cutoff date : C4591044[120CT2022]/C459103118-55 Years[25AUG2022]/&gt;55Years[16MAY2022]) Output File: /nda2ub1044/C45910441MPDC23CMB/advas001gmtsub1mevlc2f

## GMFR

Within baseline positive or baseline negative groups, Omicron BA.4/BA.5 GMFRs at 1 month after study vaccination were:

- Similar in participants 12 through 17 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg group compared with other age and vaccine groups at 1 month after vaccination.
- Higher in participants 18 through 55 and &gt;55 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30- and 60 µg groups compared with participants in the corresponding BNT162b2 Bivalent (WT/OMI BA.1) dose groups. The differences between BNT162b2 Bivalent (WT/OMI BA.4/BA.5) groups and BNT162b2 Bivalent (WT/OMI BA.1) were more substantial in the baseline negative groups.
- Generally similar in participants 18 through 55 and &gt;55 years of age who received BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at either dose.
- Generally similar between the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30- and 60-µg groups.
- Generally similar across both sexes within each age and dose group.

<div style=\"page-break-after: always\"></div>

Table 20. Geometric Mean Fold Rises From Before Study Vaccination to Each Subsequent Time Point - Study C4591044 Cohort 2 and Study C4591031 Substudy E Expanded Cohort Participants Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                                                    |                    |                       | Vaccine Group (as Randomized)      | Vaccine Group (as Randomized)      | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            |
|--------------------------------------------------------------------|--------------------|-----------------------|------------------------------------|------------------------------------|------------------------------------------|------------------------------------------|
|                                                                    |                    |                       | C4591044 BNT162b2 Bivalent (WT/OMI | C4591044 BNT162b2 Bivalent (WT/OMI | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) |
| Assay                                                              | Dosage/Age Group   | Sampling Time Point a | n b                                | GMFR c (95% CI c )                 | n b                                      | GMFR c (95% CI c )                       |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 30 μg/12 -17 years | 1 Month               | 25                                 | 17.8 (11.5, 27.5)                  | N/A                                      | N/A                                      |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 30 μg/18 -55 years | 1 Month               | 32                                 | 18.9 (12.8, 27.8)                  | 67                                       | 9.3 (7.2, 12.1)                          |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 60 μg/18 -55 years | 1 Month               | 23                                 | 22.9 (13.9, 37.8)                  | 30                                       | 8.7 (5.5, 13.5)                          |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 30 μg/>55 years    | 1 Month               | 40                                 | 22.3 (14.3, 34.6)                  | 63                                       | 5.8 (4.5, 7.5)                           |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 60 μg/>55 years    | 1 Month               | 31                                 | 21.0 (11.8, 37.4)                  | 65                                       | 8.4 (6.1, 11.4)                          |
| SARS-CoV-2 neutralization assay - Omicron BA.1 - NT50 (titer)      | 30 μg/12 -17 years | 1 Month               | 25                                 | 11.2 (7.3, 17.0)                   | N/A                                      | N/A                                      |
| SARS-CoV-2 neutralization assay - Omicron BA.1 - NT50 (titer)      | 30 μg/18 -55 years | 1 Month               | 32                                 | 17.3 (11.1, 26.9)                  | 67                                       | 13.5 (10.3, 17.7)                        |
| SARS-CoV-2 neutralization assay - Omicron BA.1 - NT50 (titer)      | 60 μg/18 -55 years | 1 Month               | 23                                 | 17.9 (11.5, 27.8)                  | 30                                       | 11.6 (6.9, 19.6)                         |
| SARS-CoV-2 neutralization assay - Omicron BA.1 - NT50 (titer)      | 30 μg/>55 years    | 1 Month               | 40                                 | 17.5 (12.2, 25.1)                  | 64                                       | 8.2 (6.1, 11.2)                          |
| SARS-CoV-2 neutralization assay - Omicron BA.1 - NT50 (titer)      | 60 μg/>55 years    | 1 Month               | 29                                 | 17.8 (10.9, 29.2)                  | 64                                       | 9.7 (6.8, 13.9)                          |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | 30 μg/12 -17 years | 1 Month               | 25                                 | 5.3 (3.7, 7.7)                     | N/A                                      | N/A                                      |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | 30 μg/18 -55 years | 1 Month               | 32                                 | 14.1 (9.1, 22.0)                   | 67                                       | 6.6 (5.2, 8.3)                           |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | 60 μg/18 -55 years | 1 Month               | 23                                 | 13.5 (7.9, 23.1)                   | 30                                       | 6.1 (3.9, 9.5)                           |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | 30 μg/>55 years    | 1 Month               | 40                                 | 9.5 (6.4, 14.0)                    | 64                                       | 5.1 (3.9, 6.5)                           |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | 60 μg/>55 years    | 1 Month               | 31                                 | 14.6 (8.4, 25.5)                   | 64                                       | 5.0 (3.7, 6.9)                           |

<div style=\"page-break-after: always\"></div>

Abbreviations: GMFR = geometric mean fold rise; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; N/A = not applicable; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: All participants enrolled in Study C4591044 Cohort 2 and subsets of approximately 100 participants selected from each age group (18-55 years, &gt;55 years) and dose group (BNT162b2 Bivalent (WT/OMI BA.1) 30μg and 60 -μg group) of Study C4591031 Substudy E expanded cohort were included in the analysis.

Note: Participants who had no serological or virological evidence (up to the 1-month post-study vaccination blood sample collection) of past SARS-CoV-2 infection (ie, negative N-binding antibody [serum] result at the study vaccination, the 7day (if available) and the 1-month post-study vaccination visits, negative NAAT [nasal swab] at the study vaccination visit, and any unscheduled visit up to the 1-month post-study vaccination blood sample collection) and had no medical history of COVID-19 were included in the analysis.

- a. Protocol-specified timing for blood sample collection.

b. n = Number of participants with valid and determinate assay results for the specified assay at both the prevaccination time point and the given sampling time point.

c. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 08JAN2023 (21:15)

(Data cutoff date : C4591044 [12OCT2022]/C4591031 18-55 Years[25AUG2022]/&gt;55 Years[16MAY2022]) Output File: ./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adva\\_s001\\_gmfr\\_1m\\_wo\\_evl\\_c2f

## Seroresponse

Within baseline positive or baseline negative groups, Omicron BA.4/BA.5 seroresponse rates at 1 month after study vaccination were:

- Similar in participants 12 through 17 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 µg compared with other age and vaccine groups.
- Similar or higher in participants 18 through 55 and &gt;55 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30-µg and 60-µg groups compared with the corresponding BNT162b2 Bivalent (WT/OMI BA.1) age and dose groups. The higher seroresponse rates in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) groups than the BNT162b2 Bivalent (WT/OMI BA.1) groups were more prominent in the baseline negative groups and the &gt;55 years of age groups.
- Generally similar between the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30- and 60-µg groups.
- Generally similar across both sexes within each age and dose group.

Table 21. Number (%) of Participants Achieving Seroresponse - Study C4591044 Cohort 2 and Study C4591031 Substudy E Expanded Cohort - Participants Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                                                    |                    |                     | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)                 | Vaccine Group (as Randomized)            | Vaccine Group (as Randomized)            |
|--------------------------------------------------------------------|--------------------|---------------------|-----------------------------------------------|-----------------------------------------------|------------------------------------------|------------------------------------------|
|                                                                    |                    |                     | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) | C4591031 BNT162b2 Bivalent (WT/OMI BA.1) |
| Assay                                                              | Dosage/Age Group   | Sampling Time Point | N b                                           | n c (%) (95% CI d )                           | N b                                      | n c (%) (95% CI d )                      |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 30 μg/12 -17 years | 1 Month             | 25                                            | 24 (96.0) (79.6, 99.9)                        | N/A                                      | N/A                                      |
|                                                                    | 30 μg/18 -55 years | 1 Month             | 32                                            | 26 (81.3)                                     | 67                                       | 47 (70.1)                                |

<div style=\"page-break-after: always\"></div>

|                                                                   |                    |         |    | (63.6, 92.8)           |     | (57.7, 80.7)           |
|-------------------------------------------------------------------|--------------------|---------|----|------------------------|-----|------------------------|
|                                                                   | 60 μg/18 -55 years | 1 Month | 23 | 20 (87.0) (66.4, 97.2) | 30  | 19 (63.3) (43.9, 80.1) |
|                                                                   | 30 μg/>55 years    | 1 Month | 40 | 36 (90.0) (76.3, 97.2) | 63  | 31 (49.2) (36.4, 62.1) |
|                                                                   | 60 μg/>55 years    | 1 Month | 31 | 24 (77.4) (58.9, 90.4) | 65  | 40 (61.5) (48.6, 73.3) |
| SARS-CoV-2 neutralization assay - Omicron BA.1 - NT50 (titer)     | 30 μg/12 -17 years | 1 Month | 25 | 23 (92.0) (74.0, 99.0) | N/A | N/A                    |
|                                                                   | 30 μg/18 -55 years | 1 Month | 32 | 23 (71.9) (53.3, 86.3) | 67  | 59 (88.1) (77.8, 94.7) |
|                                                                   | 60 μg/18 -55 years | 1 Month | 23 | 20 (87.0) (66.4, 97.2) | 30  | 22 (73.3) (54.1, 87.7) |
|                                                                   | 30 μg/>55 years    | 1 Month | 40 | 37 (92.5) (79.6, 98.4) | 64  | 44 (68.8) (55.9, 79.8) |
|                                                                   | 60 μg/>55 years    | 1 Month | 29 | 27 (93.1) (77.2, 99.2) | 64  | 44 (68.8) (55.9, 79.8) |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer) | 30 μg/12 -17 years | 1 Month | 25 | 16 (64.0) (42.5, 82.0) | N/A | N/A                    |
|                                                                   | 30 μg/18 -55 years | 1 Month | 32 | 26 (81.3) (63.6, 92.8) | 67  | 48 (71.6) (59.3, 82.0) |
|                                                                   | 60 μg/18 -55 years | 1 Month | 23 | 21 (91.3) (72.0, 98.9) | 30  | 18 (60.0) (40.6, 77.3) |
|                                                                   | 30 μg/>55 years    | 1 Month | 40 | 30 (75.0) (58.8, 87.3) | 64  | 35 (54.7) (41.7, 67.2) |
|                                                                   | 60 μg/>55 years    | 1 Month | 31 | 24 (77.4) (58.9, 90.4) | 64  | 34 (53.1) (40.2, 65.7) |

Abbreviations: LLOQ = lower limit of quantitation; N/A = not applicable; N-binding = SARS-CoV-2  nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: All participants enrolled in Study C4591044 Cohort 2 and subsets of approximately 100 participants selected from each age group (18-55 years, &gt;55 years) and dose group (BNT162b2 Bivalent (WT/OMI BA.1) 30μg and 60μg group) of Study C4591031 Substudy E expanded cohort were included in the analysis.

Note: Participants who had no serological or virological evidence (up to the 1-month post-study vaccination blood sample collection) of past SARS-CoV-2 infection (ie, negative N-binding antibody [serum] result at the study vaccination, the 7day (if available) and the 1-month post-study vaccination visits, negative NAAT [nasal swab] at the study vaccination visit, and any unscheduled visit up to the 1-month post-study vaccination blood sample collection) and had no medical history of COVID-19 were included in the analysis.

Note: Seroresponse is defined as achieving a ≥4 -fold rise from baseline. If the baseline measurement is below the LLOQ, a postvaccination assay result ≥4 × LLOQ is considered a seroresponse.

- a. Protocol-specified timing for blood sample collection.
- b. N = number of participants with valid and determinate assay results for the specified assay at both the prevaccination time point and the given sampling time point. These values are the denominators for the percentage calculations.
- c. n = Number of participants with seroresponse for the given assay at the given sampling time point.
- d. Exact 2-sided CI, based on the Clopper and Pearson method.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 10JAN2023 (20:33) (Data cutoff date : C4591044 [12OCT2022]/C4591031 18-55 Years[25AUG2022]/&gt;55 Years[16MAY2022]) Output File:

./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adva\\_s001\\_sero\\_1m\\_wo\\_evl\\_c2f

Overall, immune responses against Omicron BA.1 and the reference strain were comparable for both bivalent vaccines in baseline positive participants, and a trend of higher increases for baseline negative participants was observed in participants who received BNT162b2 Bivalent (WT/OMI BA.4/BA.5). Variability in the immune responses were observed for participants in the 2 age groups who received BNT162b2 Bivalent

<div style=\"page-break-after: always\"></div>

(WT/OMI BA.4/BA.5) and could relate to smaller number of participants in each group. There is also an increasingly heterogeneous population regarding SARS-CoV-2 infection history and the specific variant responsible for the prior infection(s), which can influence the degree of pre-existing immunity to a given variant. These and additional unmeasured factors may, in part, have contributed to the variable patterns observed across the age groups or vaccine groups for Omicron BA.1 and reference strain-neutralizing titers.

Increased neutralizing responses with BNT162b2 Bivalent (WT/OMI BA.4/BA.5) and BNT162b2 Bivalent (WT/OMI BA.1) were observed regardless of baseline SARS-CoV-2 infection status, with the greatest GMFRs observed in participants without prior infection and the higher neutralizing titers observed in participants with prior infection.

An additional immunogenicity analysis of a subset of BNT162b2-experienced adults 18 through 55 and &gt;55 years of age in C4591044 Cohort 2 who received BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μ g compared with BNT162b2-experienced adults &gt;55 years of age in C4591031 Substudy E who received BNT162b2 30 μ g as a booster (fourth) dose was performed. Substantially higher Omicron BA.4/BA.5-specific neutralization titers and higher reference-strain neutralization titers 1 month after study vaccination were reported for participants in both age groups who received BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μ g compared with an adult comparator group from C4591031 Substudy E (&gt;55 years of age) who received a booster dose of BNT162b2 at the 30μ g dose level.

In a separate analysis of a subset of the Cohort 2 immunogenicity population who received BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μ g, the vaccine elicited consistently higher Omicron BA.4.6-, BA.2.75.2-, BQ.1.1-, and XBB-specific neutralization titers at 1 month post-vaccination in participants &gt;55 years of age compared with an adult comparator group (&gt;55 years of age) from C4591031 Substudy E who received a booster dose of BNT162b2 at the 30μ g dose level. Immune responses against Omicron XBB variant were more limited compared with the other sublineages.

## Combined Cohort 2 (Groups 2 and 4) and Cohort 3 ( ≥ 18 Years of Age)

## · Immunogenicity results

Analysis of immunogenicity data at 1 month after vaccination in the evaluable immunogenicity population with or without evidence of infection up to 1 month after study vaccination for BNT162b2-experienced participants 18 through 55 years and &gt;55 years of age who received a booster (fourth dose) with BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at 30 µg demonstrated a robust vaccine-elicited immune response.

· Superiority of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μ g to BNT162b2 30 μ g in the &gt;55-year age group from C4591031 Substudy E with respect to anti-Omicron BA.4/BA.5 neutralizing titers was met. Noninferiority based on seroresponse for BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μ g to BNT162b2 30 μ g in the &gt;55 years of age was also met.

- Noninferiority of anti-reference-strain immune response based on geometric mean ratio of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μ g to BNT162b2 30 μ g in the &gt;55 years age group was met.
- Noninferiority of the anti-Omicron BA.4/BA.5 response based on GMR and seroresponse for Bivalent BNT162b2 (WT/OMI BA.4/BA.5) participants 18 through 55 in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μ g group to participants &gt;55 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μ g group were met.

<div style=\"page-break-after: always\"></div>

Table 22. Model-Based Geometric Mean Ratios - BNT162b2 Bivalent 30μg Groups of Study C4591044 Cohort 2/3 Combined and BNT162b2 30μg Group of Study C45 91031 Substudy E Expanded Cohort - Participants With or Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                                                    |              | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group Comparison                              | Age Group Comparison                       |
|--------------------------------------------------------------------|--------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|---------------------------------|---------------------------------|-------------------------------------------------------|--------------------------------------------|
|                                                                    |              | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591031 BNT162b2 30 μg         | C4591031 BNT162b2 30 μg         | > 55 Years BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg |
|                                                                    | Sampling     | 18-55 Years                                         | 18-55 Years                                         |                                                     |                                                     | >55 Years                       | >55 Years                       |                                                       |                                            |
| Assay                                                              | Time Point a | n b                                                 | GMT c (95% CI c )                                   | n b                                                 | GMT c (95% CI c )                                   | n b                             | GMT c (95% CI c )               | GMR d (95% CI d )                                     | GMR d (95% CI d )                          |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 1 Month      |                                                     |                                                     | 282                                                 | 3373.4 (3000.3, 3793.0)                             | 273                             | 1160.7 (1030.3, 1307.7)         | 2.91 (2.45, 3.44)                                     |                                            |
|                                                                    | 1 Month      | 294                                                 | 4254.2 (3779.6, 4788.4)                             | 282                                                 | 4344.4 (3850.2, 4902.1)                             |                                 |                                 |                                                       | 0.98 (0.83, 1.16)                          |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer)  | 1 Month      |                                                     |                                                     | 284                                                 | 15361.6 (14082.9, 16756.5)                          | 287                             | 11117.2 (10196.4, 12121.1)      | 1.38 (1.22, 1.56)                                     |                                            |

Abbreviations: GMR = geometric mean ratio; GMT = geometric mean titer; LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: All participants enrolled in each age group (18-55 years, &gt;55 years) in Study C4591044 Cohort 2/3 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μg group and all participants &gt;55 years of age from Study C4591031 Substudy E expanded cohort BNT162b2 30μg group who met evaluability criteria were included in the analysis.

a. Protocol-specified timing for blood sample collection.

- b. n = Number of participants with valid and determinate assay results for the specified assay at both the prevaccination time point and the given sampling time point.
- c. GMTs and 2-sided 95% CIs were calculated by exponentiating the LS means and the corresponding CIs based on analysis of logarithmically transformed neutralizing titers using a linear regression model with terms of baseline neutralizing titer (log scale) and vaccine group or age group. A separate model was fit for each comparison. Assay results below the LLOQ were set to 0.5 × LLOQ.
- d. GMRs and 2-sided 95% CIs were calculated by exponentiating the difference of LS means and corresponding CIs based on the same regression model as stated above.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 05JAN2023 (01:57)

(Data cutoff date : C4591044 Cohort 2 [12OCT2022]/Cohort 3 [31OCT2022]/C4591031 [16MAY2022]) Output File: ./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adva\\_gmr\\_mb\\_1m\\_evl\\_c23

- The proportion of participants who achieved a seroresponse to Omicron BA.4/BA.5 at 1 month after study vaccination was substantially higher for participants 18 through 55 years of age and &gt;55 years of age compared with participants 18 through 55 and &gt;55 years of age in the BNT162b2 30-µg group.

<div style=\"page-break-after: always\"></div>

Table 23. Adjusted Difference in Percentages of Participants With Seroresponse - BNT162b2 Bivalent 30μg Groups of Study C4591044 Cohort 2/3 Combined and BNT162b2 30 -μg Group of Study C4591031 Substudy E Expanded Cohort - Participants With or Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                                                    |                       | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)                     | Vaccine Group (as Randomized)                     | Vaccine Group Comparison                                               | Age Group Comparison                                               |
|--------------------------------------------------------------------|-----------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------------------------|---------------------------------------------------|------------------------------------------------------------------------|--------------------------------------------------------------------|
| Assay                                                              | Sampling Time Point a | C4591044 BNT162b2 (WT/OMI       | C4591044 BNT162b2 (WT/OMI       | C4591044 BNT162b2 (WT/OMI       | C4591031 Bivalent BNT162b2 BA.4/BA.5) 30 30 μg μg | C4591031 Bivalent BNT162b2 BA.4/BA.5) 30 30 μg μg | > 55 Years BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg / BNT162b2 30 μg | BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg 18-55 Years / >55 Years |
|                                                                    |                       | 18-55                           | Years                           | >55                             | Years                                             | >55 Years                                         | Difference% e                                                          |                                                                    |
|                                                                    |                       | N b                             | n c (%) (95% CI d )             | N b n c (%) (95% CI             | N b d )                                           | n c (%) (95% CI d )                               | (95% CI f ))                                                           | Difference% e (95% CI f ))                                         |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | 1 Month               | 294                             | 180 (61.2) (55.4, 66.8)         | 282 188                         | 273 (66.7) (60.8, 72.1)                           | 127 (46.5) (40.5, 52.6)                           | 26.77 (19.59, 33.95)                                                   | -3.03 (-9.68, 3.63)                                                |

Abbreviations: LLOQ = lower limit of quantitation; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: All participants enrolled in each age group (18-55 years, &gt;55 years) in Study C4591044 Cohort 2/3 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μg group and all participants &gt;55 years of age from Study C4591031 Substudy E expanded cohort BNT162b2 30μg group who met evaluability criteria were included in the analysis.

Note: Seroresponse is defined as achieving a ≥4 -fold rise from baseline. If the baseline measurement is below the LLOQ, a postvaccination assay result ≥4 × LLOQ is considered a seroresponse.

- a. Protocol-specified timing for blood sample collection.
- b. N = Number of participants with valid and determinate assay results for the specified assay at both the prevaccination time point and the given sampling time point. This value is the denominator for the percentage calculation.
- c. n = Number of participants with seroresponse for the given assay at the given sampling time point.
- d. Exact 2-sided CI, based on the Clopper and Pearson method.
- e. Difference in proportions, expressed as a percentage.

2-Sided CI based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category (&lt; median, ≥ median) for the difference in proportions. The median of baseline neutralizing titers was calculated based on the pooled data in 2 comparator groups.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 05JAN2023 (01:57)

(Data cutoff date : C4591044 Cohort 2 [12OCT2022]/Cohort 3 [31OCT2022]/C4591031 [16MAY2022]) Output File: ./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adva\\_dif\\_mb\\_1m\\_evl\\_c23

- The observed Omicron BA.4/BA.5 neutralizing GMTs at 1 month after study vaccination were substantially higher for participants 18 through 55 and &gt;55 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30-µg group compared with participants 18 through 55 and &gt;55 years of age in the BNT162b2 30-µg group.

<div style=\"page-break-after: always\"></div>

Table 24. Geometric Mean Titers, by Subgroup - BNT162b2 Bivalent 30μg Groups of Study C4591044 Cohort 2/3 Combined and BNT162b2 30μg Group of Study C4591031 Substudy E Expanded Cohort - Participants With or Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                                                    |                             |                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)                       | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   |
|--------------------------------------------------------------------|-----------------------------|-----------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|---------------------------------|---------------------------------|
|                                                                    |                             |                       | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591044 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 μg | C4591031 BNT162b230 μg          | C4591031 BNT162b230 μg          |
|                                                                    |                             |                       | 18-55 Years                                         | 18-55 Years                                         | >55                                                 | >55                                                 | >55 Years                       | >55 Years                       |
| Assay                                                              | Subgroup                    | Sampling Time Point a | n b                                                 | GMT c (95% CI c )                                   | n b                                                 | GMT c (95% CI c )                                   | n b                             | GMT c (95% CI c )               |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | All                         | Prevax                | 294                                                 | 569.6 (471.4, 688.2)                                | 284                                                 | 458.2 (365.2, 574.8)                                | 278                             | 205.4 (170.3, 247.7)            |
|                                                                    |                             | 1 Month               | 297                                                 | 4455.9 (3851.7, 5154.8)                             | 284                                                 | 4158.1 (3554.8, 4863.8)                             | 282                             | 938.9 (802.3, 1098.8)           |
|                                                                    | Baseline SARS- CoV-2 status |                       |                                                     |                                                     |                                                     |                                                     |                                 |                                 |
|                                                                    | Positive d                  | Prevax                | 210                                                 | 1181.4 (1005.3, 1388.3)                             | 174                                                 | 1291.7 (1027.5, 1623.8)                             | 40                              | 1939.2 (1326.0, 2835.8)         |
|                                                                    |                             | 1 Month               | 213                                                 | 6031.6 (5203.9, 6991.0)                             | 176                                                 | 6688.9 (5664.4, 7898.8)                             | 40                              | 4772.5 (3413.9, 6671.9)         |
|                                                                    | Negative e                  | Prevax                | 84                                                  | 91.9 (71.5, 118.1)                                  | 110                                                 | 88.9 (69.8, 113.4)                                  | 236                             | 139.7 (118.0, 165.3)            |
|                                                                    |                             | 1 Month               | 84                                                  | 2067.7 (1530.2, 2793.9)                             | 108                                                 | 1916.2 (1489.5, 2465.1)                             | 240                             | 718.5 (617.5, 836.0)            |

<div style=\"page-break-after: always\"></div>

|                                                                   | Male       | Prevax   | 103   | 579.3 (429.9, 780.8)       | 128   | 367.9 (263.7, 513.3)       | 129   | 219.0 (163.9, 292.7)       |
|-------------------------------------------------------------------|------------|----------|-------|----------------------------|-------|----------------------------|-------|----------------------------|
|                                                                   |            | 1 Month  | 104   | 4261.9 (3431.3, 5293.5)    | 129   | 4177.1 (3353.5, 5203.0)    | 129   | 957.0 (753.7, 1215.3)      |
|                                                                   | Female     | Prevax   | 191   | 564.4 (441.9, 720.8)       | 156   | 548.6 (402.3, 748.0)       | 149   | 194.2 (151.8, 248.5)       |
|                                                                   |            | 1 Month  | 193   | 4564.0 (3764.1, 5533.9)    | 155   | 4142.3 (3311.7, 5181.3)    | 153   | 923.9 (748.3, 1140.7)      |
| SARS-CoV-2 neutralization assay - reference strain - NT50 (titer) | All        | Prevax   | 296   | 4017.3 (3430.7, 4704.1)    | 284   | 3690.6 (3082.2, 4419.0)    | 287   | 2699.9 (2291.7, 3180.9)    |
|                                                                   |            | 1 Month  | 296   | 16323.3 (14686.5, 18142.6) | 286   | 16250.1 (14499.2, 18212.4) | 289   | 10415.5 (9366.7, 11581.8)  |
| Baseline CoV-2 status                                             | SARS-      |          |       |                            |       |                            |       |                            |
|                                                                   | Positive d | Prevax   | 213   | 7068.6 (6251.9, 7992.0)    | 174   | 8082.1 (6843.6, 9544.8)    | 41    | 14247.2 (10299.1, 19708.6) |
|                                                                   |            | 1 Month  | 212   | 19076.6 (17056.5, 21336.0) | 176   | 21273.3 (18604.2, 24325.3) | 41    | 21444.4 (17318.3, 26553.5) |
|                                                                   | Negative e | Prevax   | 83    | 942.3 (705.6, 1258.3)      | 110   | 1068.0 (835.9, 1364.6)     | 244   | 2054.8 (1749.9, 2412.8)    |
|                                                                   |            | 1 Month  | 84    | 11014.6 (8793.9, 13796.0)  | 110   | 10560.6 (8827.1, 12634.5)  | 246   | 9286.4 (8296.8, 10394.0)   |
| Sex                                                               |            |          |       |                            |       |                            |       |                            |
|                                                                   | Male       | Prevax   | 103   | 4063.1 (3178.7, 5193.7)    | 129   | 3326.9 (2586.0, 4280.1)    | 134   | 2855.0 (2246.0, 3629.0)    |
|                                                                   |            | 1 Month  | 104   | 16565.7 (14039.5, 19546.5) | 129   | 16187.3 (13769.9, 19029.1) | 134   | 11087.9 (9562.7, 12856.4)  |
|                                                                   | Female     | Prevax   | 193   | 3993.0 (3252.6, 4902.0)    | 155   | 4023.4 (3112.7, 5200.5)    | 153   | 2571.1 (2049.3, 3225.7)    |
|                                                                   |            | 1 Month  | 192   | 16193.5 (14119.1, 18572.8) | 157   | 16301.9 (13874.8, 19153.4) | 155   | 9867.2 (8475.9, 11486.9)   |

<div style=\"page-break-after: always\"></div>

Abbreviations: GMT = geometric mean titer; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: All participants enrolled in each age group (18-55 years, &gt;55 years) in Study C4591044 Cohort 2/3 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μg group and all participants &gt;55 years of age from Study C4591031 Substudy E expanded cohort BNT162b2 30μg group who met evaluability criteria were included in the ana lysis.

- a. Protocol-specified timing for blood sample collection.
- b. n = Number of participants with valid and determinate assay results for the specified assay at the given sampling time point.
- c. GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ.
- d. Positive N-binding antibody result at baseline, positive NAAT result at baseline, or medical history of COVID-19.
- e. Negative N-binding antibody result at baseline, negative NAAT result at baseline, and no medical history of COVID19.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 05JAN2023 (02:00) (Data cutoff date : C4591044 Cohort 2 [12OCT2022]/Cohort 3 [31OCT2022]/C4591031 [16MAY2022]) Output File: ./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adva\\_s001\\_gmt\\_sub\\_1m\\_evl\\_c23

- GMFRs at 1 month after study vaccination were higher for participants 18 through 55 and &gt;55 years of age in the BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30-µg groups compared with participants 18 through 55 and &gt;55 years in the BNT162b2 30-µg group.

Table 25. Geometric Mean Fold Rises From Before Study Vaccination to Each Subsequent Time Point, by Subgroup - BNT162b2 Bivalent 30μg Groups of Study C4591044 Cohort 2/3 Combined and BNT162b2 30μg Group of Study C4591031 Substudy E Expanded Cohort - Participants With or Without Evidence of Infection up to 1 Month After Study Vaccination - Evaluable Immunogenicity Population

|                                                                    |                             |            | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   | Vaccine Group (as Randomized)   |
|--------------------------------------------------------------------|-----------------------------|------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                    |                             |            | BNT162b2 BA.4/BA.5)             | BNT162b2 BA.4/BA.5)             | C4591044 Bivalent (WT/OMI 30 μg | C4591044 Bivalent (WT/OMI 30 μg | C4591031 BNT162b2 30 μg         | C4591031 BNT162b2 30 μg         |
|                                                                    |                             | Sampling a | 18-55 Years                     | 18-55 Years                     | >55 Years                       | >55 Years                       | >55 Years                       | >55 Years                       |
| Assay                                                              | Subgroup                    | Time Point | n b                             | GMFR c (95% CI c )              | n b                             | GMFR c (95% CI c )              | n b                             | GMFR c (95%CI c )               |
| SARS-CoV-2 neutralization assay - Omicron BA.4/BA.5 - NT50 (titer) | All                         | 1 Month    | 294                             | 7.8 (6.7, 9.2)                  | 282                             | 8.9 (7.5, 10.6)                 | 273                             | 4.6 (4.0, 5.2)                  |
|                                                                    | Baseline SARS- CoV-2 status |            |                                 |                                 |                                 |                                 |                                 |                                 |
|                                                                    | Positive d                  | 1 Month    | 210                             | 5.1 (4.4, 6.0)                  | 174                             | 5.2 (4.3, 6.3)                  | 39                              | 2.4 (1.8, 3.2)                  |
|                                                                    | Negative e                  | 1 Month    | 84                              | 22.5 (17.1, 29.6)               | 108                             | 21.5 (16.6, 27.9)               | 232                             | 5.1 (4.4, 5.9)                  |
|                                                                    | Sex                         |            |                                 |                                 |                                 |                                 |                                 |                                 |
|                                                                    | Male                        | 1 Month    | 103                             | 7.4 (5.6, 9.7)                  | 128                             | 11.3 (8.7, 14.8)                | 125                             | 4.4 (3.6, 5.4)                  |
|                                                                    | Female                      | 1 Month    | 191                             | 8.1 (6.6, 9.8)                  | 154                             | 7.3 (5.8, 9.2)                  | 148                             | 4.7 (3.9, 5.6)                  |
| SARS-CoV-2 neutralization assay - reference strain - NT50          | All                         | 1 Month    | 295                             | 4.1 (3.6, 4.6)                  | 284                             | 4.4 (3.8, 5.1)                  | 287                             | 3.9 (3.4, 4.4)                  |

<div style=\"page-break-after: always\"></div>

| (titer)   |          |         |     | 2.7              |     | 2.7             |     | 1.5            |
|-----------|----------|---------|-----|------------------|-----|-----------------|-----|----------------|
|           | Negative | 1 Month | 83  | 11.6 (9.0, 15.0) | 110 | 9.9 (7.8, 12.5) | 244 | 4.5 (4.0, 5.2) |
|           | Sex      |         |     |                  |     |                 |     |                |
|           | Male     | 1 Month | 103 | 4.1 (3.2, 5.1)   | 129 | 4.9 (3.9, 6.0)  | 134 | 3.9 (3.2, 4.7) |
|           | Female   | 1 Month | 192 | 4.1 (3.4, 4.8)   | 155 | 4.1 (3.4, 5.0)  | 153 | 3.9 (3.2, 4.6) |

Abbreviations: GMFR = geometric mean fold rise; LLOQ = lower limit of quantitation; N-binding = SARS-CoV-2 nucleoprotein-binding; NAAT = nucleic acid amplification test; NT50 = 50% neutralizing titer; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Note: All participants enrolled in each age group (18-55 years, &gt;55 years) in Study C4591044 Cohort 2/3 BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30μg group and all participants &gt;55 years of age from Study C4591031 Substudy E expanded cohort BNT162b2 30μg group who met evaluability criteria were included in the analysis.

- a. Protocol-specified timing for blood sample collection.
- b. n = Number of participants with valid and determinate assay results for the specified assay at both the prevaccination time point and the given sampling time point.
- c. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5 × LLOQ in the analysis.
- d. Positive N-binding antibody result at baseline, positive NAAT result at baseline, or medical history of COVID-19.
- e. Negative N-binding antibody result at baseline, negative NAAT result at baseline, and no medical history of COVID19.

PFIZER CONFIDENTIAL Source Data: adva Table Generation: 05JAN2023 (01:40)

- (Data cutoff date : C4591044 Cohort 2 [12OCT2022]/Cohort 3 [31OCT2022]/C4591031 [16MAY2022]) Output File: ./nda2\\_ub1044/C4591044\\_1MPD\\_C23\\_CMB/adva\\_s001\\_gmfr\\_sub\\_1m\\_evl\\_c23

These results suggest an anticipated improved clinical benefit against COVID-19 due to Omicron BA.4/BA.5 with BNT162b2 Bivalent (WT/OMI BA.4/BA.5) compared with BNT162b2 as a booster (fourth dose).

## 2.6.3. Discussion on clinical efficacy

This application concerns the extension of indication of the Comirnaty Original/Omicron BA.4-5 to add a new strength (1.5/1.5 µg) as a primary series (3 doses) and a booster dose for children 6 months up to less than 5 years of age.

Comirnaty Original 3 µg has been approved since October 2022 for this age group. The approval of the Original 3 µg vaccine was based on data from a randomized, observer blinded placebo-controlled trial. The VE after 3 doses in age group 6 m -&lt;5y was 80.3 % (95% CI 13.9, 96.7). The MAH has not applied for a booster indication for Original Comirnaty 3 µg for 6m-&lt;5y.

Antibodies elicited by the Original strain vaccine provide lower and short-lived protection against the Omicron strains as randomized clinical trials and observational data from all over the world have indicated. In response to the waning protection, the MAH updated the COVID-19 vaccine to a bivalent formulation to include both the Reference and Omicron strains. The first bivalent formulation Original/Omicron BA.1 15/15 µg received a booster indication for individuals 12 years and older in September 2022. The immunogenicity was evaluated in subjects older than 55 years, where approximately 230 individuals in each study arm received either Original, monovalent or bivalent vaccine including Omicron BA.1 as 4 th  dose. Superiority of Original/Omicron BA.1 (15/15 µg) was demonstrated over Original (30 µg) in sense of antibody titer against

<div style=\"page-break-after: always\"></div>

BA.1 (GMR 1.56, 95% CI 1.17, 2.08), whereas the level of anti- reference strain antibodies did not differ between study arms.

The bivalent formulation including Omicron BA.4-5 strain received a booster indication for age groups 12 and older (15/15 µg) and for 5 to &lt;12 years old (5/5 µg) later in autumn 2022. There were no clinical immunogenicity data available at the time of approval. Instead, the efficacy and immunogenicity were extrapolated from studies with the bivalent vaccine Original/Omicron BA.1 and with Original Comirnaty.

Currently submitted data comes from studies investigating Original /Omicron BA 4-5 as a fourth dose after 3 doses of Original Comirnaty. No data from primary series with the bivalent vaccine has been submitted. The MAH has shown earlier plans to investigate a primary series in the youngest age group, the study is ongoing.

## Age group 6m-&lt;5y. Pivotal data.

No dose-response study has been presented for the Original /Omicron BA 4-5 (1.5/1.5 µg) vaccine. The lowest dose in the Original vaccine study was 3 µg and the MAH does not currently have immunogenicity data from a primary series with the bivalent vaccine. Although there is no immunogenicity data of 1.5 µg mRNA, as the total amount in the bivalent vaccine are 3 µg, the immunogenicity is considered to be at the same level as for the Original Comirnaty 3 µg.

The MAH complemented that the C4591048 substudy A which investigates the immunogenicity of a primary series of Original /Omicron BA 4-5 (1.5/1.5 µg) is ongoing and as of 01 Jun 2023, Substudy A Phase 1 has completed enrolment in the 6 months to &lt;2 years cohort (target n = 90) and has reached 75% (64 out of 90) of the enrolment target in the 2 to &lt;5-year-old group. The MAH has committed to submit this data as soon as available.

Substudy B of C4591048 is an open-label study to evaluate the safety, tolerability, and immunogenicity of a third or fourth dose with the bivalent BNT162b2 (Original/Omi BA.4-5) at 3 μ g (1.5/1.5 μ g). As there is no placebo arm in the study and no efficacy will be evaluated, the open-label format is acceptable.

Approximately 300 participants in Group 2, ≥ 6 months to &lt;5 years of age, who have received 3 prior doses of BNT162b2 3 μ g, with their last dose 60 to 240 days prior to enrolment, will receive 1 dose (fourth) of bivalent BNT162b2 (Original/Omi BA.4-5) 3 μ g. The study is powered for superiority and non-inferiority evaluation, this data will be submitted later when the study is finalized, the interim CSR with safety and immunogenicity for the entire Subgroup B (N = 300) is targeted for end of June 2023.

In the current report a 1-month post dose descriptive immunogenicity data is presented for a subset of 60 participants in Group 2 of C4591048 Substudy B (the first 24 and 36 participants enrolled in ≥ 6 months to &lt;2 years age group and ≥ 2 years to &lt;5 years age group, respectively). Results include also data from a comparator subset of 60 participants ≥ 6 months to &lt;5 years of age (24 and 36 participants ≥ 6 months to &lt;2 years of age and ≥ 2 years to &lt;5 years of age, respectively) in Study C4591007 who received 3 doses of BNT162b2 at 3 μ g. The sample size presented currently comprise 60 individuals but as the data are descriptive and a larger cohort will be analysed later, the current sample size is acceptable. The time since last dose was 2-8 months. About 70 % of subjects had no history of previous COVID-19. Data for the same number of doses was presented for adults (supportive studies).

The baseline antibody level against the reference strain was higher in the group allocated to receive a 4 th  dose than in the group receiving a third dose. In the COVID-19 negative group, baseline anti-reference strain antibody level was more than four-fold higher in the bivalent Original/Omicron BA.4-5 than in the Original. After the booster dose, the anti-reference strain antibodies were in comparable level in all groups independent of the baseline COVID-19 status, antibody level at the baseline or number of earlier doses.

<div style=\"page-break-after: always\"></div>

At baseline COVID-19 negative groups, the anti-Omicron BA 4-5 levels were low in both bivalent 4 th  dose and Original as 3 rd  dose groups, however GMTs were almost three-fold higher in the bivalent group compared to the original group. GMFR was approximately 14 for bivalent group and for the Original group, 11.

Additionally, in a small subset (N= 31 in each arm) the neutralization against new circulating COVID-19 strains was evaluated using an unvalidated FFRNT assay. The results showed low antibody titers against these new strains both after 3 doses of Original and after the 4 th  dose of bivalent vaccine. After the 4 th  dose with bivalent, the antibodies were higher than after 3 rd  dose with Original, but still remained modest in comparison to the GMTs against targeted strains. The clinical benefit for these modestly higher antibodies is unknown.

In summary, the Original/Omicron BA.4-5 (1.5/1.5 μ g) vaccine given as a 4 th  dose is immunogenic in children 6m-&lt;5 y who have previously received 3 doses of Original 3 μ g. There are currently no data on primary vaccination with the bivalent vaccine in any age group although such data are expected. The assumption that the bivalent vaccine will provide sufficient protection when given as a primary vaccination is extrapolated from the demonstrated immunogenicity of the booster dose.

## Age group 5-11 years. Supportive data.

Substudy D of C4591048 is a Phase 3 open-label study to evaluate the safety, tolerability, and immunogenicity of a third or fourth dose with bivalent BNT162b2 (Original/Omi BA.4-5) 5/5 µg in approximately 250 participants at ages ≥ 5 - &lt;12 years, who were previously vaccinated with Original. As in Substudy B, the immunogenicity is compared to a cohort which has received 3 doses of Original 10 µg. No data from primary series from this cohort vaccinated with Original/Omi BA.4-5 (5/5 µg) are available.

The immunogenicity population included approximately 100 individuals in each study arm. This sample size suffices for descriptive immunogenicity analysis. About 60 % of the study population had COVID-19 earlier. The primary endpoint was descriptive GMR of GMTs in the 4 th  dose bivalent arm and comparison arm with 3 doses of Original only. The MAH used a Model Based Geometric Mean Ratio calculation and explained the methodology behind the GMR calculation. The model based result showed no substantial difference between the 4 th  dose bivalent arm and 3 rd  dose Original arm (GMR 1.2 (95% CI 0.92, 1.37)) as the model based Omicron BA.4-5 GMTs were very similar (1836 vs. 1633 respectively). The seroresponse rate to omicron BA.4/5 was also almost identical.

These data show that Original/Omicron BA.4-5 (5/5 μ g) is immunogenic as 4 th  dose in children 5y-&lt;12 y who have previously received 3 doses of Original 10 μ g. It is anticipated that this vaccine is immunogenic also as a primary series as half of the amount of mRNA is the same as in the approved Original vaccine and the Omicron BA.4-5 component has been demonstrating immunogenicity as a booster dose.

## Age group &gt;12 years. Supportive data.

Study C4591044 is a randomized, active-controlled study to evaluate the safety, tolerability, and immunogenicity of new bivalent variant vaccines in different age groups: 12-17, 18-55 and &gt;55. The study is divided into cohorts. Immunogenicity in some cohorts was studied only descriptively (Cohort 2), whereas some groups from Cohorts 2 and 3 together were analysed for superiority and non-inferiority.

The immunogenicity population in Cohort 2 were around 100 individuals in each age group, who received a 4 th  dose with Original/Omicron BA.4-5 30 μ g. For descriptive immunogenicity, 100 individuals is acceptable. Combining Cohort 2 and Cohort 3, there were almost 300 individuals in each age group (18-55 and &gt;55). As a comparison arm, approximately 300 individuals older than 55 who had received a 4 th  dose of Original 30 μ g in study C4591031, were selected. This comparison arm is valuable as all study participants have received

<div style=\"page-break-after: always\"></div>

the same number (4) of doses as in the active arm. The sample size about 300 individuals in each arm is sufficient for the superiority and non-inferiority testing.

The descriptive data from Cohort 2 demonstrated the immunogenicity of a 4th dose with Original/Omicron BA.4-5 in all studied age groups in terms of raised GMTs. The hypothesis analyses were conducted in the combined cohorts 2 and 3. The MAH used the same model based calculation for GMRs as in study C4591048 SSD. These results were presented in Table 23 and the MAH has explained that the model based GMT values of &gt;55 years Original/Omicron BA.4-5 vaccine group participants depend on the comparator group. The MAH also explained that the GMR originates from model based GMT calculation, which is considered as an intermediate estimate in order to reach a more valid and meaningful model-based GMR. If presented together in the product information, descriptive GMTs and model- based GMTs for the same groups would be confusing, therefore the presentation of descriptive non adjusted GMTs and model based GMR in the same table has been agreed.

The model-based GMR showed superiority (GMR 2.91 95% CI 2.45; 3.44) of antibody titer against Omicron BA. 4-5 after a 4 th  dose with the bivalent Original/Omicron BA. 4-5 vaccine (15/15 μ g) compared to 4 th  dose with Original 30 μ g vaccine in the age group older than 55. The non-inferior response to the reference strain was also demonstrated (GMR 1.38; 95% CI 1.22, 1.56). As non-inferiority (GMR 0.98; 95% CI 0.83, 1.16) was demonstrated also for responses to Omicron BA 4-5 between 18-55 and &gt;55 arms in the bivalent group, one can conclude that superiority of the bivalent vaccine to elicit anti Omicron BA. 4-5 response should be anticipated in the entire adult population. The non-inferior seroresponse to Omicron BA.4-5 was met between age groups older or younger than 55 years in study C4591044, but seroresponse in this study age group was higher than in C4591031 Substudy E and non-inferiority was not met (difference 26.77 % (95% CI: 19.59, 33.95)) ( Table 23 ).

Descriptive data from Cohorts 2 and 3 showed generally the same result for all age cohorts, including adolescents. There was no comparison group for 12-17 year olds from study C4591031.

These data show that the Original/Omicron BA.4-5 (15/15 μ g) vaccine is immunogenic as a 4 th  dose in individuals older than 12 years of age who have previously received 3 doses of Original 30 μ g. It is anticipated that this vaccine is immunogenic also as a primary series as half of the amount of mRNA is the same as in approved Original vaccine and Omicron BA4-5 component has been demonstrating immunogenicity as a booster dose.

## 2.6.4. Conclusions on clinical efficacy

These data show that Original/Omicron BA.4-5 (1.5/1.5 μ g) is immunogenic as a 4 th  dose in individuals older than 6m to &lt;5 y who have previously received 3 doses of Original 3 μ g.

No dose-response study has been presented for the Original /Omicron BA 4-5 (1.5/1.5 µg) vaccine and the lowest dose in the Original study was 3 µg. As altogether the bivalent vaccine contains 3 µg, it is considered that the amount of mRNA is immunogenic. The ongoing Substudy A is investigating a dose-response of Original/Omicron BA.4-5 among children younger than 5 years, data is expected to be submitted as soon as available.

The immunogenicity against newly circulating strains was low and therefore the clinical benefit against new strains is unknown.

<div style=\"page-break-after: always\"></div>

## 2.6.5. Clinical safety

To support the indication of the bivalent COVID-19 vaccine Original/Omicron BA.4-5 administered as a primary series as well as a booster dose at 1.5/1.5µg in subjects aged ≥ 6 months to &lt;5 years of age, the MAH presented data from a limited number of participants included in the study C4591048 Substudy B Group 2 Subset ≥ 6 Months to &lt;5 Years of Age. No data where the bivalent vaccine has been administered as a primary series has been provided.

In addition, data from studies C4591048 and C4591044 including subjects ≥ 5 years of age and ≥12 years of age who have received the bivalent Original/Omicron BA.4-5 vaccine as a booster dose have been provided as supportive data for extrapolation purposes.

The primary series of three doses BNT162b2 Original 3µg for children aged 6 months to &lt;5 years of age was evaluated in the EMEA/H/C/005735/X/0138 procedure.

The studies are described separately below.

## 2.6.5.1. Study C4591048 Substudy B Group 2 Subset ( ≥ 6 Months to &lt;5 Years of Age: Booster (Fourth Dose) With BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at 3 μg

One month post forth dose safety data is available for a subset of 60 subjects in this study, cut-off date is 25 November 2022.

The safety population included 24 participants ≥6 months &lt;2 years of age and 36 participants ≥2 years to &lt;5 years of age who received a fourth dose of the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 3 μ g. No participants were excluded from the safety population for any reason and all participants received the fourth dose of vaccine as assigned. Overall, median follow-up time after study vaccination was 1.8 months. Majority of participants (96.7%) completed the 1-month post vaccination visit. No participant in the ≥6 months to &lt;2 years of age group and 1 participant in the ≥2 to &lt;5 years of age group was withdrawn due to personal decision from the study as of the data cut-off date (25 November 2022).

The reactogenicity and antipyretic/pain medication were reported by using an e-diary for 7 days after study vaccination. Grading scales were based on FDA guidance. AEs are collected from the study vaccination up to 1 month after the study vaccination, and serious AEs (SAEs) are collected from study vaccination up to 6 months post-Dose. Reactogenicity was reported as follows:

Children ≥6 months to &lt;2 years of age:

- Local reactions: tenderness, redness, and swelling at the injection site
- Systemic events: fever, decreased appetite, drowsiness, and irritability

Children ≥2 to &lt;5 years of age:

- Local reactions: pain, redness, and swelling at the injection site
- Systemic events: fever, fatigue, headache, chills, vomiting, diarrhoea, new or worsened muscle pain, and new or worsened joint pain

## · Demographics

## ≥6 Months to &lt;2 Years of Age

In total, most participants were White (54.2%), with 4.2% Black or African American participants, 20.8% Asian participants, and 20.8% multiracial participants. There were 16.7% Hispanic/Latino participants. Median age was 19 months and 58.3% of participants were female. A total of 41.7% of participants had

<div style=\"page-break-after: always\"></div>

evidence of prior SARS-CoV-2 infection ('baseline positive'). Median time since last prior dose of BNT162b2 before study vaccination was 6.4 months. None of the participant received a non-study vaccine after study vaccination as of the data cut-off date.

## ≥2 to &lt;5 Years of Age

In total, most participants were White (61.1%), with 5.6% Black or African American participants, 11.1% Asian participants, and 22.2% multiracial participants. There were 30.6% Hispanic/Latino participants. Median age was 2.0 years and 55.6% of participants were male. Three (8.3%) participants were reported as obese. A total of 19.4% of participants were baseline positive for prior SARS-CoV-2 infection. Median time since last prior dose of BNT162b2 before study vaccination was 7.1 months. The medical histories of participants at study baseline included conditions and procedures typically observed in the general population for each age group.

Two (5.6%) participants received a non-study vaccine (Influenza vaccine) at least 14 days after study vaccination as allowed per protocol.

## Reactogenicity

## Local reactions

## ≥6 Months to &lt;2 Years of Age

All local reactions were mild in severity. No moderate, severe, or Grade 4 local reactions were reported. The onset for all local reactions was 1 day and resolved within 1 day after onset.

In this initial subset of 24 participants, the frequencies of local reactions reported within 7 days after the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g vaccine are much lower than the frequencies previously observed in association with the original BNT162b2 vaccine within the respective age group. According to the MAH, this is likely a factor of the small number of participants for this dataset.

<div style=\"page-break-after: always\"></div>

Figure 1.Local Reactions,byMaximumSeverity,Within7 DaysAfter theStudyVaccination-Subsetof Substudy B Group 2 - ≥6 Months to &lt;2 Years of Age - Safety Population

<!-- image -->

Note:Subset ofSubstudyBGroup 2includes thefirst 24 and36 paticipants enrolled in6months to2years agegroup and2years to5years age group,respectively.

Note:Thenumber above each bar denotesthe percentage of participantsreporting thereactionwith any sevenity.

Table Generation:13DEC2022(20:28)(CutoffDate:25NOV2022,SnapshotDate:08DEC2022)OutputFile:/nda2\\_ubped2/C4591048\\_B\\_1MPD\\_Safety/adce\\_f001\\_r\\_p2\\_6m2y

PFIZERCONFIDENTIALSDTMCreation:08DEC2022(16:32)SourceData:adfacevd

## ≥2 to &lt;5 Years of Age

Most local reactions were mild or moderate in severity. No severe or Grade 4 local reactions were reported by any participant in the ≥2 to &lt;5 years of age group who received a fourth dose of the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g. The onset for all local reactions was 1 to 2 days, and all events resolved within 1 to 3 days after onset.

In this initial subset of 36 participants, the frequencies of local reactions reported within 7 days after the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g vaccine are much lower than the frequencies previously observed in association with the original BNT162b2 vaccine within the respective age group. According to the MAH, this is likely a factor of the small number of participants for this dataset.

<div style=\"page-break-after: always\"></div>

Figure2.Local Reactions,byMaximumSeverity,Within7DaysAftertheStudyVaccination-Subsetof SubstudyB Group 2 - ≥2 to &lt;5 Years of Age - Safety Population

<!-- image -->

PFIZERCONFIDENTIALSDTMCreation:08DEC2022(16:32)SourceData:adfacevd

Note:SubsetofSubstudyBGroup2includesthefirst24and36paticipantsenrolledin6monthsto2yearsagegroup and2yearsto5yearsagegroup,respectively Note:Substudy BGroup2includes participants6months to5years of age who received3 doses ofBNT162b23g60 to240 days priorto enrollment. Note:The number above each bar denotes the percentage of participantsreporting thereaction with any severity.

TableGeneration:13DEC2022(20:28)(CutoffDate:25NOV2022,SnapshotDate:08DEC2022)OutputFile:/nda2\\_ubped2/C4591048\\_B\\_1MPD\\_Safety/adce\\_f001\\_lr\\_p2\\_2y5y

## Systemic Events

## ≥6 Months to &lt;2 Years of Age

No participants reported fever &gt;38.4 °C. Antipyretic or pain medication use was reported by 8.3% of participants after study vaccination. Most systemic events were mild or moderate in severity. No severe or Grade 4 systemic events were reported by any participant in the ≥6 months t o &lt;2 years of age group who received a fourth dose of the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g.

The median onset for all systemic events was 2 to 6 days, and all events resolved within a median duration of 1 to 3 days after onset.

In this initial subset of 24 participants, the frequencies of systemic reactions reported within 7 days after the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g vaccine are much lower than the frequencies previously observed in association with the original BNT162b2 vaccine within the respective age group. According to the MAH, this is likely a factor of the small number of participants for this dataset.

<div style=\"page-break-after: always\"></div>

Figure 3. Systemic Events, by Maximum Severity, Within 7 Days After the Study Vaccination -- Subset of Substudy B Group 2 - ≥6 Months to &lt;2 Years of Age -- Safety Population

Note:SubsetofSubstudyBGroup2includesthefirst24and36paticipantsenrolledin26monthsto&lt;2yearsagegroup and≥2yearsto&lt;5yearsagegroup,respectively Note:SubstudyBGroup2includesparticipants26months to&lt;5years ofage who received3dosesofBNT162b23μg60 to240dayspriortoenrollment. Note:Severitywasnotcollectedforuse of antipyretic or painmedication.

<!-- image -->

PFIZERCONFIDENTIALSDTMCreation:08DEC2022(16:32)SourceData:adfacevd

TableGeneration:19DEC2022(22:07)(CutoffDate:25NOV2022,SnapshotDate:08DEC2022)OutputFile:/nda2\\_ubped2/C4591048\\_B\\_1MPD\\_Safety/adce\\_f001\\_se\\_p2\\_6m2y

## ≥2 to &lt;5 Years of Age

Antipyretic or pain medication use was reported by 2.8% of participants after study vaccination. Most systemic events were mild or moderate in severity. No severe or Grade 4 systemic events were reported by any participant in the ≥2 years to &lt;5 years of age group who received a fourth dose of the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g. The median onset for most systemic events was 1 to 6 days, and most events resolved within a median duration of 1 to 2 days after onset. One participant reported headache and chills, which lasted 24 days.

In this initial subset of 36 participants, the frequencies of systemic reactions reported within 7 days after the bivalent BNT162b2 (Original/Omicron BA.4-5) at 3 μ g vaccine are lower than the frequencies previously observed in association with the original BNT162b2 vaccine within the respective age group. According to the MAH, this is likely a factor of the small number of participants for this dataset.

<div style=\"page-break-after: always\"></div>

Figure 4. Systemic Events, by Maximum Severity, Within 7 Days After the Study Vaccination - Subset of Substudy B Group 2 -≥2 to&lt;5Years of Age -Safety Population

<!-- image -->

Note:Subset ofSubstudyBGroup2includes thefirst24and36paticipants enrolledin≥6months to&lt;2yearsagegroup and≥2yearsto&lt;5years agegroup,respectively. Note:SubstudyBGroup2includesparticipants26months to&lt;5yearsofagewho received3dosesofBNT162b23μg60 to240days priorto enrollrment.

Note:Severity was notcollectedforuse ofantipyretic or painmedication.

TableGeneration:13DEC2022(20:28)（CutoffDate:25NOV2022,SnapshotDate:08DEC2022)OutputFile:/nda2\\_ubped2/C4591048\\_B\\_1MPD\\_Safety/adce\\_f001\\_se\\_p2\\_2y5y

PFIZERCONFIDENTIALSDTM Creation:08DEC2022(16:32)SourceData:adfacevd

## Adverse Events

Overall, AEs were reported by 3 (12.5%) and 1 (2.8%) participant in the ≥6 months to &lt;2 years of age group and 2 to &lt;5 years of age group, respectively. No severe, life- threatening, SAEs or AEs leading to withdrawal or death were reported from study vaccination to 1 month after study vaccination. Overall, the AE profile at 1 month post dose was generally similar to that at 7 days post dose.

No additional AEs were reported up to data cut-off date of 25 November 2022.

<div style=\"page-break-after: always\"></div>

Table 26. Number(%o) ofParticipants Reporting at Least 1 AdverseEvent From the StudyVaccinationto1 MonthAfter theStudyVaccination,bySystemOrgan Class andPreferredTerm-SubsetofSubstudyBGroup 2-≥6Mlonthsto&lt;5 years of Age -Safety Population

|                                                      | Vaccine Group (as Administered) BivalentBNT162b2 (Original/Omi BA.4/BA.5)3 μg   | Vaccine Group (as Administered) BivalentBNT162b2 (Original/Omi BA.4/BA.5)3 μg   | Vaccine Group (as Administered) BivalentBNT162b2 (Original/Omi BA.4/BA.5)3 μg   | Vaccine Group (as Administered) BivalentBNT162b2 (Original/Omi BA.4/BA.5)3 μg   | Vaccine Group (as Administered) BivalentBNT162b2 (Original/Omi BA.4/BA.5)3 μg   | Vaccine Group (as Administered) BivalentBNT162b2 (Original/Omi BA.4/BA.5)3 μg   |
|------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
|                                                      | ≥6 Months to <2 Years (N=24)                                                    | ≥6 Months to <2 Years (N=24)                                                    | ≥2 to <5 Years (N*=36)                                                          | ≥2 to <5 Years (N*=36)                                                          | ≥6 Months to <5 Years (N=60)                                                    | ≥6 Months to <5 Years (N=60)                                                    |
| System Organ Class PreferredTerm                     | (%)qu                                                                           |                                                                                 |                                                                                 | (95% CI)nb(%)(95% CI)nb (%)                                                     |                                                                                 | (95% CI9)                                                                       |
| Any adverse event                                    | 3 (12.5)                                                                        | (2.7, 32.4)                                                                     | 1 (2.8)                                                                         | (0.1, 14.5)                                                                     | 4 (6.7)                                                                         | (1.8, 16.2)                                                                     |
| Gastrointestinaldisorders                            | 1 ( 4.2)                                                                        | (0.1, 21.1)                                                                     | 0                                                                               | (0.0, 9.7)                                                                      | 1(1.7)                                                                          | (0.0, 8.9)                                                                      |
| Diarrhoea                                            | 1 ( 4.2)                                                                        | (0.1, 21.1)                                                                     | 0                                                                               | (0.0, 9.7)                                                                      | 1 (1.7)                                                                         | (0.0, 8.9)                                                                      |
| General disorders and administration site conditions | 2 (8.3)                                                                         | (1.0, 27.0)                                                                     | 1 (2.8)                                                                         | (0.1, 14.5)                                                                     | 3 (5.0)                                                                         | (1.0, 13.9)                                                                     |
| Fatigue                                              | 1 ( 4.2)                                                                        | (0.1, 21.1)                                                                     | 0                                                                               | (0.0, 9.7)                                                                      | 1(1.7)                                                                          | (0.0, 8.9)                                                                      |
| Injection site pain                                  | 1 ( 4.2)                                                                        | (0.1, 21.1)                                                                     | 0                                                                               | (0.0, 9.7)                                                                      | 1 (1.7)                                                                         | (0.0, 8.9)                                                                      |
| Injection site warmth                                | 0                                                                               | (0.0, 14.2)                                                                     | 1 (2.8)                                                                         | (0.1, 14.5)                                                                     | 1 (1.7)                                                                         | (0.0, 8.9)                                                                      |
| Pyrexia                                              | 1 ( 4.2)                                                                        | (0.1, 21.1)                                                                     | 0                                                                               | (0.0, 9.7)                                                                      | 1 (1.7)                                                                         | (0.0, 8.9)                                                                      |
| Skin and subcutaneous tissue disorders               | 0                                                                               | (0.0, 14.2)                                                                     | 1 (2.8)                                                                         | (0.1, 14.5)                                                                     | 1 ( 1.7)                                                                        | (0.0, 8.9)                                                                      |
| Erythema                                             | 0                                                                               | (0.0, 14.2)                                                                     | 1 (2.8)                                                                         | (0.1, 14.5)                                                                     | 1(1.7)                                                                          | (0.0, 8.9)                                                                      |

Note: Substudy B Group 2 includes participants ≥6 months to &lt;5 years of age who received 3 doses of BNT162b2 3 μg 60 to 240 days prior to enrollment.

Note: Subset of Substudy B Group 2 includes the first 24 and 36 participants enrolled in ≥6 months to &lt;2 years age group and ≥2 years to &lt;5 years age group, respectively.

a.N=number of participants in the specified group.Thisvalue is the denominator for the percentage calculations.

b. n = Number of participants reporting at least 1 occurrence of the specified event. For \"any adverse event,\" n = number of participantsreportingatleast 1occurrence ofany adverseevent.

c. Exact 2-sided CI, based on the Clopper and Pearson method.

PFIZER CONFIDENTIAL SDTM Creation: 08DEC2022 (16:31) Source Data: adae Table Generation: 13DEC2022 (20:27)

## Immediate Adverse Events

No participant in the ≥6 months to &lt;2 years and ≥2 to &lt;5 years of age groups were reported to have an immediate AE within 30 minutes of study vaccination.

## Related Adverse Events

AEs assessed by the investigator as related were reported by 1 (4.2%) participant in the ≥6 months to &lt;2 years of age group. These events were consistent with reactogenicity events and included fatigue (n=1) and injection site pain (n=1)

## Severe or Life-Threatening Adverse Events

No severe or life-threatening AEs were reported from study vaccination through 1 month post vaccination.

## Deaths and Serious Adverse Events

No deaths or SAEs were reported by participants in the ≥6 months to &lt;2 years of age group and ≥2 years to &lt;5 years of age group from study vaccination through 1 month post vaccination.

## Adverse Events Leading to Withdrawal

There were no discontinuations due to AEs reported from study vaccination through 1 month post vaccination for participants in the ≥6 months to &lt;2 years of age group and ≥2 years to &lt;5 years of age group.

<div style=\"page-break-after: always\"></div>

## Other Significant Adverse Events

Some AEs are of specific interest due to their autoimmune or neuroinflammatory nature, theoretical association with vaccines, or known occurrence in patients with COVID-19. From study vaccination through 1 month post dose, no AEs of lymphadenopathy, rash, anaphylaxis/hypersensitivity, appendicitis, Bell's palsy, and myo/pericarditis were reported up to 1 month post vaccination.

## MAH Conclusion

Based on the available safety data from a subset of 60 participants (the first 24 and 36 participants enrolled in ≥6 months to &lt;2 years age group and ≥2 years to &lt;5 years age group, respectively) from study vaccination through 1-month post study vaccination, the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at the 3 μ g dose level was generally well tolerated across both age groups (≥6 months to &lt;2 years of age and ≥2 to &lt;5 years of age), with mostly mild or moderate reactogenicity and few reported AEs. No new adverse reactions were identified based on the available data from this data cut.

In this initial subset of 60 participants, the frequencies of local and systemic reactions reported within 7 days after the bivalent BNT162b2 (Original/Omi BA.4/BA.5) at 3 μ g vaccine are lower than the frequencies previously observed in association with the original BNT162b2 vaccine within the respective age group. This is likely a factor of the small number of participants for this dataset.

The incidence of any AEs within 1 month post study vaccination was low (n=4). No immediate AEs, severe AEs, SAEs, or AEs leading to withdrawal were reported. No AEs of clinical interest were reported (eg, anaphylaxis/hypersensitivity, appendicitis, Bell's palsy, myo/pericarditis). No new or concerning safety findings were noted in this subset of 60 participants up to at least 1 month post vaccination data.

Based on the safety data up to 1 month post vaccination with the bivalent BNT162b2 (Original/Omicron BA.45) at the 3 μ g dose level in these 60 Study C4591048 participants ≥6 months to &lt;2 years and ≥2 years to &lt;5 years of age, the Original/Omicron BA.4-5 bivalent vaccine appears to be safe and tolerable in this population with no significant new safety information identified in this age group.

## 2.6.5.2. Study C4591048 Substudy D Group 2 (≥5 to &lt;12 Years of Age): Booster (Fourth Dose) With BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at 10 μg

The study is further described in EMEA/H/C/005735/II/0177/G procedure where the use of the bivalent Original/Omicron BA.4-5 vaccine (5/5µg) was evaluated for use as primary series.

- o The safety population included 113 participants ≥5 years to &lt;12 years of age who received a fourth dose with BNT162b2 Bivalent (Original/Omicron BA.4-5) at 10 μ g. Median follow-up time after study vaccination was 1.6 months. Cut-off date was 25 Nov 2022.
- o The safety profile within 1 month after study vaccination (fourth dose) with bivalent Original/Omicron BA.4-5 vaccine at the 10µg (5/5 µg) was generally well tolerated, with mostly mild or moderate reactogenicity and few reported AEs. No new adverse reactions were identified based on the available data from this data cut.
- o The reactogenicity profile within 7 days after administration of bivalent Original/Omicron BA.4-5 vaccine at the 10µg (5/5 µg) was generally similar to that previously observed in association with administration of BNT162b2 Original 10µg in this age group.

<div style=\"page-break-after: always\"></div>

- o The AE profile within 1 month after study vaccination was consistent with the known safety profile of BNT162b2 Original. Incidence of AEs, including severe AEs, was low. No immediate AEs, SAEs, or AEs leading to withdrawal were reported. One male participant between 10 and 17 years of age reported an event of lymph node palpable (left axillary lymph node palpable) of moderate severity with onset on Day 2 after study vaccination that resolved within 3 days. The event was assessed by the investigator as related to study intervention. Other than this 1 case of lymph node palpable, no other AEs of clinical interest were reported (eg, rash, anaphylaxis/hypersensitivity, appendicitis, Bell's palsy, myo/pericarditis). No new or concerning safety findings were noted in these 113 participants up to 1 month of post vaccination data.
- o Based on the safety data up to 1-month after study vaccination with bivalent Original/Omicron BA.45 vaccine at the 10µg (5/5µg) in 113 participants in study C4591048 participants ≥5 years to &lt;12 years of age, the bivalent Original/Omicron BA.4-5 vaccine at the 10µg (5/5µg) appears to be consistent with the known safety profile of BNT162b2.

## 2.6.5.3. Study C4591044 Cohorts 2 ( ≥ 12 Years of Age) and 3 ( ≥ 18 Years of Age): Booster (Fourth Dose) of BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at 30 or 60 μg

This study was previously evaluated in EMEA/H/C/005735/MEA/059.1 and is also described in the EMEA/H/C/005735/II/0177/G procedure.

- o In Cohort 2 (All Groups), the safety population included 528 participants ≥12 y ears of age who received a booster (fourth dose) with BNT162b2 Bivalent Original/Omicron BA.4-5 at 30 or 60 μ g. In combined Cohort 2 (Groups 2 and 4) and Cohort 3, the safety population included 619 participants who received BNT162b2 Bivalent Original/Omicron BA.4-5 at 30 μ g: 313 participants who were 18 through 55 years of age and 306 participants who were &gt;55 years of age; median follow-up time after study vaccination to the data cut off (12 Oct 2022) or withdrawal date across vaccine groups was 1.5 months.
- o The safety profile within 1 month after vaccination (Dose 4) with BNT162b2 Bivalent Original/Omicron BA.4-5 at the 30μ g dose level was well tolerated across all age groups, with mostly mild or moderate reactogenicity and few reported AEs.
- o The reactogenicity profile within 7 days after BNT162b2 Bivalent Original/Omicron BA.4-5 vaccine was generally similar to that previously observed in association with booster doses of an Omicron BA.1-modified BNT162b2 bivalent vaccine and to BNT162b2 Original within the respective age groups at the same dose. Both local reactions and systemic events for participants who received the 30μ g dose level tended to be lower for adults &gt;55 years of age compared with younger adult participants (18 through 55 years of age). There was an observed dose dependency for reactogenicity between the BNT162b2 bivalent Original/Omicron BA.4-5 where 30- and 60μ g groups with most local reactions and systemic events reported more frequently after a 60μ g dose, which is consistent with prior observations for BA.1-modified bivalent and monovalent vaccines.
- o The AE profile within 1 month after vaccination consisted of reactogenicity events, labelled reactions (eg, lymphadenopathy, arthralgia), and other AEs that occur in a general adult population. Incidence of lymphadenopathy, severe AEs, and SAEs was low. No life-threatening (Grade 4) events were reported. No new or concerning safety findings were noted 1 month after vaccination.

<div style=\"page-break-after: always\"></div>

## 2.6.5.4. Post marketing experience

No post authorization safety data for BNT162b2 Bivalent (Original/Omicron BA.4-5) in subjects aged ≥ 6 months to &lt;5 years of age has been provided. The MAH will continue to monitor all emerging post authorization safety data for BNT162b2 Bivalent (Original/Omicron BA.4-5) for pharmacovigilance and risk management purposes.

## 2.6.6. Discussion on clinical safety

To support the indication of the bivalent COVID-19 vaccine Original/Omicron BA.4-5 administered as a primary series as well as a booster dose at 1.5/1.5µg in subjects aged ≥ 6 months to &lt;5 years of age, the MAH has presented data from a limited number (n=60) of participants included in the study C4591048 Substudy B Group 2 Subset ≥ 6 Months to &lt;5 Years of age. These subjects are divided into two subgroups based on age: 24 participants ≥6 months &lt;2 years of age and 36 participants ≥2 years to &lt;5 years of age. Both groups received a fourth dose of the bivalent BNT162b2 (Original/Omicron BA.4-5) at 1.5/1.5 μ g. No data where the bivalent vaccine has been administered as a primary series has been provided.

In addition, data from studies C4591048 and C4591044 including subjects ≥ 5 years of age and ≥ 12 years of age who has received the bivalent Original/Omicron BA.4-5 vaccine as a booster dose have been provided as supportive data for extrapolation purposes.

## Study C4591048 Substudy B

The 60 subjects are presented into two subgroups based on age: 24 participants ≥6 months &lt;2 years of age and 36 participants ≥2 years to &lt;5 years of age. Both groups received a fourth d ose of the bivalent BNT162b2 (Original/Omicron BA.4-5) vaccine at 1.5/1.5 μ g. No subjects were excluded based on safety reasons. One-month post vaccination visit was completed by around 97% of the subjects and the median follow-up time after the booster dose was 1.8 months. More than half of the participants in both age groups were white. In the youngest age group 58% of participants were female and among the older children 56% were male. Median time since last prior dose of BNT162b2 Original was 6.4-7.1 months for the younger and older age groups, respectively . Baseline positive for SARS-CoV-2 infection was noted among 42% in the youngest group and in 19% of the older children.

Reactogenicity : Few and mild local reactions were reported among the 24 children aged ≥6 months &lt;2 years who received Original/Omicron BA.4-5 3µg as a fourth dose. Redness was reported among 8% of the subjects and 4% reported swelling. None of the subjects were presented with tenderness at injection site. No new safety concern is detected here. Low frequency of local reactions was reported in the 36 children aged ≥2 to &lt;5 years, most of the reactions were mild or moderate. Pain at the injection site (28%) was the most noted local reaction. No grade 4 reaction was reported.

Few and mostly mild systemic events were reported in both age groups. Among the 24 children aged ≥6 months to &lt;2 years, irritability (18%) was the most commonly reported event. None of the children reported fever &gt;38.4 o C. Antipyretic medication was used in 8% of the subjects. Among the subjects aged ≥ 2-&lt;5 years of age, fatigue (31%) was the most commonly systemic event followed by diarrhoea (6%). Most of the events were mild or moderate at severity and no grade 4 event was reported. Antipyretic or pain medication was noted among 3% of the children.

It is noted that the frequency of local and systemic events is low. The MAH suggests that the lower frequency of reactogenicity reported in this study compared to the previous study where the subjects received a

<div style=\"page-break-after: always\"></div>

primary series of the Original 3 µg vaccine (EMEA/H/C/005735/X/0138 procedure) is a factor of the small number of participants in this study. It should however be noted that in the study presented in EMEA/H/C/005735/X/0138 procedure, the frequency of the reported systemic events was almost similar among the children that received original and placebo, suggesting that the frequency of systemic events might not be too different between original and the Original/Omicron BA.4-5 in these age groups. It is however not possible to compare between studies or to draw any firm conclusions based only on 24+36 participants. Nevertheless, the low reported frequency of both local and systemic events in this study does not suggest new or additional safety concerns in terms of reactogenicity.

AEs : Up to the cutoff date, AEs were reported by 3 (12.5%) children aged ≥6 months to &lt;2 years and in one (2.8%) child in the 2 to &lt;5 years of age group. No severe, life-threatening, SAE or adverse event leading to withdrawal was reported. No AESI was reported. Two of the AEs were considered related to vaccination, these were consistent with reactogenicity events (fatigue, pain at the injection site).

No new safety concern was identified among the limited number of subjects aged 6 months to &lt;5 years receiving Original/Omicron BA.4-5 1.5/1.5 µg as a fourth dose.

## C4591048 and C4591044

In these two studies, BNT162b2 Original/Omicron BA.4-5 was administered as a fourth dose at 10 µg to subj ects aged ≥ 5 to &lt;12 years of age, at 30 µg to subjects aged ≥12 -17 years and at 30µg or 60 µg to subjects ≥18 years of age. Among the subjects that received either 30 or 60 µg, a clear trend to higher reactogenicity with higher dose was noted. No new safety concerns were identified in those studies.

## 2.6.7. Conclusions on clinical safety

BNT162b2 Original/Omicron BA.4-5 at 1.5/1.5 µg has been administered as a fourth dose to 60 subjects aged ≥6 months to &lt;5 years. Overall, the reactogenicity profile was in line with the results obtained when the monovalent BNT162b2 at 3 µg was administered as a primary series. The frequency of reported AEs and SAEs was very low.

Supportive data for extrapolation purposes has been provided, where subjects in different age groups from 5 years onwards have received the bivalent vaccine at different dose levels as a fourth dose. The results suggest a similar safety profile between the monovalent original and the bivalent Original/Omicron BA.4-5 vaccine.

From a safety perspective, this suggests that the bivalent vaccine could be used as a primary series and booster for the age group ≥6 months to &lt;5 years of age.

## 2.7. Risk Management Plan

The currently valid RMP is version 9.0 , which was approved in procedure EMEA/H/C/005735/II/0147 on 10 November 2022 and is a consolidated EU RMP version that merges RMP v 7.2 and 8.0 and addresses the PRAC preliminary assessment request to remove Myocarditis and Pericarditis, and Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD) as safety concerns in study C4591048.

Following the Renewal approval with cMA conversion to standard MA (R-0137, EC decision: 10 October 2022), C4591001 and C4591007 are re-classified from category 2 to category 3 studies.

<div style=\"page-break-after: always\"></div>

Milestones changed for studies C4591030 and C4591048; new milestone added for protocol amendment 2 of study C4591044.

Annex 2 to include changes performed in PART III.2

Annex 3 updated to include study C4591044 in Part C.

Annex 8 updated to reflect new changes.

Within the current procedure an updated RMP version 9.1 dated 01 March 2023 was submitted in support of:

- -EMEA/H/C/005735/X/0176 the line extension of the indication to infants and children 6 months to 4 years of age to receive bivalent Omicron BA.4-5 modified vaccine (Comirnaty Original/Omicron BA.4-5 (3 micrograms) for primary series and as a 4th dose booster.
- -EMEA/H/C/005735/II/0177/G the variation type II of the indication to children 5 to 11 years of age and to individuals 12 years of age and older to receive bivalent Omicron BA.4-5 modified vaccine (Comirnaty Original/Omicron BA.4-5 (10 or 30 micrograms) for primary series.

## 2.7.1. Safety Specifications

## Table SVIII.1: Summary of the Safety Concerns

| Important Identified Risks   | Myocarditis and Pericarditis                                                                                                                                     |
|------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important Potential Risks    | Vaccine-associated enhanced disease (VAED) including Vaccine-associated enhanced respiratory disease (VAERD)                                                     |
| Missing Information          | Use in pregnancy and while breast feeding                                                                                                                        |
| Missing Information          | Use in immunocompromised patients                                                                                                                                |
| Missing Information          | Use in frail patients with co-morbidities (e.g., chronic obstructive pulmonary disease [COPD], diabetes, chronic neurological disease, cardiovascular disorders) |
| Missing Information          | Use in patients with autoimmune or inflammatory disorders                                                                                                        |
| Missing Information          | Interaction with other vaccines                                                                                                                                  |
| Missing Information          | Long term safety data                                                                                                                                            |

## Discussion on safety specification

No new safety concerns have been identified and therefore the summary of safety concerns is similar as in previous version of the RMP.

## Conclusions on the safety specification

It is agreed that the safety concerns listed by the applicant are appropriate.

<div style=\"page-break-after: always\"></div>

## 2.7.2. Pharmacovigilance plan

## Routine pharmacovigilance

Section III.1 Routine pharmacovigilance was largely unchanged relative to the approved RMP version 9.0, with the exception of the following addition (added text in green):

In the section Potential Medication errors/Vial differentiation the Tozinameran/Famtozinameran 1.5/1.5 mcg formulation has been added in the text as follows:

Comirnaty Original/Omicron BA.4-5 (1.5/1.5 mcg)/dose - 6 months through 4 years of age, Dilute before use - Maroon cap : If attempted to not dilute with 2.2 mL sodium chloride 9 mg/mL (0.9%) solution, the user would only be able to extract approximately 1 dose instead of 10 doses as the filled volume is 0.4 mL. If 1.8 mL of diluent (purple cap amount) or 1.3 mL of diluent (orange cap amount) were used, this under dilution would also reduce the number of doses retrieved out of the vial, which might indicate to the HCP that there had been an error in preparation.

In Table 27 Vaccine Presentation Characteristics (below) the new formulation has been added in the last column.

<div style=\"page-break-after: always\"></div>

Table 27. Vaccine Presentation Characteristics

| Age group                                  | 12 years and older                                 | 12 years and older                           | 12 years and older                                      | 12 years and older                                        | 5 through 11 years                                 | 5 through 11 years                                              | 6 months through 4 years                          | 6 months through 4 years                                        |
|--------------------------------------------|----------------------------------------------------|----------------------------------------------|---------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------|
| INN                                        | Toziname ran                                       | Toziname ran                                 | Tozinameran/ Riltozinamera n                            | Tozinameran/ Famtozinamer an                              | Toziname ran                                       | Tozinameran/ Famtozinamer an                                    | Toziname ran                                      | Tozinameran/ Famtozinamer an                                    |
| Name                                       | Comirnaty 30 mcg/dose DILUTE BEFORE USE Purple Cap | Comirnaty 30 mcg/dose DO NOT DILUTE Grey Cap | Comirnaty Original/Omi cron BA.1 DO NOT DILUTE Grey Cap | Comirnaty Original/Omi cron BA.4-5 DO NOT DILUTE Grey Cap | Comirnaty 10 mcg/dose DILUTE BEFORE USE Orange cap | Comirnaty Original/Omi cron BA.4-5 DILUTE BEFORE USE Orange cap | Comirnaty 3 mcg/dose DILUTE BEFORE USE Maroon cap | Comirnaty Original/Omi cron BA.4-5 DILUTE BEFORE USE Maroon cap |
| Dose                                       | 30 mcg (with dilution)                             | 30 mcg (no dilution)                         | 15/15 mcg (no dilution)                                 | 15/15 mcg (no dilution)                                   | 10 mcg (with dilution)                             | 5/5 mcg (with dilution)                                         | 3 mcg (with dilution)                             | 1.5/1.5 mcg (with dilution)                                     |
| Vial cap color and Label with Color Border | Purple                                             | Grey                                         | Grey                                                    | Grey                                                      | Orange                                             | Orange                                                          | Maroon                                            | Maroon                                                          |
| Dose Volume                                | 0.3 mL                                             | 0.3 mL                                       | 0.3 mL                                                  | 0.3 mL                                                    | 0.2 mL                                             | 0.2 mL                                                          | 0.2 mL                                            | 0.2 mL                                                          |
| Amount of Diluent Needed per Vial          | 1.8 mL                                             | NO DILUTIO N                                 | NO DILUTION                                             | NO DILUTION                                               | 1.3 mL                                             | 1.3 mL                                                          | 2.2 mL                                            | 2.2 mL                                                          |
| Fill Volume                                | 0.45 mL                                            | 2.25 mL                                      | 2.25 mL                                                 | 2.25 mL                                                   | 1.3 mL                                             | 1.3 mL                                                          | 0.4 mL                                            | 0.4 mL                                                          |
| Doses per vial                             | 6 doses per vial (after dilution)                  | 6 doses per vial                             | 6 doses per vial                                        | 6 doses per vial                                          | 10 doses per vial (after dilution)                 | 10 doses per vial (after dilution)                              | 10 doses per vial (after dilution)                | 10 doses per vial (after dilution)                              |
| Formulati on                               | PBS sucrose                                        | Tris sucrose                                 | Tris sucrose                                            | Tris sucrose                                              | Tris sucrose                                       | Tris sucrose                                                    | Tris sucrose                                      | Tris sucrose                                                    |

PBS = Phosphate Buffered Saline; Tris = Tromethamine Buffer or (HOCH2)3CNH

## Summary of planned additional PhV activities from RMP

The MAH amended the following text (added text in green, deleted text in strike-through):

The MAH proposes 20 22 studies, of which 5 global, 5 6 in Europe only, 7 8 in US only, 2 in US and Canada and 1 in New Zealand/Australia. There are 9 interventional studies (C4591001, C4591007, C4591015, BNT162-01 Cohort 13, C4591024, C4591031, C4591044, C4591048 and 1 study for vaccine interactions), 3 Low-Interventional studies (C4591036, WI235284 and WI255886) and 8 10 non-interventional studies (7 9 safety and 1 effectiveness).

Besides a few editorial changes, the RMP tables summarising On-going and planned additional pharmacovigilance activities remain unchanged [and are not reproduced here].

The two newly added Non-interventional studies are:

<div style=\"page-break-after: always\"></div>

- Study C4591051 is a Comirnaty Original /Omicron BA.4-5 safety surveillance study to be conducted using secondary data from administrative claims and electronic health records from data research partners participating in the US Sentinel System.
- Study C4501052 is a Comirnaty Original/Omicron BA.1 and Comirnaty Original /Omicron BA.4-5 safety surveillance study conducted in collaboration with University Medical Center Utrecht on behalf of Vaccine Monitoring Collaboration for Europe Consortium research team VAC4EU and based on the master surveillance protocol.

Table Part III.3.1: On-going and planned additional pharmacovigilance activities

| Activity/Study title (type of activity, study title [if known] category 1-3)*   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Safety concerns addressed                                                                         | Status (planned, started)   | Date for submission of interim or final reports (planned or actual)         |
|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------|
| C4591051 (US)                                                                   | Post-approval observational studies using real-world data are needed to assess the association between COVID-19 bivalent Omicron- modified Vaccine and safety events of interest among persons administered the vaccine in the overall US population. This observational study will capture safety events (based on AESI) including myocarditis and pericarditis, in individuals of any age who received the Pfizer-BioNTech COVID-19 bivalent Omicron-modified Vaccine since its availability under an EUA using electronic health records and | Myocarditis/pericarditis Use in pregnancy Use in immunocompromised patients Long-term safety data | Planned                     | Protocol synopsis: 31 Jan 2023 Protocol: 31 May 2023 Final CSR: 31 Jan 2028 |

<div style=\"page-break-after: always\"></div>

| Activity/Study title (type of activity, study title [if known] category 1-3)*   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Safety concerns addressed                                                                                                                                                                                                                                                                                                                                                                                  | Status (planned, started)   | Date for submission of interim or final reports (planned or actual)         |
|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------------------------------------------------------|
|                                                                                 | claims data from data partners participating in the Sentinel System.                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                                                                                                                                                                                                                                            |                             |                                                                             |
| C4591052 (EU)                                                                   | Post-approval observational studies using real-world data are needed to assess the association between Pfizer- BioNTech COVID-19 bivalent Omicron- modified Vaccine and safety events of interest among persons administered the vaccine in the overall EU population. This observational study will capture safety events (based on AESI) including myocarditis and pericarditis, in individuals of any age who received the COVID-19 bivalent Omicron-modified Vaccine since its availability. | Myocarditis/pericarditis Use in pregnancy AESI-based safety events of interest including vaccine associated enhanced disease Use in immunocompromised patients Use in frail patients with co-morbidities (e.g., chronic obstructive pulmonary disease [COPD], diabetes, chronic neurological disease, cardiovascular disorders) Use in patients with autoimmune or inflammatory disorders Long term safety |                             | Protocol synopsis: 04 Jan 2023 Protocol: 30 Apr 2023 Final CSR: 31 Oct 2025 |

*Category 1 studies are imposed activities considered key to the benefit risk of the product.

Category 2 studies are Specific Obligations in the context of a marketing authorisation under exceptional circumstances under Article 14(8) of Regulation (EC) 726/2004 or in the context of a conditional marketing authorisation under Article 14(7) of Regulation (EC) 726/2004.

Category 3 studies are required additional PhV activity (to address specific safety concerns or to measure effectiveness of risk minimisation measures)

<div style=\"page-break-after: always\"></div>

## Overall conclusions on the PhV Plan

Within the context of routine pharmacovigilance the MAH is expected and has committed to take into account the introduction of any (also future) new formulation(s) upon evaluation of any new unexpected trends or patterns in adverse event reporting ( e.g. medication errors, reactogenicity, immunogenicity), as appropriate.

The full study protocol for C4591052 and C4591051 is currently ongoing.

PRAC, having considered the data submitted, is of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

PRAC also considered that routine PhV remains sufficient to monitor the effectiveness of the risk minimisation measures.

## 2.7.3. Plans for post-authorisation efficacy studies

Not applicable.

## 2.7.4. Risk minimisation measures

## Routine Risk Minimisation Measures

No changes are proposed. This is accepted.

## Additional risk minimisation measures

Not applicable.

## Overall conclusions on risk minimisation measures

PRAC having considered the data submitted was of the opinion that:

the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication(s).

## Part VI Summary of the risk management plan

PRAC concludes that the updates are administrative and acceptable.

The elements for a public summary of the RMP do not require revision following the conclusion of the procedure.

## 2.7.5. Conclusion on the RMP

After the PRAC meeting, the MAH took the opportunity and submitted RMP version 10.0, merging versions 9.2, 9.3, and 9.4 of the RMP submitted and reviewed with this procedure, procedure X180, and II177, and implementing an agreed 6 months delay for interim report of study C4591007. The CHMP considered that the risk management plan version 10.0 is acceptable.

<div style=\"page-break-after: always\"></div>

## 2.8. Pharmacovigilance

## 2.8.1. Pharmacovigilance system

The CHMP considered that the pharmacovigilance system summary submitted by the MAH fulfils the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.8.2. Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the MAH show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Labelling exemptions

The following exemptions from labelling requirements have been granted on the basis of article 63.3 of Directive 2001/83/EC. In addition, the derogations granted should be seen in the context of the flexibilities described in the Questions and Answers on labelling flexibilities for COVID-19 vaccines (EMA/689080/2020 rev.1, from 16 December 2020)5 document which aims at facilitating the preparedness work of COVID-19 vaccine developers and the associated logistics of early printing packaging activities.

- English-only labelling (inner and outer label/carton) and package leaflet* (from start of supply until end 2023).
- Without country-specific information, such as blue box requirements (from start of supply until end 2023).

All MSs (with one exception: Poland**) have agreed to extend the current derogations until the end of 2023; this will allow the MAH to make all necessary adjustments so that by Jan 2024 the MAH can revert to full EU labelling requirements.

*MAH should ensure provision of the package leaflet in national language(s) to relevant member states, separately to vaccine supply, as stated in Q2 Q&amp;A flexibilities for COVID-19 vaccines, with the exception  of Germany.

**The MAH should address this labelling exemption request directly to the Polish NCA.:

<div style=\"page-break-after: always\"></div>

## 2.9.3. Quick Response (QR) code

The updates of the QR code/URL to include further references to Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose dispersion for injection, as well as the necessary layout changes on the website shall be submitted and assessed via an Article 61.3 notification (post-authorisation).

## 2.9.4. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Comirnaty (tozinameran) is included in the additional monitoring list as a new active substance and new biological.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Introduction

This application concerns an extension of indication to add a new strength of 1.5/1.5 micrograms/dose for Comirnaty bivalent (Original/OMI BA.4-5), as primary series and booster for children 6 months-&lt; 5 years.

There are no data investigating the bivalent BNT162b2 (Original/OMI BA.4-5) as a primary series in any age group: the evaluation is solely based on extrapolation from booster studies where the product was given as the fourth dose. There are no dose-finding studies for this age group with Original or the bivalent vaccines below the 3 µg dose.

The ETF has previously concluded that the bivalent formulation may be used for primary vaccination (https://www.ema.europa.eu/en/news/etf-concludes-bivalent-original-omicron-ba4-5-mrna-vaccines-maybe-used-primary-vaccination) based on non-clinical studies and data on the immune response following natural infection with omicron BA.4/5. The data suggested that primary vaccination with the bivalent formulation should give rise to a broad immune response in unvaccinated people and that the safety profile would be comparable to the original vaccine (based on booster studies).

In accordance with the recommendations from the EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants (https://www.ema.europa.eu/en/documents/other/ecdcema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants\\_en.pdf), the vaccine posology has been simplified for all approved formulations.

## 3.2. Therapeutic Context

## 3.2.1. Disease or condition

COVID-19 is caused by SARS-CoV-2, a zoonotic virus that first emerged as a human pathogen in China and has rapidly spread around the world by human-to-human transmission.

<div style=\"page-break-after: always\"></div>

## 3.2.2. Available therapies and unmet medical need

Currently available therapies have different benefit-risk considerations depending on the stage of illness and disease manifestations. While care for individuals who have COVID-19 has improved with clinical experience, vaccination has been the most effective medical countermeasure to decrease the risk and mitigate spread of the SARS-CoV-2 virus.

There are COVID-19 vaccines available for the age group 6 months-&lt; 5 years, but none specific for any Omicron variant. While the majority of the global population has either received COVID-19 vaccination or been exposed to the virus, the need for primary vaccination is considerably smaller than previously during the pandemic, however there is still demand for a vaccine that can be used for primary vaccination.

The original Comirnaty is still available, however it may be more appropriate to use variant adapted vaccines also for primary vaccination. There is currently no Omicron vaccine approved for primary vaccination in any age group.

## 3.2.3. Main clinical studies

To support the indication of the bivalent COVID-19 vaccine Original/Omicron BA.4-5 administered as a primary series as well as a booster dose at 1.5/1.5µg in subjects aged ≥ 6 months to &lt;5 years of age, the MAH has presented data from a limited number of participants included in the study C4591048 Substudy B Group 2 Subset ≥ 6 Months to &lt;5 Years of Age . No data where the bivalent vaccine has been administered as a primary series have been provided.

In addition, data from studies C4591048 and C4591044 including subjects ≥ 5 years of age and ≥ 12 years of age who have received the bivalent Original/Omicron BA.4-5 vaccine as a booster dose have been provided as supportive data for extrapolation purposes.

## 3.3. Favourable effects

Efficacy has previously been demonstrated for primary vaccination with the Original vaccine against symptomatic COVID-19 for all age groups.

Immunogenicity data of the bivalent Original/Omicron BA.4-5 as a 4th dose in children who have earlier received 3 doses of the Original vaccine were submitted. Descriptive immunogenicity data (GMTs, GMFRs, Seroresponse rate) were presented for a small subset (N= 60) of the planned study population (N=300) at age 6m-&lt;5y.

At 1-month post, a fourth dose bivalent Original/Omi BA.4-5 at 1.5/1.5 µg in participants ≥ 6 months to &lt;5 years of age in the C4591048 Substudy B who received 3 prior doses of BNT162b2 elicited antibody responses to both BA.4-5 and the referenced strain.

The supportive data from age groups 5-&lt;12 y (5/5 µg), and 12-17, 18-55 and &gt;55 (15/15 µg) vaccinated with age group specific Original/Omi BA.4-5 vaccine demonstrated the immunogenicity of Original/Omi BA.45 as 4th dose after 3 doses of Original vaccine.

These data show that Original/Omicron BA.4-5 (1.5/1.5 μ g) is immunogenic as a 4th dose in individuals older than 6m to &lt;5 y who have received 3 prior doses of Original 3 μ g. Immunogenicity studies in naïve mice showed that when compared to the original vaccine, the bivalent Omicron BA.4/BA.5 vaccine (combination of

<div style=\"page-break-after: always\"></div>

BNT162b2 and BNT162b2 Omicron BA.4/BA.5) elicited a greater breadth of neutralizing antibody responses against all variants and sub-lineages tested.

## 3.4. Uncertainties and limitations about favourable effects

There are no clinical data from a primary series with a bivalent Original/Omi BA.4-5 vaccine submitted. This is valid for all age groups including children at age 6m- &lt;5 y receiving Original/Omi BA.4-5 at 1.5/1.5 µg. The clinical data submitted for the bivalent vaccine originate exclusively from booster studies.

While the principle of extrapolation of efficacy of a bivalent booster dose to a bivalent primary series is accepted, no dose-response study has been presented for Original /Omicron BA 4-5 (1.5/1.5 µg). There were previous concerns about the immunogenicity of the total dose of 3ug in the youngest children, which has prompted a three-dose schedule. Notably, the lowest dose in the Original vaccine study was 3 µg. There are no data currently presented which could show that 1.5 µg of Original suffices to give a broad immune response that would be expected to provide protection against severe disease.

The comparison between immune responses to a fourth dose of a bivalent vaccine and a third dose of original vaccine is of less relevance, as the vaccinees have received a different number of doses. Thus, the following results would have been of interest when comparing 4 th  doses of both vaccines:

- Higher Omicron BA.4\\_5-specific neutralizing titers compared with the titers in a comparator group of participants in C4591007 Phase 2/3 who received 3 doses of Original 3 µg.
- Similar reference strain-specific titers compared with the titers in the comparator group of participants in C4591007 Phase 2/3 who received 3 doses of BNT162b2.

There is no immune correlate of protection established so far. The extent of increased efficacy given a certain increment in immunogenicity, is not known. The same pertains to the breadth of the immune response as well as the duration of protection.

The immunogenicity against newly circulating strains was shown to be low. Therefore, the clinical benefit of Original/Omicron BA. 4-5 against new strains is unknown.

## 3.5. Unfavourable effects

The reactogenicity profile appears to be mild among the 60 subjects aged ≥6 months to &lt;5 years of age that received bivalent Original/Omicron BA.4-5 at 1.5/1.5 µg as a fourth dose. The most commonly reported local reaction was redness (8%) among the youngest children aged ≥6 months to &lt;2 years of age and pain at injection site (28%) among children aged ≥2 -&lt;5 years. For systemic events irritability (18%) was most commonly reported among the youngest children and fatigue (31%) among the older children. Antipyretic or pain medication was used among 3-8% of the children.

No new safety concern was identified among the limited number of subjects aged 6 months to &lt;5 years receiving Original/Omicron BA.4-5 at 1.5/1.5 µg as a fourth dose.

## 3.6. Uncertainties and limitations about unfavourable effects

The study population is limited, including only 24 participants ≥6 months &lt;2 years of age and 36 participants ≥2 years to &lt;5 years of age .

<div style=\"page-break-after: always\"></div>

Safety data for BNT162b2 Original/Omicron BA.4-5 at 1.5/1.5 µg is only available when administered as a fourth dose, none of the age groups has received the bivalent vaccine as a primary series.

It is noted that the frequency of local and systemic events is low. The MAH suggests that the lower frequency of reactogenicity reported in this study compared to the previous study where subjects received a primary series of the Original 3 µg (EMEA/H/C/005735/X/0138 procedure) is a factor of the small number of participants in this study. It should however be noted that in the study presented in EMEA/H/C/005735/X/0138 procedure, the frequency of the reported systemic events was almost similar among the children that received original and placebo, suggesting that the frequency of systemic events might not be too different between original and the Original/Omicron BA.4-5 in these age groups. It is however not possible to reliably compare between studies or to draw any firm conclusions based only on 24+36 participants.

## 3.7. Effects Table

Table 28. Effects Table for Comirnaty Original/Omicron BA.45 at 1.5/1.5µg for children aged ≥6 months to &lt;5 years of age (data cut -off: 25 Nov 2022).

| Effect                                 | Short Description                                                       | Unit                           | Treatme nt                             | Control                                 | Uncertainties/ Strength of evidence                                                          | References                |
|----------------------------------------|-------------------------------------------------------------------------|--------------------------------|----------------------------------------|-----------------------------------------|----------------------------------------------------------------------------------------------|---------------------------|
| Favourable Effects                     | Favourable Effects                                                      | Favourable Effects             | Favourable Effects                     | Favourable Effects                      | Favourable Effects                                                                           | Favourable Effects        |
| Immunog enicity against Omicron BA.4-5 | 4 th dose bivalent (1.5/1.5) µg to 6m-<5y , after 3 doses original 3 µg | GMT (95% CI)                   | After 4 th dose with bivalent Baseline | After 3 doses of Original 3 µg Baseline |                                                                                              | Study C4591048 Substudy B |
|                                        |                                                                         | Base- line                     | N=54 192.5 (120.4, 307.8)              | N=54 70.5 (51.1, 97.2)                  | Small sentinel cohort from study, which intends to have larger cohort and hypothesis testing |                           |
|                                        |                                                                         | 1m post dose                   | N=58 1695.2 (1151.8, 2494.9)           | N=54 607.9 (431.1, 857.2)               | Minimal sample size for descriptive immunogenicity evaluation                                |                           |
|                                        |                                                                         | GMFR (95% CI)                  | 9.1 (6.3, 13.3)                        | 8.6 (6.3, 11.7)                         | Comparator has received numerically less doses (3) than active arm (4)                       |                           |
|                                        |                                                                         | Seror espo nse rate % (95% CI) | 38 out of 54 70.4 %(56.4, 82.0 %)      | 33 out of 54 (61.1 %) (46.9, 74.1 %)    |                                                                                              |                           |

<div style=\"page-break-after: always\"></div>

| Effect                                 | Short Description                                                           | Unit                      | Treatme nt                     | Control                        | Uncertainties/ Strength of evidence                                                                  | References                     |
|----------------------------------------|-----------------------------------------------------------------------------|---------------------------|--------------------------------|--------------------------------|------------------------------------------------------------------------------------------------------|--------------------------------|
| Immunog enicity against Omicron BA.4-5 | 4 th dose bivalent (5/5) µg to 5-<12y , after 3 doses original 3 µg         | GMT (95% CI) 1m post dose | N= 101 1836.1 (1593.8, 2115.2) | N= 112 1632.5 (1427.5, 1867.0) | Comparator has received numerically less doses (3) than active arm (4). Model based descriptive GMR. | Study C4591048 Substudy D      |
|                                        |                                                                             | GMR                       | 1.12 (0.92, 1.37)              | 1.12 (0.92, 1.37)              |                                                                                                      |                                |
| Immunog enicity against Omicron BA.4-5 | 4 th dose bivalent (15/15) µg to >55 , after 3 doses original 3 µg          | GMT (95% CI) 1m post dose | N= 282 3373.4 (3000.3, 3793.0) | N= 273 1160.7 (1030.3, 1307.7) | Active arm and comparator have both received 4 doses                                                 | Study C4591044                 |
|                                        |                                                                             | GMR                       | 2.91 (2.45, 3.44)              | 2.91 (2.45, 3.44)              | Bivalent/Original among >55                                                                          | Superiority met                |
|                                        | 4 th dose bivalent (15/15) µg to >55 and 18- 55 after 3 doses original 3 µg | GMT (95% CI) 1m post dose | N= 282 4344.4 (3850.2, 4902.1) | N= 294 4254.2 (3779.6, 4788.4) |                                                                                                      |                                |
|                                        |                                                                             | GMR                       | 0.98 (0.83, 1.16)              | 0.98 (0.83, 1.16)              | Bivalent 18-55/ bivalent >55                                                                         | Non-inferiority met            |
| Unfavourable Effects                   | Unfavourable Effects                                                        | Unfavourable Effects      | Unfavourable Effects           | Unfavourable Effects           | Unfavourable Effects                                                                                 | Unfavourable Effects           |
| Redness at injection site              | ≥6 months to <2 years                                                       | %                         | Dose 4: 8%                     | N/A                            | Transient events, majority mild to moderate severity                                                 | Study C4591048 Substudy B N=24 |
| Pain at injection site                 | ≥2 - <5 years                                                               | %                         | Dose 4: 28%                    | N/A                            |                                                                                                      | Study C4591048 Substudy B N=36 |
| Irritability                           | ≥6 months to <2 years                                                       | %                         | Dose 4: 18%                    | N/A                            |                                                                                                      | Study C4591048 Substudy B N=24 |
| Fatigue                                | ≥2 - <5 years                                                               | %                         | Dose 4: 31%                    | N/A                            |                                                                                                      | Study C4591048 Substudy B N=36 |
| Fever                                  | ≥6 months to <2 years                                                       | %                         | Dose 4: 4%                     | N/A                            |                                                                                                      | Study C4591048 Substudy B N=24 |
|                                        | ≥2 - <5 years                                                               | %                         | Dose 4: 0%                     | N/A                            |                                                                                                      | Study C4591048 Substudy B N=36 |

<div style=\"page-break-after: always\"></div>

Abbreviations: GMT: geometric mean titer; GMR: geometric mean ratio; CI: confidence interval

## 3.8. Benefit-risk assessment and discussion

## 3.8.1. Importance of favourable and unfavourable effects

The benefit of the product is the induction of an anti-SARS-CoV-2 immune response, which is likely to protect against severe COVID-19 disease. The original vaccine has proven highly effective in this regard, when used as a primary series.

Considering the following, the extrapolation of the efficacy of a bivalent original/variant vaccine from boosting to a primary series is considered in principle possible.

- Bivalent Original/Omicron BA.1 has demonstrated superior immune responses to BA.1 and noninferior responses to the reference strain in older age groups
- Any bivalent original/variant vaccine is considered to have similar characteristics as the Original/Omicron BA.1 vaccine
- Booster responses of the same magnitude can be extrapolated to primary vaccination
- It is unknown when primary vaccination data will be available
- It is likely that primary vaccination with a vaccine covering currently circulating strains is superior against these, compared to primary vaccination with the original vaccine

As the total amount of mRNA in the bivalent vaccine is 3 µg, it is considered that the amount of mRNA is immunogenic. The ongoing Substudy A of C4591048 is investigating dose-response of Original/Omicron BA.45 among children younger than 5 years, data is expected to be submitted as soon as available.

The safety profiles of Comirnaty variant vaccines have not differed in a relevant way. Moreover, the reactogenicity of the selected dose in the smallest children may be considered low. Thus safety may be extrapolated from the booster scenario to the primary series.

## 3.8.2. Balance of benefits and risks

The benefit/risk balance is considered positive for Original/Omicron BA.4-5 at 1.5/1.5 µg among children 6m&lt;5y as both primary series and a booster dose

## 3.9. Conclusions

The overall benefit/risk balance of the bivalent BNT162b2 Original/Omicron BA.4-5 is considered positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, immunogenicity and safety, the CHMP considers by consensus that the benefit-risk balance of Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose is favourable

<div style=\"page-break-after: always\"></div>

in the following indication:

Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.

The use of this vaccine should be in accordance with official recommendations.

The CHMP therefore recommends the extension of the marketing authorisation for COMIRNATY subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Official batch release

In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The Marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.